https://biospectrumindia.com/rssfeed/states/maharashtra maharashtra https://biospectrumindia.com/news/108/28643/toothsis-parent-company-makeo-raises-rs-90-cr-to-scale-asias-largest-consumer-dental-tech-platform.html https://biospectrumindia.com/news/108/28643/toothsis-parent-company-makeo-raises-rs-90-cr-to-scale-asias-largest-consumer-dental-tech-platform.html Tue, 13 Oct 2026 14:43:39 +0530 Mumbai-based MakeO (parent company of the leading Indian clear aligner brand, Toothsi), has raised Rs 90 crore in funding. The round was led by Singularity AMC alongside participation from funds and family offices such as DSP family office, Genesis, Unispace ventures. The funding underscores investor confidence in MakeO's mission to build a world class aligner and dental technology platform for India and Southeast Asia. This fundraise follows on MakeO’s acquisition of Singapore headquartered Zenyum, expanding its presence across Southeast Asian dental-care markets. Together, the group now operates a combined network of about 1,100 partner dentists in 10 countries across India, Singapore, Malaysia, Vietnam, Taiwan, Hong Kong, and Japan. This positions the group among Asia's top aligner and oral-care platforms. MakeO has also acquired Apple Dental, a 20-clinic chain in Andhra Pradesh and Telangana, strengthening its presence beyond India's major metros. MakeO's integrated planning and manufacturing hub in the Mumbai Metropolitan Region (MMR) for its US-FDA approved aligners, is among the largest integrated facilities of its kind, producing over a million aligners a year, reaching dentists and consumers across 150+ Indian cities and exporting to 10+ countries through the Toothsi and Zenyum networks. Dr Pravin Shetty, Co-founder, MakeO, said: “We are building a truly digital, AI-first dental-orthodontic platform. At the heart of MMR, we have set up a US FDA – 510(k) cleared aligner product manufacturing facility with a 3D virtual AI based orthodontic treatment planning centre of excellence.” ]]> https://biospectrumindia.com/news/108/28602/lupin-introduces-worlds-first-fixed-dose-triple-combination-drug-for-copd-management.html https://biospectrumindia.com/news/108/28602/lupin-introduces-worlds-first-fixed-dose-triple-combination-drug-for-copd-management.html Tue, 06 Oct 2026 16:59:03 +0530 Mumbai-based pharma major Lupin has launched Formoflo-G® MDI, the world's first fixed-dose triple combination metered-dose inhaler (MDI) for chronic obstructive pulmonary disease (COPD) in India, following approval from the Drug Controller General of India (DCGI). The launch marks a significant advancement in respiratory care, expanding treatment options for patients living with COPD. Lupin Formoflo-G® is a first-of-its-kind MDI that combines Glycopyrronium Bromide, Formoterol Fumarate and Fluticasone Propionate for the long-term management and treatment of moderate to severe COPD. The product is available as a twice-daily, single-strength fixed dose, bringing hope to more than 55 million people living with COPD in India, a condition that remains a leading cause of death and disability. Commenting on the launch, Nilesh Gupta, Managing Director, Lupin, said, "As respiratory diseases continue to impact millions across India, access to effective therapies remains critical. Formoflo-G® MDI reflects our commitment to addressing unmet patient needs through differentiated, high-quality therapies. By combining innovation with accessibility, we aim to improve outcomes for patients living with respiratory diseases." Ranked #2 in the respiratory therapy segment in India (IQVIA, MAT Mar 2026), Lupin continues to strengthen its leadership in respiratory care with the launch of Formoflo-G® MDI, reinforcing its focus on addressing unmet patient needs through innovation-driven therapies. ]]> https://biospectrumindia.com/news/108/28608/neuberg-diagnostics-and-nm-medical-to-build-integrated-diagnostics-network-in-maharashtra.html https://biospectrumindia.com/news/108/28608/neuberg-diagnostics-and-nm-medical-to-build-integrated-diagnostics-network-in-maharashtra.html Tue, 06 Oct 2026 21:30:50 +0530 Neuberg Diagnostics has announced the consolidation of its Maharashtra operations with NM Medical, bringing together some of the state's most respected diagnostic brands and clinical leaders under one unified network. The partnership combines NM Medical's four decades of expertise in advanced radiology, cardiology and preventive wellness with Neuberg's specialised capabilities in Genomics, Metabolomics, Proteomics, Digital Pathology, Immunohistochemistry, Molecular Diagnostics, Nephropathology and Neuropathology.   Patients across Mumbai and Maharashtra will benefit from convenient access to routine and highly specialised testing, advanced imaging and comprehensive preventive wellness through an expanding network of integrated diagnostic centres, advanced pathology laboratories, wellness centres and collection centres. For clinicians, bringing imaging, pathology, molecular diagnostics and genomics together will provide a more comprehensive view of each patient, supporting earlier detection, precise diagnosis, personalised treatment decisions and better disease monitoring. The Maharashtra platform will be led by Dr Nilesh Shah as Chairman, Dr Ajay Shah as Chief Mentor - Pathology, Dr Asish Atre as Chief of Radiology, and Dr Kunal Sehgal and Dr Jay Mehta as Heads of Pathology. Rahil Shah will serve as CEO - Maharashtra, Preventive Wellness & Africa Operations, Neuberg Group, driving the integration and expansion of the network. Under this leadership, Neuberg will expand across Maharashtra through integrated diagnostic centres, advanced pathology laboratories, comprehensive wellness centres and collection centres, bringing advanced diagnostic services closer to patients and clinicians. ]]> https://biospectrumindia.com/news/108/28571/longevity-healthcare-startup-vytalyou-raises-rs-9-cr-to-expand-clinic-network.html https://biospectrumindia.com/news/108/28571/longevity-healthcare-startup-vytalyou-raises-rs-9-cr-to-expand-clinic-network.html Wed, 30 Sep 2026 14:57:43 +0530 Mumbai-based Vytalyou, a doctor-led longevity and preventive healthcare startup, has raised Rs 9 crore in a pre-series A funding round from Chetan Jain of Pharma Dose and Ratan Jain of Venus Industries at a valuation of approximately Rs 33 crore. The company will use the funds to expand its Mumbai network of Incremental Lifestyle Clinics. Founded in 2025 by Molecular oncologist Dr Chirantan Bose and Radiologist Dr Preetesh Bhandari, Vytalyou is building a network of doctor-led longevity clinics. Its model combines predictive diagnostics with a broad range of new generation personalised preventive therapies to help push back chronic lifestyle diseases and add healthy years to life. The Mumbai expansion will take its network to three centres, including its existing facility in Powai. Vytalyou plans to expand to 10 locations across India in coming years. The company aims to reduce the number of sick years and enable people to live healthier lives. While routine health-checks spin out conventional reports, Vytalyou’s exemplary Predictive Longevity report is aimed to identify degenerative health conditions well in advance. Thereafter a medically curated preventive and regenerative therapeutic approach is used to guide the personalised programmes. At the core of its offering is an AI-based algorithm which defines Vytalyou’s Predictive Longevity Evaluation, assessing an individual’s health profile, biological ageing and potential areas of future risk. Doctors review the findings and use them to shape a medically supervised plan. Depending on individual needs, this may include lifestyle guidance, further assessment and therapeutic programmes focused on cellular and mitochondrial health, with follow-ups to monitor the progress. “Our focus is on increasing healthy years of life. The AI-based algorithm is unlike any other health check that helps our doctors build a more comprehensive picture of an individual’s organ-systems and shape a personalised programme, which includes interventions focused on cellular and mitochondrial health. Once the body’s own cellular repair and regenerative mechanisms are reset, health takes a new trajectory” said Dr Chirantan Bose, Founder, Vytalyou.   ]]> https://biospectrumindia.com/news/108/28513/deeptek-unveils-global-access-pricing-for-ai-powered-tb-screening.html https://biospectrumindia.com/news/108/28513/deeptek-unveils-global-access-pricing-for-ai-powered-tb-screening.html Mon, 21 Sep 2026 13:27:04 +0530 Pune-based DeepTek, a global leader in AI-powered radiology, has launched Global Access Pricing, a new pricing model enabled through its access agreement with Unitaid and the Clinton Health Access Initiative (CHAI). The initiative makes DeepTek’s WHO-recommended Chest X-ray AI solution significantly more affordable for eligible public-sector and not-for-profit healthcare providers across 138 low- and middle-income countries (LMICs), helping TB programmes expand screening within existing budgets. Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming an estimated 1.23 million lives in 2024. While chest X-rays are critical for TB screening, shortages of radiologists continue to limit timely diagnosis in many high-burden countries. Under Global Access Pricing, eligible programmes can access DeepTek’s AI solution at approximately one-third of its previous pricing, potentially enabling health systems to screen up to three times more people within the same budget. The annual subscription includes unlimited AI analyses per connected X-ray unit, installation, training, product updates, maintenance and technical support, with no hidden add-on costs. The solution supports online, offline and hybrid deployment, including mobile and remote healthcare settings. Beyond TB, DeepTek’s AI detects 20+ clinically relevant chest abnormalities, with transparent pricing also available for additional indications such as cardiomegaly, silicosis and lung cancer.   ]]> https://biospectrumindia.com/news/108/28509/nm-medical-unveils-mumbais-first-open-standing-mri-machine.html https://biospectrumindia.com/news/108/28509/nm-medical-unveils-mumbais-first-open-standing-mri-machine.html Fri, 18 Sep 2026 17:41:57 +0530 NM Medical has announced the launch of Mumbai's first Open Standing MRI machine. The new facility is now operational at NM Medical's center at Marine Lines, Mumbai. Conventional closed MRI machines require patients to lie still inside a narrow tunnel. This Open Standing MRI allows imaging in sitting, standing, and lying positions instead. This helps radiologists assess the spine, joints, and musculoskeletal system under natural, weight bearing conditions, in the same postures where many patients usually feel pain. It is especially suited for patients with claustrophobia or anxiety, elderly patients, patients with mobility challenges, and those who find conventional scanners restrictive. Capturing images while the body bears its own weight can reveal spinal and joint problems that may not show up on a scan taken lying down. This helps doctors decide between conservative treatment and surgery and supports more accurate surgical planning. The machine uses advanced G Scan (Gravity Scan) technology, with Q Spine software for detailed analysis of the spine under load, and True Motion technology to capture movement of joints and the cervical spine. The open design removes the confined tunnel found in traditional MRI machines. Scans do not involve ionising radiation, and most examinations are completed within 20 to 45 minutes. ]]> https://biospectrumindia.com/news/108/28486/aksigen-ivf-expands-science-led-fertility-care-with-new-integrated-centre-in-navi-mumbai.html https://biospectrumindia.com/news/108/28486/aksigen-ivf-expands-science-led-fertility-care-with-new-integrated-centre-in-navi-mumbai.html Tue, 15 Sep 2026 17:01:38 +0530 Aksigen IVF has announced the launch of its new 5,000 sq. ft. fertility centre in Panvel, Maharashtra, marking another step in expanding access to quality fertility care across Navi Mumbai, Raigad and neighbouring regions. The new centre reflects Aksigen IVF's science-led model of fertility care, bringing together advanced embryology, full diagnostic services, personalised clinical pathways, digital laboratory systems and patient education under one roof. Designed around quality, transparency and clinical governance, the centre aims to expand access to evidence-based fertility care across Navi Mumbai, Raigad and neighbouring regions. A key highlight of the Panvel centre is the Bharat Daftary Knowledge Centre (BDKC), the first of its kind immersive IVF Knowledge Centre, in Navi Mumbai & Raigad region, designed to help patients understand fertility, IVF treatment and reproductive health through interactive and technology-enabled learning experiences. The Panvel centre offers fertility consultations and advanced diagnostic services, supported by an advanced embryology laboratory at its core. Designed with a strong emphasis on precision, consistency and patient safety, the laboratory operates within rigorously validated environmental controls and follows SOP-driven workflows. This ensures high standards of quality and reliability across every stage of the IVF journey, including fertilisation, embryo culture and cryopreservation. The centre provides a full range of assisted reproductive technologies, including In Vitro Fertilisation (IVF), Intracytoplasmic Sperm Injection (ICSI), Intracytoplasmic Morphologically Selected Sperm Injection (IMSI), Preimplantation Genetic Testing (PGT/PGD), Laser Assisted Hatching, advanced embryo culture and cryopreservation. The centre is also equipped with the LensHooke CASA X12 Pro, an AI-enabled semen analysis platform capable of assessing double strand DNA Fragmentation Index (DFI), providing objective and reproducible semen analysis that provides deeper insights into male fertility to support informed treatment planning.    ]]> https://biospectrumindia.com/news/108/28466/tracky-launches-16d-indias-first-16-day-continuous-glucose-monitoring-system.html https://biospectrumindia.com/news/108/28466/tracky-launches-16d-indias-first-16-day-continuous-glucose-monitoring-system.html Sat, 12 Sep 2026 00:12:12 +0530 Mumbai-based Drstore Healthcare Services, a connected healthcare and medical device ecosystem company, through its smart medical devices and technology brand Tracky, has launched India’s first 16-day CGM system Tracky 16D, an integrated continuous glucose monitoring (CGM) system that provides up to 16 days of continuous glucose insights. While most glucose monitoring systems provide insights for up to 14 days, Tracky 16D extends monitoring to 16 days, giving users a more comprehensive understanding of how their glucose levels respond to food, physical activity, medication, and everyday routines through an easy-to-wear wearable device. Along with an improved mean absolute relative difference (MARD) of 8.58 per cent, the device features an integrated sensor and transmitter in a compact, lightweight design that is comfortable to wear and simple to apply. The platform brings together glucose data with nutrition, medication, exercise, sleep, blood pressure, and body composition, while features such as AI-powered health assistance, Bluetooth auto-sync, Nightscout integration, and the redesigned Tracky Health interface enable users to monitor, understand, and manage their health from a single connected experience. ]]> https://biospectrumindia.com/news/108/28449/government-supports-commercialisation-of-3-d-printed-patient-specific-bone-graft.html https://biospectrumindia.com/news/108/28449/government-supports-commercialisation-of-3-d-printed-patient-specific-bone-graft.html Wed, 09 Sep 2026 22:19:50 +0530 The Technology Development Board (TDB) under the Department of Science and Technology (DST), Government of India, has provided financial assistance to Ceramat, in Palghar, Maharashtra, for a project titled 'Calcium Phosphate-based Standard and Customised Patient-Specific Grafts by 3D Printing through Digital Light Processing Technology and Extrusion-Based Device'.  The project aims to commercialise advanced, patient-specific bone grafts using indigenously manufactured bioceramic materials and 3D printing technologies.  The use of indigenous calcium phosphate-based materials combined with advanced additive manufacturing is expected to expand Ceramet's current biomaterial capabilities, allowing it to expand beyond traditional graft products to more sophisticated, digitally designed, and patient-specific solutions. This initiative will also help the company offer a wide range of bioceramic and orthobiological products through an integrated domestic manufacturing system. The company's product portfolio includes technologically advanced biomaterials such as hydroxyapatite, beta-tricalcium phosphate, biphasic calcium phosphate, and bioactive glass, which are used in orthopedics, oral care, cosmetics, and industrial sectors. ]]> https://biospectrumindia.com/news/108/28437/sun-pharma-signs-agreement-with-us-government-to-prioritise-access-to-affordable-medicines.html https://biospectrumindia.com/news/108/28437/sun-pharma-signs-agreement-with-us-government-to-prioritise-access-to-affordable-medicines.html Sat, 05 Sep 2026 13:57:24 +0530 Mumbai-based Sun Pharmaceutical Industries joined several pharmaceutical companies at a White House ceremony to announce agreements with the US government aimed at prioritising access to affordable medicines for millions of American patients. As part of its agreement, Sun Pharma will extend Most Favored Nation (MFN) pricing to state Medicaid programmes. Sun Pharma also commits to MFN pricing for future innovative medicine launches. The agreement recognises Sun Pharma’s investment in the US market by delaying Section 232 tariffs on innovative pharmaceutical products for over two years. Sun Pharma initially built its US presence on a foundation of high-quality generics followed by an increasing emphasis on innovative and specialty medicines. The company ranks second by prescriptions in US dermatology and continues to expand across dermatology and immunology, cutaneous oncology, and ophthalmology, complementing a robust consumer health products and generics business. The US is Sun Pharma’s largest market for innovative medicines and a cornerstone of its long-term growth strategy, generating approximately 27% of the company’s global revenue. Commitment to the US market was further underscored earlier this year through Sun Pharma’s definitive agreement to acquire Organon & Co. at an enterprise value of $11.75 billion - a milestone that reflects Sun Pharma's continued investment in American patients, healthcare providers, and communities. ]]> https://biospectrumindia.com/news/108/28434/dadachanji-group-launches-kaisha-pharma-for-glass-packaging.html https://biospectrumindia.com/news/108/28434/dadachanji-group-launches-kaisha-pharma-for-glass-packaging.html Fri, 04 Sep 2026 21:41:49 +0530 Mumbai-headquartered Dadachanji Group has launched Kaisha Pharma, a premier global platform engineered to serve the pharmaceutical and biotechnology sectors worldwide. As part of a substantial multi-million-euro commitment, the Group has already deployed an initial investment of €45 million to accelerate infrastructure, scale, and operational capabilities. Kaisha Pharma enters the market with a complete tubular glass portfolio — ampoules, vials, prefilled syringes, and cartridges — together with advanced Ready-to-Use (RTU) platforms for vials, prefilled syringes, and cartridges. These solutions are designed to enable safer, faster, and more efficient fill-finish operations while meeting the increasingly stringent expectations of global pharmaceutical manufacturers. The manufacturing complex will span over 300,000 square feet, with fully integrated state-of-the-art production lines, sophisticated high-end camera inspection systems, and fully equipped laboratories incorporating the latest analytical and testing equipment.  ]]> https://biospectrumindia.com/news/108/28416/agilent-launches-new-laboratory-solutions-in-india.html https://biospectrumindia.com/news/108/28416/agilent-launches-new-laboratory-solutions-in-india.html Thu, 03 Sep 2026 16:05:25 +0530 Agilent Technologies has announced the India launch of the Agilent 9500 Triple Quadrupole ICP-MS, the new 8890B and 8860B Gas Chromatography Systems with GC Assist, and OpenLab Sync, Agilent's new Lab Execution System (LES) that brings guided digital workflows directly to the bench. Together, the solutions address three critical areas of laboratory operations: analytical performance, instrument productivity and workflow execution. The Agilent 9500 Triple Quadrupole ICP-MS helps laboratories generate reliable results across complex sample matrices. Designed for applications ranging from pharmaceutical testing and food safety to environmental analysis and advanced materials research, the system simplifies elemental analysis through new technologies that reduce analytical interferences and streamline operation. The new Agilent 8890B and 8860B Gas Chromatography Systems with GC Assist help laboratories keep instruments running efficiently through built-in monitoring, diagnostics and guided maintenance.  OpenLab Sync digitises laboratory procedures that are traditionally managed on paper, creating guided digital workflows that improve consistency, traceability and audit readiness.  The products were unveiled at a customer event in Mumbai that brought together scientists, laboratory leaders and quality professionals from the pharmaceutical, food, environmental, chemicals and research sectors.  ]]> https://biospectrumindia.com/news/108/28417/novonesis-injects-600-m-to-build-next-generation-enzyme-production-facility-in-india.html https://biospectrumindia.com/news/108/28417/novonesis-injects-600-m-to-build-next-generation-enzyme-production-facility-in-india.html Thu, 03 Sep 2026 16:48:38 +0530 Denmark-based Novonesis will expand its facility in Patalganga, Maharashtra and build one of the world’s most advanced enzyme production facilities. The €600 million investment will increase Novonesis’ production capacity to meet rising worldwide demand for the company’s biosolutions and strengthen the flexibility and resilience of its global supply network. The Patalganga expansion is a milestone in Novonesis’ strategy and key to achieving the company’s growth ambitions. The facility, which is expected to be fully operational in 2030, will produce enzymes for a broad range of industries, including biofuels, household care, and food and beverages. This state-of-the-art facility will be integrated into the company’s global production footprint and bring Novonesis closer to customers across the Middle East, India, and Africa. These markets represent an important and growing part of the company’s business and are expected to grow faster than developed markets in the coming years. Patalganga is part of a series of investments Novonesis has made to strengthen its global production setup and serve customers more effectively. Facilities in Rayong, Thailand; Franklinton, North Carolina; Taicang, China; Araucaria, Brazil; and West Allis, Wisconsin, have also been expanded as part of this effort.  ]]> https://biospectrumindia.com/news/108/28424/rpg-active-pharma-acquires-api-business-of-raghava-life-sciences-for-rs-135-cr.html https://biospectrumindia.com/news/108/28424/rpg-active-pharma-acquires-api-business-of-raghava-life-sciences-for-rs-135-cr.html Thu, 03 Sep 2026 19:35:00 +0530 Mumbai-based RPG Life Sciences has announced that its wholly owned subsidiary, RPG Active Pharma (RPGAP), has entered into a Business Transfer Agreement to acquire the Active Pharmaceutical Ingredients (API) and Intermediates business undertaking of Raghava Life Sciences on a going-concern basis through a slump sale. Acquisition of the API and intermediates business undertaking for consideration up to Rs 135 crore, subject to customary adjustments and closing conditions, adds approximately 300 KL of installed capacity in a state-of-the-art EU-GMP approved plant and a portfolio of 22 commercialised APIs plus 7 under development, with strong regulatory approvals.  The acquisition is the next step in RPGAP's consolidation play based on a well-planned buy-and-build strategy to bolster organic growth and create an integrated, scaled API focused organization. Following the recent acquisition of Actis Generics, this transaction broadens RPGAP's manufacturing base, product portfolio, regulatory capabilities and customer access across geographies. Raghava operates a modern API manufacturing facility near Hyderabad, spread across approximately 9 acres, with around 300 KL of installed capacity and a dedicated R&D set-up. ]]> https://biospectrumindia.com/news/108/28407/luma-fertility-plans-to-expand-to-30-centres-nationally.html https://biospectrumindia.com/news/108/28407/luma-fertility-plans-to-expand-to-30-centres-nationally.html Wed, 02 Sep 2026 13:23:53 +0530 Mumbai-based startup Luma fertility, backed by Peak XV’s Surge, with participation from Ameera Shah (Metropolis Healthcare) and Vijay Taparia (B2V Ventures), has announced strong momentum in its inaugural year, with its flagship Mumbai centre reaching break-even while recording a 77% self-cycle success rate, 120 ongoing pregnancies and 22 Luma babies. The company expects to grow revenue by 30% quarter-on-quarter going forward, reflecting its growing patient base, treatment volumes and strong clinical outcomes. Building on this momentum, Luma plans to expand to 30 centres nationwide, with three additional centres in Mumbai marking the next phase of its expansion. As part of its commitment to making quality fertility care more accessible, Luma has also announced the Luma Hope Grant, which will fully fund 30 complete IVF treatment cycles beginning with the first cohort of 10 cycles for eligible individuals and couples. The initiative aims to address one of the most significant barriers to fertility treatment: affordability. By covering the cost of complete treatment cycles, Luma hopes to enable more people to pursue parenthood without financial constraints determining the quality of care they can access. Luma aims to build a new model of Fertility Care 2.0, where technology enhances clinical decision-making, transparency builds trust, and patient experience remains central to care. Its launch of India’s first outcome-oriented egg-freezing programme, Twelve for Herself, reflects this commitment to making fertility preservation more informed, transparent and outcome-focused.  Luma includes RFID-based gamete tracking, which provides enhanced traceability and identification of eggs, sperm and embryos at every stage of treatment, as well as AI-supported clinical workflows applied from initial patient assessment through embryo grading.  ]]> https://biospectrumindia.com/news/108/28396/maharashtra-fda-cancels-drug-sale-licence-of-ciplas-pune-cf-unit-over-compliance-irregularities.html https://biospectrumindia.com/news/108/28396/maharashtra-fda-cancels-drug-sale-licence-of-ciplas-pune-cf-unit-over-compliance-irregularities.html Sat, 29 Aug 2026 00:00:00 +0530 In a significant regulatory development for India’s pharmaceutical distribution ecosystem, the Maharashtra Food and Drug Administration (FDA) has cancelled the drug sale licence of a Pune-based Carrying and Forwarding (C&F) unit of Cipla Pharma & Life Sciences Limited following the identification of multiple compliance irregularities. The action, which came into effect on Thursday, follows regulatory scrutiny of the unit’s drug storage and distribution practices, including issues related to stock management, storage infrastructure, handling of expired medicines and compliance with an earlier recall direction. The development brings renewed attention to the increasingly rigorous compliance expectations surrounding pharmaceutical distribution and supply-chain operations in India, where maintaining product integrity extends well beyond manufacturing facilities to warehousing, inventory management, documentation, recalls and downstream distribution. Reactin Plus inspection triggers regulatory scrutiny According to the Maharashtra FDA, an inspection conducted in June identified concerns relating to Reactin Plus Tablets, a prescription medicine. Officials reportedly found that the medicine’s packaging carried an unauthorised claim describing the product as an “analgesic and antipyretic”. Following the inspection, the regulator seized stock valued at approximately Rs 11.19 lakh and directed the company to recall the tablets it classified as “misbranded”. The FDA subsequently alleged that the recall directions were not fully complied with. The regulator’s concerns, however, extended beyond the product labelling issue. A further inspection of the C&F unit’s drug sale and distribution system identified what the FDA described as improper storage arrangements and discrepancies between purchase and sale records and computerised inventory. The inspection also reportedly found differences between physical stock and computerised records, inadequate pallet and rack arrangements, and deficiencies in the documentation and procedures used for handling expired medicines. Medicines were also reportedly found stored directly on the floor at the facility. Together, these findings prompted the state regulator to move beyond corrective observations and take the more consequential step of cancelling the unit’s drug sale licence. Drug distribution emerges as a critical compliance frontier The regulatory action highlights an important dimension of pharmaceutical quality management: compliance does not end when a medicine leaves the manufacturing line. For pharmaceutical companies operating increasingly complex distribution networks, C&F facilities form an important bridge between manufacturers and downstream markets. Inventory reconciliation, appropriate storage, traceability, recall execution and documentation therefore remain integral elements of pharmaceutical quality and supply-chain governance. The Pune development illustrates how regulators are scrutinising not merely the quality of medicines themselves, but also the systems responsible for storing, tracking, recalling and distributing them. In an industry where supply chains have become more sophisticated and increasingly digital, discrepancies between physical inventory and electronic records can attract significant regulatory attention. Equally, an effective recall mechanism depends on companies being able to rapidly identify affected inventory, trace its movement and demonstrate that regulatory directions have been implemented. Maharashtra FDA signals stricter enforcement Maharashtra FDA Commissioner Tukaram Mundhe indicated that the regulator intends to maintain a firm approach towards violations across the pharmaceutical manufacturing and distribution chain. “Any violation of rules by any entity involved in the manufacture and distribution of medicines will invite strict action as per law,” Mundhe said, adding that the department would not show leniency on matters concerning drug safety and public health. The statement signals the regulator’s broader emphasis on accountability throughout the pharmaceutical value chain, particularly as India continues to strengthen its reputation as one of the world’s most important pharmaceutical manufacturing and supply hubs. The episode could consequently have relevance beyond an individual C&F facility. Robust warehousing practices, real-time inventory reconciliation, documented procedures for expired medicines and demonstrably effective product-recall systems are becoming increasingly important components of pharmaceutical compliance. Cipla contests FDA order, says no product safety concerns alleged Cipla Pharma & Life Sciences has contested the Maharashtra FDA’s decision. The company has also sought to distinguish the regulatory proceedings concerning the C&F operation from the safety and quality profile of its medicines. “As the issue is under judicial consideration, it would not be appropriate to comment further on the proceedings at this stage,” the company said. Importantly, Cipla further clarified that the order does not allege concerns relating to the “safety, quality or efficacy” of its products and, according to the company, does not involve or indicate a patient-safety issue. The matter is therefore now characterised by two distinct positions: the Maharashtra FDA’s enforcement action based on alleged regulatory and distribution-system irregularities, and Cipla’s decision to contest the order while emphasising that the action does not allege deficiencies in product safety, quality or efficacy. Why the development matters for India’s pharma industry For India’s pharmaceutical sector, the Pune case underscores the widening definition of quality and compliance. Historically, conversations around pharmaceutical quality have often centred on manufacturing plants, Good Manufacturing Practices (GMP), laboratory controls and finished-product testing. But modern pharmaceutical oversight increasingly encompasses the entire product journey — from manufacturing and release to storage, transportation, inventory control, distribution and, when required, recall. This makes C&F operators, warehouses and distribution centres increasingly important components of a pharmaceutical company’s overall quality architecture. As Indian pharmaceutical companies expand both domestic and international operations, stronger integration between quality systems and supply-chain infrastructure will be essential. Accurate digital and physical inventory reconciliation, documented storage practices and rapid recall execution are not simply operational efficiencies; they are increasingly fundamental regulatory requirements. The Maharashtra FDA action serves as a reminder that regulatory compliance must remain continuous across the pharmaceutical value chain. For companies, the larger takeaway is equally clear: the integrity of a medicine is protected not only by how it is manufactured, but also by how effectively it is stored, documented, traced, distributed and, when necessary, recalled. Cipla Pharma & Life Sciences Limited is an entity associated with Cipla Limited. The regulatory matter concerning the Pune C&F unit remains under judicial consideration.   Editor’s Note This is a developing story. BioSpectrum India will continue to follow the developments closely and update this report as further information and official responses become available. ]]> https://biospectrumindia.com/news/108/28379/piramal-alternatives-injects-rs-215-cr-in-kolors-healthcare-to-drive-next-phase-of-growth.html https://biospectrumindia.com/news/108/28379/piramal-alternatives-injects-rs-215-cr-in-kolors-healthcare-to-drive-next-phase-of-growth.html Wed, 26 Aug 2026 14:06:23 +0530 Mumbai-based Piramal Alternatives, the fund management division of the Piramal Group, has announced an investment of Rs 215 crore in Hyderabad-based Kolors Healthcare India, one of the market leaders in wellness chain industry in South India. The investment has been made through Piramal Alternatives’ India Credit Opportunities Fund II (PCF II) and will support Kolors’ next phase of growth, including the expansion of its clinic network, enhancement of existing infrastructure, diversification of its service portfolio and the strategic transformation of its centres under the “Kolors 2.0” initiative. Commenting on this development, Kalpesh Kikani, CEO, Piramal Alternatives, said “Kolors has built a strong brand and differentiated presence in the rapidly evolving wellness and preventive healthcare segment. Its focus on customer outcomes, disciplined execution and continued investment in technology and service innovation positions it well for sustainable growth. We look forward to supporting the management team in scaling the platform and creating long-term value.” Vijaya Krishna, MD, Kolors Healthcare India, said "The capital will enable us to accelerate clinic expansion, strengthen our infrastructure, broaden our service offerings and advance our Kolors 2.0 transformation." Venkata Shivaji Kuna, Executive Director, Kolors Healthcare India, said, “India’s growing wellness challenges require solutions that are accessible, personalised and outcome-driven. The combined strengths of Piramal Alternatives and Kolors will help us address these needs at scale. Through Kolors 2.0, we aim to build a stronger wellness platform that solves real lifestyle and preventive healthcare needs across India.” India’s wellness and preventive healthcare ecosystem is undergoing a significant transformation, supported by increasing consumer awareness, greater focus on preventive health, rising disposable incomes and growing demand for personalised wellness and aesthetic solutions. Against this backdrop, Kolors is well positioned to build on its established regional presence and expand its offering across high-growth segments. The investment further strengthens Piramal Alternatives’ track record of partnering with high-quality mid-market businesses and providing tailored capital solutions across the capital structure to support growth, transformation and value creation. ]]> https://biospectrumindia.com/news/108/28381/qure-ai-appoints-mihir-bhanushali-as-executive-vice-president-global-health-.html https://biospectrumindia.com/news/108/28381/qure-ai-appoints-mihir-bhanushali-as-executive-vice-president-global-health-.html Wed, 26 Aug 2026 19:02:05 +0530 Mumbai-based Qure.ai, an AI technology company focused on healthcare, has announced the appointment of Mihir Bhanushali as Executive Vice President, Global Health, as the company deepens its investment in AI-powered healthcare across low- and middle-income countries (LMICs). Bhanushali joins Qure.ai from Freshworks, where he was Senior Director, Global Sales. A seasoned commercial leader, he has built and scaled high-growth businesses across global markets, with earlier leadership roles at Rippling and Whatfix spanning sales, go-to-market strategy and commercial transformation. At Qure.ai, Bhanushali will lead the next phase of the company's growth across LMICs, with a focus on Africa, Southeast Asia, South Asia and Latin America. His mandate spans the company's solutions for infectious diseases, including tuberculosis and HIV, and care delivery across frontline health systems. Qure.ai is expanding beyond screening and early diagnosis into broader care delivery. At the centre of this expansion is Aira, Qure.ai's AI doctor and clinical co-pilot for frontline healthcare, which brings clinical intelligence, digital workflows and care coordination closer to the point of care, with applications across primary care, telemedicine, HIV, infectious diseases and pandemic preparedness.   ]]> https://biospectrumindia.com/news/108/28353/medicover-hospitals-launches-new-transcranial-magnetic-stimulation-lab-in-mumbai.html https://biospectrumindia.com/news/108/28353/medicover-hospitals-launches-new-transcranial-magnetic-stimulation-lab-in-mumbai.html Fri, 21 Aug 2026 17:45:50 +0530 Medicover Hospitals, Navi Mumbai, has launched its Advanced Transcranial Magnetic Stimulation (TMS) Laboratory, expanding access to non-invasive brain stimulation therapy for patients with selected psychiatric and neurological conditions. The facility will offer evidence-based TMS protocols for conditions including treatment-resistant depression, obsessive-compulsive disorder (OCD), anxious depression, post-traumatic stress disorder (PTSD), smoking cessation, and migraine, along with selected neurological applications where scientific evidence is evolving. These include stroke rehabilitation, post-stroke speech and language disorders, neuropathic pain, fibromyalgia, Parkinson’s disease, cerebellar ataxia, Alzheimer’s disease, and tinnitus. TMS uses controlled magnetic pulses to stimulate specific areas of the brain. The treatment is non-invasive and does not require surgery or general anaesthesia. Depending on the condition and protocol, TMS may be used to influence brain circuits involved in mood regulation, cognition, movement, pain processing, and other neurological functions. Patients undergo a detailed clinical assessment before treatment, and the protocol is selected according to the individual's condition and treatment goals. The new facility will provide TMS for Major Depressive Disorder, Treatment-Resistant Depression, Obsessive-Compulsive Disorder, Anxious Depression, Post-Traumatic Stress Disorder, smoking cessation, and migraine, along with selected neurological applications such as stroke rehabilitation and post-stroke speech and language difficulties. Other neurological conditions, including neuropathic pain, fibromyalgia, Parkinson’s disease, cerebellar ataxia, Alzheimer’s disease and tinnitus, may be considered for appropriate patients based on clinical assessment and available evidence. ]]> https://biospectrumindia.com/news/108/28308/kshipra-health-solutions-unveils-l3tx-red-light-therapy-cap-to-support-evidence-based-hair-restoration.html https://biospectrumindia.com/news/108/28308/kshipra-health-solutions-unveils-l3tx-red-light-therapy-cap-to-support-evidence-based-hair-restoration.html Fri, 14 Aug 2026 17:07:18 +0530 As hair loss concerns intensify among both men and women, people are increasingly seeking science-backed treatment options. Addressing this need, Mumbai-based Kshipra Health Solutions LLP has introduced L3Tx, a medical-grade LED Red Light Therapy Cap that supports hair regrowth while controlling intense hair fall by relying on clinically studied Low-Level Light Therapy (LLLT), also known as photobiomodulation. A brainchild of Kirtesh Jain and Utpal Limkar, Kshipra Health Solutions is envisioning making evidence-based, non-invasive hair restoration increasingly accessible by combining scientific innovation and patient-friendly technology, easing their use at home under a dermatologist’s guidance.  Using 120 medical-grade LEDs, the L3Tx Red Light Therapy Cap emits red light at a controlled wavelength of nearly 640 nm. The light energy treatment stimulates cellular activity within hair follicles. Relying on photobiomodulation, the therapy helps increase ATP (cellular energy) production, improves scalp circulation, reduces oxidative stress, and supports the natural hair growth cycle. Instead of replacing treatments suggested by dermatologists, L3Tx complements them given its wide-scale adaptability to therapies including Minoxidil, Finasteride, Platelet-Rich Plasma (PRP) and Growth Factor Concentrate (GFC). The L3Tx device is US FDA cleared and houses medical-grade LED technology supporting long-term use under professional guidance. Kshipra Health Solutions is working with dermatologists and hair restoration specialists to raise awareness around hair health, early diagnosis, and evidence-based treatments. Through education and innovation, the company aims to empower individuals to make informed decisions while advancing a more scientific approach to hair restoration. ]]> https://biospectrumindia.com/news/108/28288/wockhardt-launches-antibiotic-academy-for-scientific-dialogue-to-tackle-multidrug-resistance.html https://biospectrumindia.com/news/108/28288/wockhardt-launches-antibiotic-academy-for-scientific-dialogue-to-tackle-multidrug-resistance.html Mon, 10 Aug 2026 20:38:45 +0530 Mumbai-based pharma firm Wockhardt has announced the launch of Antibiotic Academy, an open scientific learning platform accessible to the registered medical fraternity across India. It aims to facilitate continuous medical education through the exchange of knowledge, scientific discussions, and the sharing of real-world clinical experience among healthcare professionals. This Academy is the first step in building a nationwide scientific movement. Wockhardt hopes to collaborate with clinicians across the country to strengthen the fight against antimicrobial resistance (AMR). Ultimately, the true measure of success will be the number of patients whose lives are saved through better-informed clinical decisions. "There is an urgent need not only to have a new antibiotic like Zaynich, but also to have a science-based platform that fosters constructive dialogue on antimicrobial resistance and its appropriate management. It is essential to use the right antibiotic for the right patient at the right time. We hope this Academy will create a deeper understanding of the current realities of drug resistance and promote evidence-based solutions that enable clinicians to save patients' lives," said Dr. Habil Khorakiwala, Founder Chairman, Wockhardt. "Practices that were considered appropriate a decade ago have been refined by new evidence on diagnosis, dosing, treatment duration and de-escalation. Any initiative that brings clinicians together to exchange knowledge and remain closely connected to science is a step in the right direction. Resistant organisms must be defeated—and patients must win" said Dr Subramaniam Swaminathan, President Clinical Infectious Diseases Society, India. ]]> https://biospectrumindia.com/news/108/28245/encube-ethicals-files-drhp-with-sebi-for-rs-3000-cr-ipo.html https://biospectrumindia.com/news/108/28245/encube-ethicals-files-drhp-with-sebi-for-rs-3000-cr-ipo.html Mon, 03 Aug 2026 15:01:46 +0530 Mumbai-based Encube Ethicals has filed its Draft Red Herring Prospectus (DRHP) with capital markets regulator, Securities and Exchange Board of India (SEBI) for its Initial Public Offering (IPO). The IPO, with a face value of Re 1, is a complete offer for sale of Rs 3000 crore by promoters – Mehul Madhusudan Shah, and Investor Selling Shareholder - Frontier Investment Holdings Pte. Ltd. The issue is being made through the book-building process, in line with SEBI ICDR Regulations, wherein not more than 50% reserved for Qualified Institutional Buyers (QIBs), not less than 15% for Non-Institutional Investors (NIIs), and not less than 35% for Retail Individual Investors (RIIs). Incorporated in 1995, the company is global specialty pharmaceutical formulations platform with deep domain expertise in technically complex topical and transdermal dosage forms, serving 50 countries including regulated markets such as the United States, UK and Europe, and India as of March 31, 2026. The company operates through three business verticals: its Global Generics business, Global Contract Development and Manufacturing Organization (CDMO) business, and India Branded Formulations business. Each serves different end markets and customer segments, supported by a unified platform comprising R&D, manufacturing infrastructure, quality management systems, and supply chain capabilities. The company serves as a comprehensive development and manufacturing partner for some of the global pharmaceutical companies across various geographies. Its revenue from operations was Rs 1,848.7 crore during FY26 as against Rs 1,085.9 during FY24.   ]]> https://biospectrumindia.com/news/108/28193/nova-ivf-unveils-advanced-embryology-lab-in-pune.html https://biospectrumindia.com/news/108/28193/nova-ivf-unveils-advanced-embryology-lab-in-pune.html Fri, 24 Jul 2026 22:10:37 +0530 Nearly 1 out of 6 couples face infertility across India, impacting both male and female equally. Male factor infertility now contributes to nearly 40–50% of infertility cases, while specialists are also seeing at least 30% of younger women in their late 20s and early 30s presenting with poor egg equality reflecting changing reproductive health trends. Addressing this growing need, Nova IVF Fertility, Lullanagar, Pune has launched an embryology laboratory built to internationally accepted standards. Equipped with advanced incubators, AI-assisted sperm and embryo assessment, electronic witnessing systems and continuous air quality monitoring, the facility is designed to help in embryo development, enhance patient safety and support more precise IVF outcomes.  Advanced safety systems such as RFID-based electronic witnessing, stringent quality control and continuous monitoring help ensure every embryo is handled with the highest level of precision and safety.  The IVF Laboratory is the heart of a fertility treatment as the embryo quality determines at least 40-60% of the result of IVF treatment. The laboratory provides highly controlled conditions where eggs, sperm and embryos are nurtured during the most critical stages of treatment. Dr PGL Lalit Kumar, Head Embryology & Scientific Director, Nova IVF Fertility, said, "In an IVF Lab, we are replicating what mother nature does in the womb. We follow all processes as per the ART Act 2021. We take utmost measures to ensure embryos are being safeguarded. To prevent the risk of gamete and embryo mix ups, we have implemented electronic witnessing system, a precision led technology in place, which monitors the gametes and embryos at all steps of IVF process. We also provide intense training to our embryologists across 120+ centers in 75+ cities in our embryology training academy in all practical aspects required in an IVF Laboratory." ]]> https://biospectrumindia.com/news/108/28175/hikal-commissions-cgmp-pilot-plant-in-pune-to-strengthen-pharma-capabilities.html https://biospectrumindia.com/news/108/28175/hikal-commissions-cgmp-pilot-plant-in-pune-to-strengthen-pharma-capabilities.html Wed, 22 Jul 2026 15:53:27 +0530 Hikal Limited, a leading partner to global pharmaceutical, crop protection and specialty chemical companies, has announced the successful commissioning of its enhanced current Good Manufacturing Practice (cGMP)-compliant pilot plant facility at its Pune Research & Technology (R&T) campus. The expansion strengthens Hikal's integrated capabilities across process development, scale-up, technology transfer and clinical-stage manufacturing at its Innovation Campus at Pune, enabling the company to partner more effectively with global pharmaceutical customers from early development through commercial manufacturing readiness. The upgraded pilot plant supports process development, technology transfer and clinical-stage manufacturing while adhering to global quality and regulatory expectations. By creating a stronger bridge between laboratory-scale research and commercial-scale production, the facility is designed to help customers accelerate development timelines, improve process robustness and generate high-quality material for regulated development programmes. It also enables the manufacture and supply of preclinical and clinical-phase development materials from the same R&T campus, allowing scientists and engineers to closely monitor processes, enhance cross-functional collaboration and reduce technology-transfer timelines to support timely project delivery for its innovator customers The new pilot facility is designed to support flexible, cGMP-compliant scale-up across a wide range of chemistries. Its infrastructure includes reactors ranging from 20 litres to 2,000 litres, with stainless steel and glass-lined materials of construction as well as distillation and filtration through advanced equipment, including Hastelloy Agitated Nutsche Filter Dryers (ANFD) The facility also offers broad process capabilities, including cryogenic reactions, hydrogenation capabilities and high-temperature reactions and high-vacuum distillation capabilities etc. ]]> https://biospectrumindia.com/news/108/28169/lupin-spins-out-two-oncology-programmes-to-kaveri-therapeutics-to-advance-oncology-strategy.html https://biospectrumindia.com/news/108/28169/lupin-spins-out-two-oncology-programmes-to-kaveri-therapeutics-to-advance-oncology-strategy.html Tue, 21 Jul 2026 13:43:34 +0530 Mumbai-based pharma major Lupin has announced the strategic spin-out of two oncology programmes – LNP7457 (PRMT5) and LNP8701 (SOS1),  through its wholly owned subsidiary, Lupin Inc., into Kaveri Therapeutics Inc., a US-based clinical-stage oncology company.  Kaveri will advance these programmes through global clinical trials. Under the terms of the agreement, Lupin Inc. will have a significant equity stake in Kaveri, provide seed funding, and grant them exclusive rights to the programmes. Kaveri will operate as an independent entity under the leadership of Chief Executive Officer Kristi Jones, a seasoned biopharmaceutical leader with a strong track record of building and advancing innovative companies, and Chief Medical Officer Dr Robert Pierce, who brings deep clinical expertise and will lead the company’s clinical development strategy.  Kaveri will seek to raise additional capital to fund its clinical development efforts. Notably, both programmes have demonstrated encouraging clinical progress, with LNP7457 (PRMT5) and LNP8701 (SOS1) each reporting positive data at the American Society of Clinical Oncology (ASCO) meeting in 2025 and 2026, respectively. ]]> https://biospectrumindia.com/news/108/28161/emcure-to-expand-use-of-poviztra-for-mash-indication-following-cdsco-approval.html https://biospectrumindia.com/news/108/28161/emcure-to-expand-use-of-poviztra-for-mash-indication-following-cdsco-approval.html Mon, 20 Jul 2026 17:50:04 +0530 Pune-based Emcure Pharmaceuticals has announced that Poviztra®, its co-marketed brand of innovator semaglutide (rDNA origin), will now be available for the treatment of non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis (F2-F3), following the Central Drugs Standard Control Organization's (CDSCO) approval of Wegovy® for the indication. The approval makes the innovator molecule from Novo Nordisk, the first and only GLP-1 receptor agonist approved in India for the treatment of the disease. It enables Emcure and its subsidiaries to offer the new indication through Poviztra®, expanding access to innovator semaglutide for patients living with a progressive liver disease that has long faced limited treatment options. MASH develops when excess fat accumulation in the liver leads to chronic inflammation, fibrosis and progressive liver damage. Closely linked with obesity, type 2 diabetes and other metabolic disorders, the disease is often asymptomatic until advanced stages, making timely diagnosis and intervention critical. The approval is supported by results from the global Phase III ESSENCE trial, in which semaglutide demonstrated resolution of steatohepatitis in 63% of patients and improvement in liver fibrosis in 37% of patients. One in three patients achieved both resolution of steatohepatitis and improvement in liver fibrosis, highlighting semaglutide's potential to address the underlying disease in addition to its established metabolic benefits. Poviztra® contains innovator semaglutide (rDNA-origin) that has already established its role in chronic weight management in persons living with obesity and are overweight with co-morbid conditions (example Hypertension, Dyslipedemia, Type 2 Diabetes, etc). Poviztra® is also approved and marketed already for obese patients with established cardiovascular disease as well as more recently for management of adolescent obesity with pediatric patients above 12 years and above.  ]]> https://biospectrumindia.com/news/108/28166/viatris-launches-support-project-in-maharashtra-to-combat-drug-resistant-tuberculosis.html https://biospectrumindia.com/news/108/28166/viatris-launches-support-project-in-maharashtra-to-combat-drug-resistant-tuberculosis.html Mon, 20 Jul 2026 21:56:05 +0530 Mylan Laboratories, a part of global healthcare company Viatris, has announced the launch of a new tuberculosis (TB) support project in Nagpur, Maharashtra.  The project, with a special focus on drug-resistant TB (DR-TB), is being implemented in partnership with the non-profit organisation Doctors For You, Nagpur Municipal Corporation and the City TB Office, Nagpur under a Public-Private Partnership model. TB continues to be a significant public health challenge in India, with the Nagpur district facing growing challenges in expanding TB preventive treatment coverage and strengthening molecular diagnostic capacity. The project is an 18-month initiative aligned with the Government of India’s National Tuberculosis Elimination Programme, adopting its Detect-Treat-Prevent-Build approach. It comprises timely and accurate diagnosis, TB preventive treatment uptake among household contacts, nutritional support for TB and DR-TB patients, and integrated coordination across diagnostic, preventive, and support services. Under the project, the key interventions would be processing more than 26,000 samples across four locations in the Nagpur district, household tracing of confirmed TB and DR-TB patients targeting 22,000 households and distributing more than 450 nutrition kits. “Since 2020, we’ve screened more than 1.5 million people for TB in India. Over the past five years, Viatris supported the TB Control Initiative, reaching more than 58,000 people in rural and tribal areas of Gadchiroli district, Maharashtra. We will continue to explore ways to support regional and national health priorities and look forward to continued collaboration for the health and well-being of people in Maharashtra,” said Lina Andersson, Head of Global Sustainability, Viatris.   ]]> https://biospectrumindia.com/news/108/28137/sharrp-ventures-leads-rs-100-cr-investment-in-naturis-cosmetics-first-institutional-funding-round.html https://biospectrumindia.com/news/108/28137/sharrp-ventures-leads-rs-100-cr-investment-in-naturis-cosmetics-first-institutional-funding-round.html Thu, 16 Jul 2026 17:05:34 +0530 Naturis Cosmetics, a CDMO specialising in the beauty & personal care (BPC) sector, has raised Rs 100 crore in its first external funding round. The investment was led by Sharrp Ventures, with participation from Mirabilis Investment Trust (Infosys Co-founder K. Dinesh Family Office), financial growth equity investors Anicut Capital and Niveshaay, D2C ecosystem leaders including Suyash Saraf (Hyperscale Ventures) and Yogesh Kabra, along with several prominent angel investors from pharma and specialty chemical ecosystems.  The Mumbai-based company has partnered with several pharmaceutical companies like Glenmark and Dr. Reddy’s Laboratories for new-age OTC and cosmeceuticals backed by unique technologies.  The fresh capital will enable Naturis Cosmetics to accelerate its vision of leading the next decade of innovation and growth in the BPC sector. It aims to become the platform of choice for beauty, personal care, and wellness brands across D2C, FMCG, and OTC pharma. The company also plans to expand its geographical presence across the country by establishing a new state-of-the-art production unit in Vapi, spanning 225,000 sq. ft, an experience centre in the NCR region, and a new R&D centre in Mumbai. Additionally, it will significantly scale its team across verticals.  Over the next five years, Naturis intends to diversify into high-growth categories, including men’s grooming, body care, colour cosmetics, fragrances, and exports, while strengthening its capabilities in OTC pharma. The company also plans to deepen its innovation funnels with both existing and new brands.    ]]> https://biospectrumindia.com/news/108/28128/warburg-pincus-buys-mumbai-based-pharma-firm-integrace-for-rs-1200-cr.html https://biospectrumindia.com/news/108/28128/warburg-pincus-buys-mumbai-based-pharma-firm-integrace-for-rs-1200-cr.html Wed, 15 Jul 2026 19:21:51 +0530 Warburg Pincus, the pioneer of global growth investing, has announced the acquisition of Integrace, a leading domestic formulations company focused on orthopaedics and gynecology, for Rs 1200 crore. Integrace has built a differentiated portfolio of more than 20 brands across attractive high-growth markets. Through its scientific marketing practices, the company has built trusted relationships with over 45,000 healthcare professionals across India, supported by a high-quality specialist prescriber base across orthopaedics and gynecologists. Industry veteran Rehan Khan, former Managing Director at MSD and Abbott India, will join Integrace as Chief Executive Officer to lead the company's next phase of growth in partnership with Warburg Pincus. As part of the transaction, existing shareholders True North and Temasek will fully exit their investment in the company. Warburg Pincus has been investing in India for three decades and, over time, has built one of the country's most established healthcare investment franchises. The firm has partnered with leading businesses across pharmaceuticals, medical technology, healthcare services and life sciences, including Metropolis, Laurus Labs, MedPlus, Meril Life Sciences and Appasamy Associates. The investment in Integrace builds on this long-standing track record of partnering with exceptional management teams to create scaled, market-leading healthcare businesses. ]]> https://biospectrumindia.com/news/108/28154/gennova-biopharma-sells-mrna-biz-to-immunoscript-life-science-for-rs-139-5-cr.html https://biospectrumindia.com/news/108/28154/gennova-biopharma-sells-mrna-biz-to-immunoscript-life-science-for-rs-139-5-cr.html Sun, 19 Jul 2026 14:29:52 +0530 Emcure Pharmaceuticals has announced that its subsidiary, Gennova Biopharmaceuticals, has entered into a Business Transfer Agreement (BTA) to divest its mRNA business to Immunoscript Life Science. The transaction will be executed for a lump sum cash consideration of Rs 139.5 crore. This strategic move allows Gennova to reorganise operations and focus on core areas such as research and development, manufacturing, and marketing of biotechnology-based products, including biosimilars and adjacent therapeutic platforms. During FY2025-26, Gennova reported a turnover of Rs 491.7 crore.   The buyer, Immunoscript Life Science, is a Pune-based company promoted by Dr Sanjay Singh, formerly a director of Gennova. The company is focused on precision immunology, combining biological engineering, artificial intelligence and scalable biomanufacturing to develop next-generation vaccines and advanced therapeutics. Immunoscript was incorporated in April 2026 and is not part of Emcure's promoter or group companies.    ]]> https://biospectrumindia.com/news/108/28113/rpg-life-sciences-partners-with-archerchem-healthcare-to-launch-naprosyn-es.html https://biospectrumindia.com/news/108/28113/rpg-life-sciences-partners-with-archerchem-healthcare-to-launch-naprosyn-es.html Mon, 13 Jul 2026 17:23:37 +0530 Mumbai-based RPG Life Sciences has partnered with Archerchem Healthcare to launch Naproxen and Esomeprazole combination for the first time in India by strengthening the existing business relationship with Archerchem. Naprosyn ES is a combination of Naproxen and Esomeprazole, designed to deliver effective anti-inflammatory solution along with gastro-protection. The combination has been co-developed by Archerchem Healthcare along with its development partner. RPG LS will exclusively market and distribute Naprosyn ES across the country and Mumbai-based Archerchem as the exclusive supplier.   The product addresses a significant unmet need in patients requiring long-term Nonsteroidal Anti-Inflammatory Drug (NSAID) therapy, particularly those at risk of gastrointestinal complications. The differentiated formulation is expected to improve patient compliance and enable safer long-term pain management, especially among elderly and gastro-sensitive populations.   RPG Life Sciences will leverage the strong legacy and brand recall of Naprosyn brand and lean on its robust reach to a wide spectrum of doctors, including super-specialists, along with pan-India distribution network to drive distribution. The launch aligns with RPG Life Sciences’ continued focus on building a differentiated portfolio in chronic therapy segments. Naprosyn ES is available pan-India. ]]> https://biospectrumindia.com/news/108/28115/emcure-consolidates-gennova-biopharma-ownership-sharpens-focus-on-biologics.html https://biospectrumindia.com/news/108/28115/emcure-consolidates-gennova-biopharma-ownership-sharpens-focus-on-biologics.html Mon, 13 Jul 2026 18:04:36 +0530 Pune-based Emcure Pharmaceuticals has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals, alongside a leadership transition, as it sharpens its focus as a biologics and biosimilars company. Emcure is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova a wholly owned subsidiary. Gennova will be led by Samit Mehta and will focus on its biologics franchise — Elaxim®/TENECTASE®, Vintor®, Xgrast®/PEGEX® and Hamsyl® — biosimilars development, and adjacent therapeutic platforms, leveraging its established mammalian and microbial biomanufacturing platforms. Samit Mehta, Whole Time Director &CEO, Gennova Biopharmaceuticals Limited, said, “As part of the One Emcure framework, Gennova will continue to anchor the Group's biologics and biosimilars capabilities. Our work will complement Emcure's broader R&D and pipeline priorities, with a focus on execution, quality and disciplined development across our chosen therapy areas.” The transaction is not expected to have a material impact on Emcure’s consolidated financials or its capital allocation framework. The company’s deleveraging trajectory, capex plans and R&D investment plans remain unchanged. ]]> https://biospectrumindia.com/news/108/28093/avni-wellness-raises-rs-4-cr-to-scale-operations-in-femtech-and-womens-wellness-market.html https://biospectrumindia.com/news/108/28093/avni-wellness-raises-rs-4-cr-to-scale-operations-in-femtech-and-womens-wellness-market.html Thu, 09 Jul 2026 17:01:19 +0530 Mumbai-based startup Avni Wellness, a science-backed women's health brand building an integrated ecosystem across menstrual hygiene, cycle nutrition, and awareness-led care, has raised Rs 4 crore in a strategic funding round as it looks to scale its operations in India’s rapidly evolving femtech and women’s wellness market.The company operates in a category that is undergoing a structural shift, moving away from fragmented hygiene-led consumption toward lifecycle-based health models that integrate nutrition, preventive care, and long-term hormonal wellness. The feminine hygiene products market is projected to reach Rs 70.20 billion by 2025, reflecting steady category growth. However, women’s nutritional and hormonal wellness remains significantly underpenetrated in comparison, indicating a large whitespace for science-led brands to build more integrated and preventive health solutions. The round was led by Proteus Partners, Avni's earliest institutional backer, with the team playing an active role in building the ecosystem alongside the founder. Operator-investors Puru Gupta and Sreejith Moolayil (ex co-founders of True Elements) bringing direct D2C category expertise, while Dr A. Velumani (ex founder, Thyrocare) and impact investor Somya Nigam invested through Bharat ke Super Founders. Avni Wellness said the capital will be used to strengthen its digital commerce engine, expand its cycle nutrition portfolio, and scale its women led micro entrepreneur network to 10,000 entrepreneurs  across Bharat. Avni Wellness’ portfolio includes India’s first patented antimicrobial reusable pad and a liposomal iron supplement aimed at better nutrient absorption to address widespread iron deficiency among Indian women. The brand also offers solutions across PCOS care, calcium support, UTI and vaginal health, and seed-based hormonal nutrition, creating a comprehensive lifecycle approach to women’s health. ]]> https://biospectrumindia.com/news/108/28044/qr678-enters-european-market-with-germany-as-strategic-launchpad-for-qr678-x-pro.html https://biospectrumindia.com/news/108/28044/qr678-enters-european-market-with-germany-as-strategic-launchpad-for-qr678-x-pro.html Tue, 30 Jun 2026 13:56:16 +0530 Mumbai-based QR678® has announced its entry into the European market following the successful notification of its flagship formulation, QR678 X-PRO® Professional Hair Strengthening & Revitalising Formula, on the European Union Cosmetic Products Notification Portal (CPNP). The notification marks a key regulatory milestone enabling the introduction of QR678® products within the European Union, with Germany selected as the initial launch market. The expansion into Europe represents a significant advancement in QR678®'s global growth journey and reflects the increasing international adoption of structured, science-led approaches in hair biology and regenerative aesthetics. Germany has been identified as a strategic gateway market, given its strong clinical infrastructure, established dermatology ecosystem and role as a leading centre for medical aesthetics in Europe. This development builds on QR678®'s expanding international footprint across Asia and the Middle East, reinforcing its position as a globally recognised translational research and development platform in hair and scalp science. With over 150,000 patients treated globally across more than 1,000 clinics, QR678® continues to scale its presence through clinician-led adoption and protocol-driven use across markets. QR678® is a globally patented translational and clinical research and development platform in hair science, built on a deep understanding of hair follicular biology, regenerative aesthetics and structured biological signalling. ]]> https://biospectrumindia.com/news/108/28041/jupiter-hospital-deploys-indias-first-ai-driven-chiller-optimisation-system.html https://biospectrumindia.com/news/108/28041/jupiter-hospital-deploys-indias-first-ai-driven-chiller-optimisation-system.html Mon, 29 Jun 2026 18:48:27 +0530 Jupiter Hospital, Dombivli, Thane, has implemented India’s first healthcare deployment of Johnson Controls India’s Chiller Plant Optimiser (CPO), bringing artificial intelligence (AI) into one of the most critical yet often overlooked areas of hospital infrastructure—cooling systems. Designed as a fully on-premises solution, the CPO processes and stores all operational data within the hospital premises, without relying on the cloud. This ensures high levels of cybersecurity and data privacy, a key requirement for healthcare environments. Cooling infrastructure in hospitals extends far beyond comfort. Critical spaces such as operation theatres, ICUs, blood banks, pharmacies and imaging suites depend on tightly controlled temperature, humidity and air quality. Stable cooling is also essential for the reliable operation of high-value diagnostic equipment such as MRI and CT systems. Any disruption can affect clinical workflows, equipment uptime, medication storage and infection-control environments. HVAC systems account for 40–60% of a hospital’s total energy consumption, making them one of the largest contributors to operating costs. The chiller plant alone can account for up to 35% of a hospital’s electricity consumption. The AI-driven CPO integrates and automatically controls the entire chiller ecosystem, including chillers, primary pumps, condenser pumps and cooling towers. Using real-time adaptive controls, the system continuously adjusts equipment performance based on cooling demand and ambient conditions. The platform provides real-time visibility into plant operations and power consumption. Engineering teams can remotely monitor performance, receive control updates and track operational changes instantly. Every optimisation decision taken by the AI server generates notifications and control messages, ensuring complete transparency and traceability. Compared with traditional manual systems, the Chiller Plant Optimiser is expected to deliver energy savings of 15–20% on chiller plant consumption. Based on current estimates, this translates into an annual reduction of 127,500 kg of CO₂ emissions, supporting the hospital’s sustainability and ESG goals.   ]]> https://biospectrumindia.com/news/108/28012/reliance-owned-karkinos-healthcare-crosses-one-lakh-hpv-dna-tests.html https://biospectrumindia.com/news/108/28012/reliance-owned-karkinos-healthcare-crosses-one-lakh-hpv-dna-tests.html Wed, 24 Jun 2026 22:14:37 +0530 Karkinos Healthcare, a 100% step-down subsidiary of Reliance Industries Limited, has completed HPV DNA screening for over one lakh women across India, marking an important milestone in expanding access to high-quality cervical cancer screening and follow-up care. Cervical cancer prevention is often limited not only by access to screening, but also by loss to follow-up after a positive result. Mumbai-based Karkinos Healthcare’s model addresses both challenges through World Health Organization-recommended HPV DNA testing and a digitally enabled continuum of care that integrates awareness, screening, tracking, triage, navigation, and follow-up. The milestone has been achieved through multiple implementation models across diverse geographies, including public-health programmes, public-private partnerships, CSR supported initiatives, nurse-assisted and self-sampling programmes, district-level screening efforts, and focused outreach for underserved and high-risk communities. A large share of the women reached are those who, by circumstance or distance, may not otherwise have had access to screening. The achievement demonstrates that high-quality HPV DNA testing can be delivered at scale in India through technology-driven care pathways. The learnings and infrastructure developed through this programme can support wider adoption of organised cervical cancer screening and contribute to India’s cervical cancer elimination efforts. Commenting on this milestone, Dr Neerja Bhatla, Consultant, Early Detection and Women Wellness, Karkinos Healthcare, who is also a Padma Shri awardee and globally acclaimed leader in women’s health and oncology, said, “The evidence has been clear for some time that HPV DNA testing is the most reliable primary screen we have for cervical cancer. What matters now is not testing at scale alone but also ensuring that every woman who tests positive is carried through to diagnosis and treatment across the care continuum. A programme that can demonstrate that linkage at this volume, and well beyond the big cities, is exactly the direction India’s cervical cancer elimination effort needs.” ]]> https://biospectrumindia.com/news/108/28001/sun-pharma-acquires-100-outstanding-shares-of-innovcare-lifesciences-for-rs-271-cr.html https://biospectrumindia.com/news/108/28001/sun-pharma-acquires-100-outstanding-shares-of-innovcare-lifesciences-for-rs-271-cr.html Mon, 22 Jun 2026 15:57:03 +0530 Mumbai-based Sun Pharmaceutical Industries has agreed to acquire 100% outstanding shares of Innovcare Lifesciences, a company based in Mumbai and engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. The acquisition consideration is approximately Rs 271.2 crore in cash. While no governmental or regulatory approvals have been disclosed as required for the acquisition, the expected completion timeline is on or before 31 July 2026. The revenue from operations of Innovcare Lifesciences for FY 2025-26 was reported as Rs 94.06 crore. Sun Pharma will gain complete ownership of Innovcare Lifesciences upon completion of the transaction, expanding its presence in pharmaceutical, nutraceutical and cosmeceutical product categories. ]]> https://biospectrumindia.com/news/108/27986/virbac-announces-transition-of-globion-into-virbac-biologicals-to-strengthen-biologicals-and-vaccines-platform.html https://biospectrumindia.com/news/108/27986/virbac-announces-transition-of-globion-into-virbac-biologicals-to-strengthen-biologicals-and-vaccines-platform.html Thu, 18 Jun 2026 19:29:09 +0530 Mumbai-based Virbac Animal Health India has announced the successful integration of Globion into its ecosystem and its transition to Virbac Biologicals. This marks a significant milestone in strengthening Virbac’s biologicals and vaccines capabilities, with a focused emphasis on poultry. The transition reflects the coming together of strong scientific expertise, advanced manufacturing capabilities, and a shared commitment to advancing animal health outcomes. It further reinforces Virbac’s long-term strategy of delivering high-quality, science-led, and trusted solutions to veterinarians, poultry farmers, and animal health stakeholders. Virbac Biologicals will serve as a key pillar within Virbac’s animal health portfolio, enhancing its vaccines and biologicals platform and strengthening its ability to develop innovative solutions that support disease prevention, productivity, and sustainable animal healthcare. Looking ahead, Virbac Biologicals will continue to focus on science, quality, innovation, and customer trust, while further strengthening its manufacturing and research capabilities to meet the evolving needs of the animal health sector. “This integration brings together complementary scientific expertise and manufacturing strength, enabling us to better serve veterinarians, poultry farmers, and animal health stakeholders across IMEA. Our focus remains firmly on innovation, quality, and delivering trusted solutions that create long-term value for our customers and partners”, said Natesan Thanthoni, Area Director – India, Middle East & Africa (IMEA), Virbac Animal Health. ]]> https://biospectrumindia.com/news/108/27987/iit-b-opens-new-path-for-tackling-high-cholesterol-and-fat-related-disorders.html https://biospectrumindia.com/news/108/27987/iit-b-opens-new-path-for-tackling-high-cholesterol-and-fat-related-disorders.html Thu, 18 Jun 2026 19:38:22 +0530 Tucked inside liver cells, there are microscopic compartments called lipid droplets, temporary reservoirs for fats such as triglycerides and cholesterol. The liver packages some of these fats into tiny particles called very low-density lipoproteins (VLDL) and releases them into the bloodstream. But push this system too hard with a consistently high-fat diet, and then this natural process is disturbed and causes a dangerous build-up of lipids, paving the way for obesity, diabetes, and heart disease. Now, researchers at the Indian Institute of Technology, Bombay (IIT-B), along with collaborators from the Indian Institute of Science Education and Research (IISER) Pune, and IISER Kolkata, have uncovered one of the key cellular mechanisms that can interrupt this VLDL release from the liver by targeting the physical movement of lipid droplets instead of enzymes, receptors, or genes that are traditionally used for lowering lipids in the bloodstream. Importantly, interrupting this cellular mechanism does not cause lipid buildup in the liver—a critical safety advantage for future drug development. The findings open a potential new avenue for treating disorders such as high cholesterol and high triglycerides, as well as conditions like fatty liver disease. The work is at a preclinical stage, requiring future studies to assess long-term safety, optimise peptide delivery, and evaluate efficacy in mammals. Nevertheless, the study points toward a promising direction that has so far received little attention in the treatment of metabolic diseases. ]]> https://biospectrumindia.com/news/108/27957/mumbai-based-startup-denthome-secures-strategic-investment-from-bizdateup.html https://biospectrumindia.com/news/108/27957/mumbai-based-startup-denthome-secures-strategic-investment-from-bizdateup.html Sat, 13 Jun 2026 16:02:29 +0530 BizDateUp, in partnership with actor Taher Shabbir and producer-director Ashutosh Shah, has made a strategic investment in Mumbai-based startup Dent@Home, acquiring 25% stake in the company. Recently featured on Shark Tank India Season 5, the healthcare startup is pioneering portable and at-home dental care services for hospital-bound, homebound, immobile, and elderly patients. The investment will support the company's next phase of growth as it expands its bedside dental care model across India, with a focus on making professional oral healthcare more accessible, convenient, and patient-centric. Dent@Home has been working towards bridging the gap in oral healthcare accessibility by offering professional emergency & critical dental services at patient's homes and hospital bed particularly for elderly individuals, people with mobility challenges, and those seeking convenient access to quality dental care. The company plans to further strengthen its service network, enhance customer experience, and expand its operational footprint across key markets. The investment comes at a time when home-based healthcare services are witnessing growing adoption across India, driven by increasing senior citizens population, accessibility issues and personalized essential care. As healthcare delivery models continue to evolve to the increased youth immigration abroad and rising life expectancy, mobile healthcare solutions are emerging as an important component of elderly patient-centric care. ]]> https://biospectrumindia.com/news/108/27943/qubehealth-pay-closes-series-a-at-rs-416-cr-valuation-.html https://biospectrumindia.com/news/108/27943/qubehealth-pay-closes-series-a-at-rs-416-cr-valuation-.html Thu, 11 Jun 2026 16:44:44 +0530 QubeHealth-Pay, the healthcare payments processing company, has closed its Series-A funding round at a valuation of Rs 416 crore, backed by a clutch of deep-tech, fintech, and impact-focused family office funds that see healthcare as fintech’s next defining category. Unicorn India Ventures, IA Growth Opportunities Fund, Brew Opportunities Fund, Finvolve Ventures, FirstPort Capital, Maithan Family Office, and others participated in the round. When QubeHealth-Pay last announced its funding, in late 2024, it had indicated it would raise its Series A at a valuation of around Rs 270 crore. The strength of investor demand for vertical fintech — in a market as ripe for disruption as Indian healthcare — saw the round close at a significantly higher valuation. Qube is a vertical fintech: a financial platform engineered for the specific workflows of a single industry (i.e. Healthcare) rather than a one-size-fits-all product. Through its app, Indians pay for their family’s healthcare bills — at any hospital, clinic, doctor, diagnostic centre or pharmacy, anywhere in the country, with no network restrictions — earning instant cash-backs, and accessing instant medical finance for expenses their insurance does not cover. It also embeds access to employer health benefits funds, a user’s mutual fund savings, and government direct benefit funds, while rewarding each healthcare payment. Qube processed Rs 100 crore of healthcare payments in FY2025-26, is on a run-rate to cross Rs 240 crore in FY2026-27, and is targeting more than $1 billion by FY2029-30. Over 15,000 hospitals, clinics, and speciality providers — spanning diagnostics, dental, eye, skin, mental health, and more — hold special partnerships with Qube. ]]> https://biospectrumindia.com/news/108/27939/indias-pharma-exports-to-reach-50-billion-by-2030.html https://biospectrumindia.com/news/108/27939/indias-pharma-exports-to-reach-50-billion-by-2030.html Wed, 10 Jun 2026 21:25:26 +0530 The Department of Commerce, Government of India, organised an outreach programme at the Regional Office of the Pharmaceuticals Export Promotion Council of India (Pharmexcil) in Mumbai to highlight the Department’s major achievements, reforms and policy initiatives over the last 12 years. Mohit Yadav, Joint Secretary, Department of Commerce, highlighted India’s strong export trajectory, growing market diversification and deepening trade relations with key partner countries. He said the Government is working closely with industry to strengthen export capabilities, improve competitiveness and support India’s transition from volume-led exports to value-led exports. The sector has grown from about $20 billion in 2014 to nearly $60 billion in 2026 and is expected to reach $130 billion by 2030. India’s pharmaceutical exports have increased from $14 billion in FY 2015 to about $31 billion in FY 2026, registering a compound annual growth rate of 7.4 percent, with the ambition to reach $50 billion by 2030. The Joint Secretary noted that Maharashtra occupies a special place in India’s pharmaceutical journey. Mumbai, Pune, Chhatrapati Sambhajinagar, Tarapur and nearby clusters have emerged as important centres of pharmaceutical manufacturing, research, exports and skilled talent. Maharashtra’s pharmaceutical industry employs more than 200,000 people, including pharmacists, scientists and skilled manufacturing workers, and remains a major contributor to India’s pharma production and exports. He further said that India is emerging as a hub for pharmaceutical knowledge services. Multinational pharmaceutical companies are increasingly establishing Global Capability Centres (GCCs) in India, employing more than 100,000 professionals and attracting investments of over $1 billion. These centres support analytics, clinical operations, regulatory science, pharmacovigilance, digital health and research. The Joint Secretary stated that India’s trade agreements with key partners will open new opportunities for the pharmaceutical sector. Looking ahead, he said the next phase of growth will be defined by India’s movement from volume to value. Generics will remain the foundation of the sector, while future growth will increasingly be shaped by biosimilars, biologics, gene therapies, specialty medicines, vaccines, complex generics, contract manufacturing, medical devices and greater self-reliance in Active Pharmaceutical Ingredients and Key Starting Materials.   ]]> https://biospectrumindia.com/news/108/27928/agilus-diagnostics-launches-idylla-system-for-rapid-detection-of-cancer-mutations.html https://biospectrumindia.com/news/108/27928/agilus-diagnostics-launches-idylla-system-for-rapid-detection-of-cancer-mutations.html Tue, 09 Jun 2026 19:44:30 +0530 Agilus Diagnostics, subsidiary of Fortis Healthcare, has launched the automated Idylla molecular diagnostics system at its Goregaon laboratory in Mumbai, enabling rapid detection of cancer-related genetic mutations within 2.5 to 3 hours. The launch marks a significant advancement in accelerating clinical decision-making and expanding access to precision oncology in India. The Idylla system is a fully integrated, cartridge-based molecular testing platform that combines sample processing, nucleic acid extraction, amplification and detection into a single automated workflow. By minimising manual intervention and pre-analytical variability, the system delivers highly accurate and reproducible results in a significantly shorter timeframe compared to conventional molecular testing methods, which can take several days. This capability is particularly critical in oncology, where timely identification of actionable biomarkers plays a decisive role in guiding targeted therapies. The platform enables rapid detection of clinically relevant mutations, including: EGFR – commonly associated with lung cancer in Indian and Asian populations KRAS and NRAS – key markers in colorectal and pancreatic cancers BRAF – present across multiple tumor types, including melanoma and colorectal cancer Additionally, the system supports detection of emerging biomarkers such as MSI (Microsatellite Instability) and IDH1/IDH2, which are increasingly important in determining eligibility for advanced targeted and immunotherapies. With this addition, Agilus Diagnostics further enhances its integrated oncology diagnostics ecosystem, enabling faster, more efficient biomarker-driven treatment pathways and improved access to advanced cancer care. ]]> https://biospectrumindia.com/news/108/27929/ojas-maxivision-eye-hospital-expands-further-in-mumbai-with-new-centre.html https://biospectrumindia.com/news/108/27929/ojas-maxivision-eye-hospital-expands-further-in-mumbai-with-new-centre.html Tue, 09 Jun 2026 22:02:07 +0530 Ojas Maxivision Super Speciality Eye Hospitals has further strengthened their presence in Mumbai with the launch of the new centre in Juhu, while becoming one of the first eye care networks in the city to offer a comprehensive suite of next-generation vision correction and cataract technologies. As part of this expansion, the hospital has introduced the combination of ELITA SILK and WaveLight® Plus InnovEyes for the first time in Mumbai both under one brand (Bandra Centre), further reinforcing its position as a Centre of Refractive Excellence. WaveLight® Plus InnovEyes represents the next generation of personalised laser vision correction. The platform uses advanced artificial intelligence to create a highly detailed 3D digital twin of the patient's eye and virtually simulate treatment outcomes before surgery. The expansion further strengthens the collaboration between Ojas Eye Hospital and Maxivision Super Speciality Eye Hospitals, with Ojas Maxivision aiming to expand its network from 3 centres currently to 30 centres by FY31, serving over 3 lakh patients annually. By offering both technologies within a single Centre of Refractive Excellence, Ojas Maxivision enables surgeons to recommend the technology that is truly best suited to the individual patient, reinforcing the hospital's commitment to personalised eye care. Dr G. S. K. Velu, Chairman and Managing Director, Maxivision Super Speciality Eye Hospitals, mentioned, “Mumbai represents one of the most important growth markets for us in Western India. We are also planning to add three more centres in Mumbai in near future to make our hold stronger in the market.” Western India continues to be a key growth zone for Maxivision, contributing approximately 30-35% to overall revenues, with Mumbai accounting for nearly 30-35% of the West zone business. The network is targeting 20-25% CAGR growth across the West over the next five years. ]]> https://biospectrumindia.com/news/108/27930/fujifilm-india-announces-first-installation-of-ai-powered-digital-mammography-system-at-nm-medical.html https://biospectrumindia.com/news/108/27930/fujifilm-india-announces-first-installation-of-ai-powered-digital-mammography-system-at-nm-medical.html Tue, 09 Jun 2026 22:19:45 +0530 Fujifilm India, a leader in advanced diagnostic imaging solutions, has announced the installation of its latest AI Powered Digital Mammography System, AMULET SOPHINITY at NM Medical, Mmbai. India’s healthcare ecosystem is witnessing a growing emphasis on preventive healthcare and early disease detection, particularly in women’s health. According to estimates from the Indian Council of Medical Research, National Cancer Registry Programme, breast cancer is projected to remain the leading cancer among women in India, with over 2.32 lakh cases estimated in 2025.   As timely screening continues to play a critical role in enabling early diagnosis and improving clinical outcomes, rising awareness, expanding access to diagnostic services, and increasing adoption of advanced imaging technologies are further accelerating the need for clinically reliable, patient-friendly, and workflow-efficient mammography solutions across healthcare institutions in the country.Designed with a strong focus on patient comfort, diagnostic precision, and workflow efficiency, AMULET SOPHINITY represents Fujifilm’s next-generation mammography platform built around the philosophy of “Sophisticated Features. Human Comfort.”   The system integrates advanced AI-enabled technologies, high-definition imaging capabilities, and ergonomically designed patient-centric features to support radiologists and technologists in delivering accurate, efficient, and comfortable breast imaging experiences.Further strengthening workflow efficiency and positioning accuracy, the system integrates Fujifilm’s REiLI Medical AI technologies, including Intelligent AEC for optimised dose management based on breast composition, Positioning MAP for reproducible positioning support, and AI-driven Positioning Analysis tools that assist technologists in continuously improving imaging quality and consistency.The AMULET SOPHINITY platform also features a compact, space-saving footprint through integrated system architecture, enabling easier deployment across high-throughput hospitals, diagnostic centres, and space-constrained imaging environments. Its streamlined workflow design, user-friendly operation console, and rapid quality control tools further support operational efficiency and reliable clinical performance. ]]> https://biospectrumindia.com/news/108/27934/p-d-hinduja-hospital-signs-mou-with-dr-homi-bhabha-state-university-to-jointly-conduct-pg-allied-health-courses.html https://biospectrumindia.com/news/108/27934/p-d-hinduja-hospital-signs-mou-with-dr-homi-bhabha-state-university-to-jointly-conduct-pg-allied-health-courses.html Tue, 09 Jun 2026 22:55:27 +0530 Mumbai-based P.D. Hinduja Hospital & Medical Research Centre has signed a Memorandum of Understanding (MoU) with Dr. Homi Bhabha State University (HBSU) to jointly conduct postgraduate (PG) allied (paramedical) health courses. The hospital has been offering allied health sciences skill-based education in strategic partnership with the Lifesupporters Institute of Health Sciences (LIHS) for over a decade. The MoU aims to address the growing demand of skilled healthcare professionals and strengthen the quality of paramedical education in India. The programme expected to commence in August 2026 will be offered across multiple specialised areas with an intake of 20-30 students per course. Leveraging the academic expertise of Dr. Homi Bhabha State University, the clinical strengths of P. D. Hinduja Hospital, and the training expertise of LIHS, this collaboration seeks to bridge this critical gap and aligns with recent government priorities focused on strengthening allied healthcare education and workforce development. As part of this initiative, skill based postgraduate certificate programs will be offered in areas such as Pathology Technician, Dialysis Technician, Operation Theatre Technician (OT), Intensive Care Unit Technician (ICU), Radiology Technician, Medical Records & Health Information Technician, Neurology Technician, Central Sterile Supply Department Technician (CSSD), and Endoscopy Technician. The courses are designed to make students industry-ready within one year through a structured and intense training plan. ]]> https://biospectrumindia.com/news/108/27896/alkem-labs-introduces-semaglutide-in-single-shot-pre-filled-syringes.html https://biospectrumindia.com/news/108/27896/alkem-labs-introduces-semaglutide-in-single-shot-pre-filled-syringes.html Tue, 02 Jun 2026 18:20:47 +0530 Mumbai-based Alkem Laboratories has announced the launch of semaglutide in single-shot pre-filled syringes in multiple dose strengths at price starting Rs 350. Alkem is the first company in India to introduce semaglutide in single-shot pre-filled syringe format, expanding treatment options for patients and lowering entry barriers with its affordable pricing. The ready-to-use single shot pre-filled syringe format offers enhanced access, and convenience. The company has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise. In March 2026, Alkem had already launched semaglutide in pre-filled disposable and reusable injection pens format in the Indian market. The company has also received regulatory approval for semaglutide vials, which will be launched soon. ]]> https://biospectrumindia.com/news/108/27888/cdsco-grants-marketing-authorisation-to-wockhardts-drug-zaynich-for-treatment-of-complicated-utis-.html https://biospectrumindia.com/news/108/27888/cdsco-grants-marketing-authorisation-to-wockhardts-drug-zaynich-for-treatment-of-complicated-utis-.html Mon, 01 Jun 2026 19:36:33 +0530 Mumbai-based Wockhardt has announced that the Central Drugs Standard Control Organisation (CDSCO) has granted authorisation for the import and marketing of its indigenously discovered and developed, first-in-class breakthrough antibiotic, Zaynich® (Zidebactam / Cefepime) in India. The approval is for the treatment of adult patients (≥18 years) with complicated urinary tract infections (cUTI), including pyelonephritis, as well as cases with concurrent Gram negative bacteremia. The approval is supported by results from the pivotal ENHANCE-1 study, a multinational, randomized, double-blind Phase 3 clinical trial evaluating the efficacy and safety of Zaynich® compared with meropenem in patients with cUTI, including pyelonephritis. ZAYNICH® is an injectable antibiotic comprising of a β-lactam enhancer antibiotic, Zidebactam and Cefepime, a cephalosporin antibacterial drug. Zidebactam selectively inhibits penicillin-binding protein-2 (PBP2) while Cefepime primarily targets penicillin-binding protein-3 (PBP3) in Gram negative bacterial pathogens. Cefepime and zidebactam work together by binding to multiple PBPs, leading to bacterial killing. ZAYNICH has also received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the US FDA. ]]> https://biospectrumindia.com/news/108/27852/platinum-industries-enters-life-sciences-sector-with-focus-on-apis-and-intermediates.html https://biospectrumindia.com/news/108/27852/platinum-industries-enters-life-sciences-sector-with-focus-on-apis-and-intermediates.html Tue, 26 May 2026 16:23:37 +0530 Mumbai-based Platinum Industries, an innovation-driven specialty chemicals company, has announced its strategic entry into the life sciences sector, marking a significant step in its next phase of growth. As part of this expansion, the company has appointed Dr Abhigyan Upadhyay to lead its new life sciences enterprise. This move reflects Platinum Industries’ continued evolution from delivering advanced chemistry solutions to enabling applications that directly impact human health, an extension of its broader philosophy of translating chemistry into care through innovation, quality, and responsibility. The company aims to build a disciplined, research-driven, and globally scalable presence in high-value life sciences segments.  Dr Upadhyay brings over 25 years of global leadership experience across life sciences, regulated manufacturing, diagnostics, and research-led environments. In his previous roles, he has led large-scale businesses and driven transformation and market expansion across international markets in life sciences. He has also contributed immensely during the COVID-19 pandemic leveraging his critical life sciences capabilities by being involved in various clinical trials and research initiatives.   Platinum Industries is set to foray into the life sciences sector through its wholly owned subsidiary, Rivadu Lifesciences. The company will adopt a phased, innovation-led approach to building its life sciences business, with an initial focus on research-driven segments such as APIs and intermediates, working closely with partners and leveraging its strengths in execution and market access to build a scalable model with a strong presence not just in India, but across key international markets, including the Middle East, the United States, Europe, and Asia.  ]]> https://biospectrumindia.com/news/108/27839/hinduja-foundation-kings-college-london-launch-2026-healthcare-scholarship.html https://biospectrumindia.com/news/108/27839/hinduja-foundation-kings-college-london-launch-2026-healthcare-scholarship.html Mon, 25 May 2026 18:53:26 +0530 Hinduja Foundation, the philanthropic arm of the Mumbai-based Hinduja Group, has announced scholarships 2026 for Indian origin students to pursue the MSc in MedTech Innovation & Entrepreneurship at King’s College London. In 2024, the Hinduja Foundation UK made a significant philanthropic donation to King’s College London to establish the Hinduja King’s Health Partners’ Academy. This partnership includes support for  full four-year PhD studentships in healthcare technologies at the School of Biomedical Engineering and Imaging Sciences and one year MSc. MedTech Innovation and Entrepreneurship will benefit healthcare communities in both the UK and India. Furthermore, the partnership has brought nurses’ training, observer ships and online leadership training courses provided by Guy’s and St Thomas’ Hospitals NHS Foundation Trust to the P.D. Hinduja Hospital, Mumbai. Three PhD and two MSc Hinduja scholars started their studies at Kings College London in October 2025 and one PhD scholar joined in February 2026. Applications are still welcome for four PhDs and five MSc scholarships for the coming 2026- 2027 academic year starting in October. Applications are open until 30 May 2026. Meanwhile five MSc MedTech Innovation and Entrepreneurship scholarships are available – one at 80 pe cent and four at 50 per cent for Indian citizens.  The scholarships will empower Indian students with access to global expertise, real-world healthcare environments, and innovation-led learning, enabling them to address critical clinical needs and contribute to the future of healthcare in India and globally at King’s College London, recognised for its excellence in education and research. It is committed to driving positive and sustainable change through impactful research, outstanding education, and service to society, both in the UK and globally. ]]> https://biospectrumindia.com/news/108/27797/borderplus-launches-indias-first-national-standardised-exam-for-nurses-seeking-international-careers.html https://biospectrumindia.com/news/108/27797/borderplus-launches-indias-first-national-standardised-exam-for-nurses-seeking-international-careers.html Tue, 12 May 2026 14:32:51 +0530 BorderPlus, a Mumbai-based global talent mobility platform, has announced the launch of B.R.I.D.G.E (BorderPlus International Deployment and Global Mobility Exam), the country's first standardised national examination designed to assess and prepare Indian nurses for international placement, with a primary focus on career opportunities abroad. B.R.I.D.G.E introduces a merit-based scholarship model with a total pool worth Rs 1 crore+, designed to directly reduce the cost of training the nurses are required to undergo to upskill themselves for an international career. The exam is structured across three sections: Basic Clinical Skills, which tests foundational nursing knowledge including patient safety, vitals, and medication management; International Career Readiness, which assesses cross-cultural communication, language proficiency, and global healthcare awareness; and a Psychometric Assessment that evaluates resilience, adaptability, and decision-making. The 80-minute examination will be held on 19 July 2026 at BorderPlus Finishing School centres in Pune, Kochi, and Noida, with registrations closing on 30 June 2026. The results will be announced on 10 August 2026. The exam is open to B.Sc. Nursing and GNM diploma holders, fresh graduates and experienced nurses alike preferably below 35 years of age. The 2026 cohort is limited to 300 seats, with candidates ranked beyond that placed on a waitlist. "Germany has an urgent, growing need for skilled nurses and India has the talent to meet it. What's been missing is a structured, trustworthy bridge between the two. B.R.I.D.G.E gives nurses a fair, standardised way to demonstrate their readiness, and gives us the ability to identify and invest in the right candidates at scale. We want this opportunity to reach every eligible nurse in the country” said Ashish Labroo, Business Head, BorderPlus. ]]> https://biospectrumindia.com/news/108/27770/germanys-ottobock-teams-up-with-celcius-logistics-to-build-prosthetics-warehouse-and-logistics-distribution-in-india.html https://biospectrumindia.com/news/108/27770/germanys-ottobock-teams-up-with-celcius-logistics-to-build-prosthetics-warehouse-and-logistics-distribution-in-india.html Thu, 07 May 2026 15:32:57 +0530 Celcius Logistics, a leading domestic 3PL logistics player providing end-to-end cold-chain solutions, has partnered with Ottobock India, the Indian arm of Germany’s Ottobock, to set up a dedicated prosthetics warehouse and logistics distribution hub in India. The company has also launched a tech enabled warehouse facility in Thane.  The facility will support the medical supply chain by reducing turnaround times and enabling nationwide access to prosthetic and assistive devices. Mumbai-based startup Celcius Logistics will leverage its network to manage the distribution of prosthetic limbs across India, enabling movement of products to clinics and partners in multiple regions. The 3,000 sq. ft. facility features ambient storage, 110 slotted angle racks with over 700 bin locations, and a 100 sq. ft. temperature-controlled area for sensitive medical materials. Designed to support efficient inventory management and faster order fulfilment, the facility operates through processes aligned with standard quality and handling protocols. The facility is equipped to manage over 2,000 SKUs and support seamless distribution across 24 clinics and more than 200 independent partners, including associations with the Government of India. Prosthetic manufacturing and distribution require controlled storage conditions to maintain product integrity, durability and performance. The inclusion of a dedicated temperature-controlled zone within the facility supports proper handling of sensitive components and ensures consistent quality, enabling reliable delivery of prosthetic solutions to patients. Celcius will manage end-to-end warehouse operations and transportation, leveraging its in-house WMS(warehouse management solutions) and TMS(Transport management solutions) for inbound, outbound, inventory management, and nationwide distribution. The facility is exclusively dedicated to Ottobock and is now operational, under a five-year contract. Looking ahead, the partners plan to expand the warehouse capacity by 25% within the next year, in line with growing demand and scale of operations. ]]> https://biospectrumindia.com/news/108/27764/thyrocare-opens-new-state-of-the-art-genomics-lab-in-navi-mumbai.html https://biospectrumindia.com/news/108/27764/thyrocare-opens-new-state-of-the-art-genomics-lab-in-navi-mumbai.html Wed, 06 May 2026 19:27:29 +0530 Thyrocare Technologies, a leading healthcare diagnostics company in India to have achieved 100% NABL accreditation across all its laboratories, has announced the launch of its state-of-the-art genomics laboratory in Navi Mumbai. With this launch, Thyrocare is expanding its portfolio with a new range of speciality tests in genomics, powered by a state-of-the-art facility equipped with advanced next-generation sequencing technologies and supported by robust bioinformatics and data interpretation capabilities. Designed for high-throughput genomic analysis, the laboratory enables accurate, consistent, and scalable testing, delivering high standards of reporting excellence. This is further supported by a newly onboarded specialised on-ground team, ensuring seamless delivery and accelerating adoption of these advanced testing capabilities. Sharing his thoughts on the same, Rahul Guha, MD & CEO, Thyrocare and API Holdings said, 'At Thyrocare, we have consistently focused on building a diagnostics platform that is scalable, standardised, and accessible. The launch of our genomics laboratory marks a significant step forward in this journey, as we expand into advanced, high-impact areas of testing. As healthcare continues to move towards predictive and preventive care, genomics will play a critical role in enabling early insights and better clinical decision-making. With this expansion, we aim to make advanced genomics testing more accessible and affordable while continuing to build on our proven model of high-throughput, quality-driven diagnostics.”  The launch of the new genomics lab by Thyrocare in Mumbai highlights a pivotal shift towards preventive and data-driven healthcare in India. By the integration of advanced genetic insights with its strong diagnostic network, the company aims to support a more data-driven, preventive and personalised approach to healthcare in India.  ]]> https://biospectrumindia.com/news/108/27646/path-and-chri-introduce-amr-safe-disposal-innovation-challenge-2026.html https://biospectrumindia.com/news/108/27646/path-and-chri-introduce-amr-safe-disposal-innovation-challenge-2026.html Sat, 11 Apr 2026 00:00:00 +0530 In an effort to address antimicrobial resistance (AMR) and reduce the environmental risks associated with improper antibiotic disposal, the Centre for Health Research and Innovation (CHRI), a PATH affiliate, has launched the AMR Safe Disposal Innovation Challenge 2026 in collaboration with GSK cares, a CSR initiative. The challenge is open to students, innovators, researchers, and startups across India, inviting them to develop practical and scalable solutions that encourage responsible antibiotic disposal at the community level. Improper disposal of antibiotics, such as throwing them in household waste or flushing them, allows drug residues to enter soil and water systems, contributing to the growing threat of antimicrobial resistance. Through this initiative, CHRI aims to bring greater attention to this issue while supporting solutions that can work in real-world settings.  Participants are encouraged to submit ideas across a range of approaches, including safe collection and disposal systems, community-led awareness models, environmentally responsible practices, and technology-enabled platforms that improve access to safe disposal options. Selected solutions will be taken forward for potential pilot deployment across select districts in Maharashtra, giving teams an opportunity to test and refine their ideas in real community settings. Participants will also receive guidance from experts in antimicrobial resistance and public health, while continuing to retain full ownership of their intellectual property. Entries will be evaluated based on innovation, feasibility, scalability, and their potential to create meaningful public health impact. ]]> https://biospectrumindia.com/news/108/27593/4basecare-signs-mou-with-maharashtra-govt-to-establish-centre-of-excellence-for-precision-oncology.html https://biospectrumindia.com/news/108/27593/4basecare-signs-mou-with-maharashtra-govt-to-establish-centre-of-excellence-for-precision-oncology.html Tue, 31 Mar 2026 00:00:00 +0530 Bengaluru-based startup 4baseCare has signed a Memorandum of Understanding (MoU) with the Government of Maharashtra to establish a Centre of Excellence for Precision Oncology in the state.  The MoU aims to integrate genomic-driven cancer care into Maharashtra’s public health system. As part of the collaboration, 4baseCare will deploy its OncoTwin platform, an artificial intelligence (AI)-based tool that enables oncologists to derive actionable treatment insights by mapping each patient’s genomic and clinical profile against large, real-world outcomes datasets. OncoTwin was recently selected for the MSK iHub programme of Memorial Sloan Kettering Cancer Centre, New York, USA. The MoU signing took place at PULSE 2026, India’s leading Healthcare and Medical Education Summit, that was held in Mumbai recently.  Commenting on the MoU, Hitesh Goswami, CEO & Co-Founder, 4baseCare, said, “This MoU marks an important step towards creating more effective and personalized cancer treatment approaches, and we are pleased to see Maharashtra taking the lead in making this easily accessible to a wider population. At 4baseCare, our aim is to integrate genomic insights into routine cancer care, enabling oncologists to make more informed, evidence-based treatment decisions.” The Centre of Excellence will focus on enabling access to precision oncology, building local clinico-genomic datasets, and supporting oncologists across government healthcare institutions in Maharashtra with data-backed treatment insights. The Centre will be equipped with Next Generation Sequencing (NGS) technology to enable comprehensive genomic profiling for cancer patients. This will support Oncologists in making more targeted, personalised treatment decisions based on each patient’s genomic profile.   ]]> https://biospectrumindia.com/news/108/27594/rusan-pharma-unveils-indigenously-developed-aposan-3ml-pen-for-management-of-parkinsons-disease.html https://biospectrumindia.com/news/108/27594/rusan-pharma-unveils-indigenously-developed-aposan-3ml-pen-for-management-of-parkinsons-disease.html Tue, 31 Mar 2026 00:00:00 +0530 Rusan Healthcare, the marketing and distribution arm of Mumbai-based Rusan Pharma, has announced the launch of the multi-dose delivery pen device - APOSAN® 3ml Pen (Apomorphine Hydrochloride solution for injection in cartridge)(10 mg/ml)(3 ml pre-filled cartridges) for treatment of motor fluctuations commonly known as ‘ON-OFF’ episodes in patients suffering from Parkinson’s disease (PD). In 2018, Rusan was the first company in India to launch APOSAN® Apomorphine Hydrochloride solution for injection (10 mg/ml) (2ml and 5ml ampoules). Since APOSAN®’s launch in India, Rusan has observed remarkable clinical impact and consistently positive patient experiences, underscoring Apomorphine’s value as a transformative option in Parkinson’s management. The company now offers the complete range of Apomorphine Hydrochloride in different fill volumes, namely - 2ml injection, 3ml in pre-filled cartridge with a ‘Multi-dose PEN device’, and 5ml for continuous ‘Infusion PUMPS’ to meet distinct clinical scenarios in PD management, such as rapid rescue from OFF episodes using PEN devices and sustained symptom control using infusion PUMPS. PD is estimated to affect nearly 10 to 11.7 million people globally, with India accounting for a significant and growing share of the patient population. However, the clinical perception is shifting: Early‑Onset Parkinson’s Disease (EOPD), defined as diagnosis after the age of 20 years and before 50 years, now represents a growing share of the global burden, with incidence and prevalence tripling between 1990 and 2021. The APOSAN® 3ml PEN offers a multi-dose, dial-a-dose mechanism with an enhanced dose-visibility window, thereby enabling accurate and consistent dose administration. The APOSAN® 3ml PEN reduces handling complexity and supports safer, more reliable self-administration, reducing the risk of dosing errors. The APOSAN® 3ml PEN device’s lightweight, portable design enables convenient, dependable subcutaneous administration at home, empowering patients to manage their therapy promptly.   ]]> https://biospectrumindia.com/news/108/27580/maharashtra-holds-immense-potential-as-global-destination-for-integrated-healthcare-and-recovery-cm.html https://biospectrumindia.com/news/108/27580/maharashtra-holds-immense-potential-as-global-destination-for-integrated-healthcare-and-recovery-cm.html Fri, 27 Mar 2026 00:00:00 +0530 Highlighting the state’s long-term vision for healthcare, Chief Minister Devendra Fadnavis emphasised that Maharashtra holds immense potential to become a global destination for integrated healthcare and recovery. As the state progresses towards its 2047 vision, healthcare is being positioned not only as a social responsibility but also as a key driver of innovation, investment, and economic growth. Platforms like PULSE 2026 are expected to play a pivotal role in this journey by fostering centres of excellence, strengthening clinical research, encouraging collaboration between industry and academia, and attracting global partnerships. Chief Minister Devendra Fadnavis, Maharashtra was speaking after inauguration of PULSE 2026, India’s leading Healthcare and Medical Education Summit in Mumbai, on 27 March 2026.  The Chief Minister also highlighted the state’s focus on strengthening medical education, expanding postgraduate seats, integrating artificial intelligence in healthcare delivery, and developing a three-tier cancer care model to ensure continuity of treatment across regions.  Hasan Mushrif, Minister for Medical Education added, "Maharashtra is building a future-ready healthcare ecosystem by expanding medical education, strengthening infrastructure, and integrating technology, ensuring accessible, affordable, and quality care for every citizen."  Dedicated tracks on Digital Health & AI, Clinical Innovation, and Education Futures will explore scalable community healthcare models, virtual hospitals, AI-driven learning pathways, and emerging care delivery frameworks. Sessions will also address preventive and traditional medicine, chronic disease management, and the evolution of integrated, patient-centric care. The second day will focus on Health Systems & Workforce Transformation, highlighting strategies to build resilient healthcare systems, alongside discussions on startups, policy, governance, and medical ethics. Critical themes such as medical data sovereignty, national regulatory vision, and global scalability of Indian healthcare innovations will be explored.     ]]> https://biospectrumindia.com/news/108/27553/blockchain-for-impact-partners-with-csir-national-chemical-laboratory-and-iiser-in-pune.html https://biospectrumindia.com/news/108/27553/blockchain-for-impact-partners-with-csir-national-chemical-laboratory-and-iiser-in-pune.html Tue, 24 Mar 2026 00:00:00 +0530 A new partnership has been announced between Blockchain for Impact (BFI) and CSIR- National Chemical Laboratory (NCL), aimed at accelerating translational biomedical research and enabling healthcare impact. At its core, this collaboration is about moving promising science beyond the lab, into pathways that can shape better diagnostics, therapies, and patient outcomes.The projects being supported under this partnership are geared toward addressing critical disease areas:•⁠ ⁠Glioblastoma, through innovative metabolic modulation strategies•⁠ ⁠Sickle cell anemia, via next-generation hemoglobin modulators•⁠ ⁠Heart failure and osteoarthritis, through development of a biosimilar By enabling research and facilitating its journey toward application, this partnership seeks to build stronger innovation pipelines within India’s biomedical ecosystem. In addition, BFI has partnered with the Indian Institute of Science Education and Research (IISER) Pune to further efforts in translating biomedical research.This collaboration is anchored in advancing a deeper understanding of disease biology. The supported project uses advanced models and analytical techniques to understand how metabolic and immune systems interact, with the aim of identifying new targets for earlier diagnosis and improved treatment of chronic inflammatory liver diseases.Through this partnership, BFI and IISER Pune seek to strengthen pathways that connect discovery led research with real impact, contributing to effective healthcare solutions. ]]> https://biospectrumindia.com/news/108/27517/terumotata-elxsi-offshore-development-centre-opens-in-pune.html https://biospectrumindia.com/news/108/27517/terumotata-elxsi-offshore-development-centre-opens-in-pune.html Thu, 19 Mar 2026 00:00:00 +0530 Tata Elxsi, a global leader in design and technology services, and Terumo Corporation, a global medical innovation company, have inaugurated the ‘Terumo–Tata Elxsi Offshore Development Centre’ in Pune. This dedicated centre will support the development of Terumo’s cardiac and vascular solutions, strengthening engineering and innovation capabilities while enabling continuous lifecycle support across international markets. The centre brings together multidisciplinary teams, with Tata Elxsi’s expertise in design, engineering, verification, regulatory compliance, and localisation, along with the thoughtful application of AI, GenAI, and digital capabilities in software engineering. This enables faster development and regional adaptation while addressing the growing demand for patient-centric medical devices with improved cost efficiency and product differentiation. The collaboration advances the reliability and performance of cardiac and vascular technologies, supporting their global availability and helping ensure they meet industry standards and the evolving needs of healthcare providers and patients. Fumihisa Hirose, Company President, Cardiac & Vascular Company Terumo Corporation, said, “This new Offshore Development Center strengthens our ability to innovate faster and deliver high-quality medical technologies across global markets. Tata Elxsi’s integrated design, engineering, and regulatory expertise will help us accelerate our global product roadmap while maintaining the highest standards of safety and compliance.” Sreevatsa Sahasranaman, Sr. Vice President & Head – Healthcare & Life Sciences, Tata Elxsi, said, “This Offshore Development Center represents a comprehensive long-term partnership model with Terumo Corporation to bring Tata Elxsi’s multi-disciplinary, cross-functional and deep domain expertise to drive innovation and cost efficiencies across Terumo’s Cardiovascular portfolio. We are committed to combining design, engineering, and regulatory capabilities, enhanced by the latest AI- and GenAI-powered technologies, to help Terumo bring next-gen medical technologies to global and emerging markets.” ]]> https://biospectrumindia.com/news/108/27369/entod-pharma-unveils-ai-bio-engineered-collagen-skin-serum.html https://biospectrumindia.com/news/108/27369/entod-pharma-unveils-ai-bio-engineered-collagen-skin-serum.html Sat, 21 Feb 2026 00:00:00 +0530 Mumbai-based Entod Pharmaceuticals has announced the launch of COLLADERM™️, a global breakthrough in regenerative skincare. Officially unveiled at the 54th National Conference of the Indian Association of Dermatologists, Venereologists & Leprologists (DERMACON 2026), COLLADERM™️ introduces a first-in-class transdermal collagen gel serum designed for deep, structural skin regeneration. The product is now officially available in the market from February onwards. Developed in the UK using advanced AI-driven bio-engineering and exclusively licensed to Entod Pharmaceuticals for the Indian market, the COLLADERM™️formulation has been further optimised at the company’s DSIR-approved R&D centre in India. The product has been refined to address Indian skin biology, climatic conditions, and real-world clinical requirements. Collagen plays a central role in skin resilience, hydration, elasticity, and visible firmness. However, conventional collagen formats face practical limitations: injectable options are procedure-based and costly, oral collagen absorption can be inconsistent, and topical collagen often struggles to penetrate beyond the skin surface. COLLADERM™️ is engineered to overcome these barriers through advanced collagen bio-engineering and transdermal delivery science, supporting visible skin renewal, enhanced hydration, improved firmness, and a rejuvenated appearance. At the core of COLLADERM™️ is Entod’s proprietary Quattro Collagen System, which integrates Type III and Type XVII Recombinant Vegan Collagens (RVC), previously unavailable in India, in both high and low molecular weights for multi-depth biological action. This system is supported by TRANSCELLAR™️, a cold-processed transdermal liposomal delivery platform engineered to enhance penetration and cellular uptake. The formulation is further enriched with hyaluronic acid, glycerin, and vitamin C, supporting hydration, permeability, and collagen co-activation.   ]]> https://biospectrumindia.com/news/108/27317/maharashtra-opens-wellness-hub-for-holistic-sickle-cell-disease-care.html https://biospectrumindia.com/news/108/27317/maharashtra-opens-wellness-hub-for-holistic-sickle-cell-disease-care.html Wed, 11 Feb 2026 00:00:00 +0530 Novo Nordisk Education Foundation (NNEF) and Government Medical College and Hospital (GMC), Nagpur have inaugurated the first ‘Sickle Cell Wellness Hub’ in the state of Maharashtra aiming to deliver comprehensive and long-term care for people living with sickle cell disease (SCD).  This public-private partnership, supported by National Alliance of Sickle Cell Organisations (NASCO) as the knowledge partner, is aligned to the Government of India’s commitment of eradicating SCD from India by 2047 as part of its National Sickle Cell Anaemia Elimination Mission (2023) . Speaking on the sidelines of the ceremony, Vikrant Shrotriya, Managing Trustee, NNEF said, “Nearly 2 million Indians are estimated to be affected with sickle cell disease.  Among them, the tribal communities are the worst affected due to poorer health conditions, high morbidity & mortality and limited access to healthcare services." The SCD Wellness Hub will offer holistic care for people from economically constrained backgrounds living with the disease in the state of Maharashtra. A host of services shall be provided including timely diagnosis, access to care, constant monitoring, dietary adjustments and counselling for other self-care activities. The hub aims at improving the existing infrastructure for SCD care to make it children-friendly, while strengthening capacity building initiatives among healthcare professionals (HCPs) for better disease management. Additionally, regular educational and awareness camps shall be organised for people living with SCD and various caregivers. Maharashtra carries the one of the highest SCD burden in India, with Vidarbha being a high-prevalence region, particularly among tribal and socio-economically vulnerable communities. The prevalence of sickle cell carriers in different tribes across Maharashtra varies from 0 to 35%1. According to data published by the Ministry of Health & Family Welfare, 23,258 people have been identified to be living with SCD basis the ongoing screenings.  This underscores the urgent need for structured, accessible, and continuous care models. The SCD Wellness Hub in Nagpur is expected to improve early diagnosis and continuity of care for patients across the state. It also endeavours to enhance disease awareness and health-seeking behaviour by building capacity of healthcare providers at multiple levels. Additionally, it aims to reduce disease-related complications through better monitoring and adherence and contribute to state and national SCD elimination goals. ]]> https://biospectrumindia.com/news/108/27280/neuberg-launches-advanced-cytogenetics-fish-karyotyping-in-mumbai-for-cancer-prenatal-diagnosis.html https://biospectrumindia.com/news/108/27280/neuberg-launches-advanced-cytogenetics-fish-karyotyping-in-mumbai-for-cancer-prenatal-diagnosis.html Wed, 04 Feb 2026 00:00:00 +0530 Neuberg Sehgal Path Lab, a leading name in diagnostic services, has announced the launch of cutting-edge cytogenetics testing technology at its facilities in Mumbai. This advanced diagnostic tool is poised to revolutionise the approach to both cancer diagnostics and prenatal testing, offering a higher level of precision and personalisation for patients. Cytogenetics, a specialised field that focuses on studying genetic material within cells, is now available at Neuberg Sehgal Path Lab, utilising two powerful techniques: Fluorescent In-Situ Hybridisation (FISH) and Conventional Karyotyping. This technology enables the precise identification of chromosomal abnormalities, including translocations, deletions, and insertions—key indicators of various genetic disorders and cancer types. A rare offering by standalone labs in India, Cytogenetics is primarily conducted in large, standardised labs such as Tata Medical Center in Kolkata, Tata Memorial in Mumbai, CMC Vellore, and SGPGI in Lucknow. genetic abnormalities. Cytogenetics offers highly accurate detection of chromosomal abnormalities, aiding in the diagnosis of conditions such as Down syndrome during prenatal testing, as well as a variety of cancers, including acute promyelocytic leukaemia (APML) and Burkitt’s lymphoma. The cost of cytogenetic testing is relatively affordable compared to high-end molecular genetics, offering significant value for both prenatal and cancer diagnostics. ]]> https://biospectrumindia.com/news/108/27222/novo-medi-sciences-launches-next-gen-varicella-vaccine-built-on-advanced-formulation.html https://biospectrumindia.com/news/108/27222/novo-medi-sciences-launches-next-gen-varicella-vaccine-built-on-advanced-formulation.html Fri, 23 Jan 2026 00:00:00 +0530 Mumbai-based Novo Medi Sciences (Novo Group) has announced the launch of NEXIPOX PLUS®, the most recent innovation in Varicella vaccine since decades. NEXIPOX PLUS® has been developed with a clear focus on addressing the unique clinical, environmental, and operational needs of Indian patients and healthcare settings, making Novo Medi Sciences the only company to proactively upgrade varicella vaccine specifically for India. Live attenuated varicella vaccines are inherently thermolabile, making formulation stability and potency retention critical to ensuring effective immunisation outcomes. Recognising the challenges posed by real-world Indian conditions, NEXIPOX PLUS® has been developed with 2X trehalose-based stabiliser system, representing a significant evolution in formulation that are result oriented. By replacing conventional stabilisers such as gelatin and mannitol, the formulation enhances viral stability, preserves potency, and significantly reduces the risk of allergic reactions and antigen crystallisation-related issues, supporting more reliable vaccine performance across storage, handling, and administration.  The prevalence of chickenpox remains high in India, and the introduction of NEXIPOX PLUS® aligns with broader public health goals of reducing disease burden and improving vaccination compliance. Designed with affordability, scalability, and operational reliability in mind, the vaccine supports adoption in private practice and strengthens the overall immunisation ecosystem. NEXIPOX PLUS® is approved by the Drugs Controller General of India (DCGI) for use from 12 months of age. Backed by patented technology across 156 countries, the product reflects strong global regulatory readiness, with international expansion strategies being evaluated based on public health needs and sustainable supply considerations. ]]> https://biospectrumindia.com/news/108/27168/mumbai-opens-first-centre-of-excellence-for-craniofacial-temporomandibular-joint-surgery.html https://biospectrumindia.com/news/108/27168/mumbai-opens-first-centre-of-excellence-for-craniofacial-temporomandibular-joint-surgery.html Mon, 12 Jan 2026 00:00:00 +0530 S L Raheja Hospital, A Fortis Associate, has announced the launchof Mumbai’s first Centre of Excellence (CoE) for ‘Craniofacial & Temporomandibular Joint (TMJ) Surgery’, a centre to provide comprehensive and specialised care to patients with structural and functional issues, and injuries in the facial & jaw area. The newly launched CoE for TMJ Surgery is equipped to manage a wide range of conditions, such as jaw pain and stiffness, jaw locking or clicking, facial asymmetry, craniofacial deformities, cleft lip and palate, facial trauma, jaw cysts & tumours, and facial reconstruction. The centre focuses on applying minimally invasive and precision-based techniques to help restore jaw functionality and alleviate pain while promoting a faster recovery process. TMJ disorders are most commonly seen among adults aged 20 to 45 years, though they can affect people of all age groups. According to Dr Tofiq Bohra, Head – Craniofacial & TMJ Surgery, S. L. Raheja Hospital – A Fortis Associate, the hospital sees close to 50 TMJ-related patients every month; and this number has been increasing over the years.  The centre offers comprehensive, lifelong care for patients with cleft lip and palate, including surgical repair and rehabilitation from childhood through adulthood. The Multidisciplinary team at the CoE for TMJ Surgery works to restore facial structure and functioning for patients with cleft related conditions,  supported by expert dental team. Under the leadership of Dr Bohra, who has completed advanced training for TMJ Mini Residency at University of Maryland, USA - the centre brings together a robust team of oral and maxillofacial surgeons, pain specialists, neurologists, physiotherapists, and speech therapists to deliver comprehensive care that focuses on both function and aesthetics. This multi-disciplinary team will offer a range of services including nonsurgical treatments for pain to complex TM joint reconstruction, supported by advanced 3D imaging and planning.   ]]> https://biospectrumindia.com/news/108/27170/6-health-tech-startups-at-iit-b-to-receive-upto-rs-6-cr-cumulative-seed-funding.html https://biospectrumindia.com/news/108/27170/6-health-tech-startups-at-iit-b-to-receive-upto-rs-6-cr-cumulative-seed-funding.html Mon, 12 Jan 2026 00:00:00 +0530 The Technology Innovation Hub (TIH) at the Indian Institute of Technology (IIT) Bombay under the Department of Science and Technology (DST), Govt of India successfully concluded ATMAN 3.0, its eight-week accelerator programme designed to transform early-stage HealthTech startups into investment-ready businesses. The programme culminated in a Demo Day bringing together investors, healthcare leaders, industry experts, and policymakers to engage with some of the most promising healthcare innovations in the country. ATMAN 3.0 saw strong participation from across India, with 173 HealthTech startups pitching their ideas to TIH IIT Bombay. Following a rigorous selection and mentoring process, 6 startups emerged as winners from the final cohort of 13 accelerated ventures. On Demo Day, the selected startups were recommended for a total cumulative seed funding amounting to Rs 6 crore, with each startup receiving funding support of up to Rs 1 crore, subject to evaluation outcomes. The shortlisted startups are Prezitech Health Pvt Ltd, (Precigo: a snap-on needle tracking system for ultrasound machines for real-time procedural planning and guidance during high precision medical interventions), Attox Research Laboratories Pvt Ltd. (AMRIT for antimicrobial resistance),  Queliz Lifetech Pvt Ltd. (UltraHand, a robotic rehabilitation device), Deepfacts Private Ltd. (proRITHM is an AI-powered remote patient monitoring platform using a compact wireless, wearable device to track vitals in real time), MicroHeal and Raycura Medical Technologies (BETTER  a rehabilitation device for stroke/paralysis recovery). The gathering featured a keynote address by Dileep Mangsuli, Chairman of Cancer Treatment Services International and Senior Vice President at Siemens Healthineers, who noted, that the future of healthcare lies in delivering quality care at scale across geographies, with artificial intelligence playing a pivotal role in early screening and prevention. ]]> https://biospectrumindia.com/news/108/27026/medtronic-and-symbiosis-international-open-state-of-the-art-experience-centre-in-pune.html https://biospectrumindia.com/news/108/27026/medtronic-and-symbiosis-international-open-state-of-the-art-experience-centre-in-pune.html Thu, 04 Dec 2025 00:00:00 +0530 Symbiosis International (Deemed University), through its constituent institute, the Symbiosis Centre for Health Skills (SCHS), has entered a strategic collaboration with a global leader in healthcare technology Medtronic to establish the Symbiosis Medtronic Experience Centre, The TechKnow Verse, a pioneering training facility designed to advance healthcare education, training and practice in India. The Experience Centre in Pune represents India's first-of-its-kind integrated facility, bringing advanced surgical training and cadaver-based learning under one roof.  This state-of-the-art facility provides hands-on cadaver training using advanced Cranial, Spinal, and Orthopedic technologies including brain and spinal robotics, surgical navigation systems, and 3D imaging underscoring our commitment to experiential learning, innovation, and stronger academic–industry collaboration. The Experience Centre is designed as a continuous learning ecosystem that hopes to empower neurosurgeons, orthopedic, spine and ENT surgeons to learn essential skills through early exposure to experiential training. The Center aims to offer a platform to hone clinical techniques by practicing in real-world scenarios which will enable trainees to deliver quality patient care. Mandeep Singh Kumar, Managing Director & Vice President, Medtronic India, emphasised the shared vision behind the collaboration, "This collaboration underscores our shared commitment to advancing healthcare education and empowering clinicians with the latest healthcare technology and knowledge to address evolving clinical needs. At Medtronic, everything we do is guided by our mission to alleviate pain, restore health, and extend life. By elevating standards of care and improving patient outcomes, we continue to make that mission a reality." "This partnership is a tremendous opportunity for lifelong learning that will strengthen our healthcare professionals' clinical foundations," said Dr Rajiv Yeravdekar, Provost of the Faculty of Medical and Health Sciences at Symbiosis International University. "By providing access to advanced technologies and experiential training, we are directly contributing to improved patient outcomes and excellence in medical practice.". The Centre is expected to train super-specialists - neurosurgeons, spine surgeons, ortho surgeons & ENT surgeons, strengthening India’s healthcare workforce and contributing directly to improved patient success and serving as a hub for capacity-building, innovation and academic–industry collaboration. ]]> https://biospectrumindia.com/news/108/26959/govt-supports-techinvention-lifecare-for-development-of-16-valent-pneumococcal-conjugate-vaccine.html https://biospectrumindia.com/news/108/26959/govt-supports-techinvention-lifecare-for-development-of-16-valent-pneumococcal-conjugate-vaccine.html Fri, 21 Nov 2025 00:00:00 +0530 The Technology Development Board (TDB), Department of Science & Technology, Government of India, has sanctioned financial support to Mumbai-based startup TechInvention Lifecare for the establishment of a commercial-scale cGMP facility for the production of an indigenously developed 16-valent Pneumococcal Conjugate Vaccine (PCV-16). The supported project aims to strengthen India’s capability in next-generation conjugate vaccines and reduce long-term dependence on imported products through domestic innovation and manufacturing. The PCV-16 technology is built on a strategically selected panel of 16 pneumococcal serotypes, representing strains most associated with invasive pneumococcal disease (IPD), antimicrobial resistance and high fatality risks in India and other low- and middle-income countries. While 13 serotypes overlap with existing global PCV platforms, the inclusion of three emerging serotypes—12F, 15A and 22F—provides broader coverage against evolving non-vaccine serogroups, reinforcing the public-health value of this indigenous approach. The project reflects a science-based re-evaluation of serotype prioritisation, designed to support cost-effective immunisation for children, the elderly and vulnerable populations. The early upstream and downstream development was conducted at TechInvention’s BSL-2 facility within the BSC BioNEST Bio-Incubator, RCB Faridabad, and later advanced to the company’s GMP-aligned high-containment R&D centre, ‘HORIZON’, in Navi Mumbai. An Indian patent has been filed to safeguard the unique serotype design and process innovations. With TDB’s support, the project will now move towards full-scale cGMP manufacturing, ensuring that advanced conjugate vaccine technologies are developed, validated and commercialised within the country. The initiative is expected to significantly bolster India’s self-reliance in critical vaccines, enhance domestic biomanufacturing capacity and create pathways for future multivalent platforms.   ]]> https://biospectrumindia.com/news/108/26891/tenthpin-expands-footprint-in-india-with-launch-of-centre-for-life-sciences-cloud-solutions-in-pune.html https://biospectrumindia.com/news/108/26891/tenthpin-expands-footprint-in-india-with-launch-of-centre-for-life-sciences-cloud-solutions-in-pune.html Thu, 06 Nov 2025 00:00:00 +0530 Switzerland-based Tenthpin Management Consultants, a global leader in management and technology consulting for Life Sciences companies, has announced the launch of Centre for Life Sciences Cloud Solutions in Pune, establishing a Global Centre of Excellence dedicated to cloud and artificial intelligence (AI)-driven solutions to help transform Life Sciences business. The mission of this centre is to develop and deploy future-ready cloud solutions for Pharmaceutical, Medtech, Biotech, Healthcare, Animal Health and CDMOs to help them address the specific compliance & life science industry related nuances, enabling regulatory compliance, real-time insights, seamless data integration and enhanced collaboration across the global value chain. This will allow Life Sciences companies to accelerate breakthroughs and improve patient outcomes. These cloud solutions are becoming specifically relevant in the new therapies, Biotech and Advanced Therapeutic Medicinal Products, the new Internet of Medical Things (IoMT) as well as in the next generation of CDMOs. The latest state-of-art facility at Baner was inaugurated by Michael Schmidt, Founder and Member of the Executive Board of Tenthpin in the presence of Stephanie Marx, Partner and Key Account Delivery lead and Sachin Bhure, Partner and Managing Director, Tenthpin India.   Tenthpin Solutions, a group company of Tenthpin is also expanding its footprint in India. The new Pune centre will serve as a global hub for innovation — further enhancing next-generation cloud-based products and accelerators that help Life Sciences companies simplify complexity, ensure regulatory compliance and scale efficiently in a rapidly evolving digital ecosystem. This centre will also collaborate with local research institutions, universities, and industry partners to drive advancements of Life Sciences in India.   ]]> https://biospectrumindia.com/news/108/26870/alkem-foundation-and-iit-b-to-set-up-advanced-research-centre-for-immuno-therapeutics-and-regenerative-medicines.html https://biospectrumindia.com/news/108/26870/alkem-foundation-and-iit-b-to-set-up-advanced-research-centre-for-immuno-therapeutics-and-regenerative-medicines.html Mon, 03 Nov 2025 00:00:00 +0530 Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories, and Indian Institute of Technology Bombay (IIT-B) have announced a strategic collaboration to set up a first-of-its-kind research centre in India dedicated to immuno-therapeutics and regenerative medicines. Under this collaboration, Alkem Foundation will fund the establishment of “Alkem Centre for Advanced Research and Development of Applied Immuno-Therapeutics and Regenerative Medicines” in the IIT Bombay campus. This is a pioneering step in fostering cutting-edge research and innovation in complex disease areas, which have significant unmet medical needs. Alkem Foundation will contribute a substantial 20-25% of its cumulative CSR obligations over seven years on this research centre. This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines. The partnership brings together Alkem’s pharmaceutical industry insights and experience in developing healthcare solutions, and IIT Bombay’s expertise in biomedical engineering, biosciences, and translational research, along with a pool of globally trained faculty, to create a distinctive innovation and translation ecosystem. The research centre is being developed with an objective of building a comprehensive ecosystem that enables innovation, research, and skill development in complex and underserved therapy areas, and bridging critical gaps in infrastructure, talent, and translational capability, especially in the area of high precision medicines. The initiative will augment IIT Bombay’s multidisciplinary approach to healthcare integrating biology, engineering, and data science to advance human health. The Institute’s pioneering research spans biotechnology, biomedical engineering, and cell and gene therapy, forming the foundation for next-generation immuno-therapeutics and regenerative medicine. Building on this strong foundation, the new research centre will expand into emerging areas such as gene editing and biomaterials and technology to bolster immuno-therapeutics and regenerative medicines using unique models based on futuristic techniques for delivery and edition. It will also serve as a training and incubation hub for clinician-scientists and biotech entrepreneurs, strengthening India's translational research ecosystem in life sciences. It will draw upon IIT Bombay's core faculty and have mentors from IIT Bombay and Alkem, as well as global experts from premier universities, who will advise on the research programmes. ]]> https://biospectrumindia.com/news/108/26820/icici-bank-pledges-rs-625-cr-to-set-up-radiation-therapy-facilities-at-tata-memorial-centre-navi-mumbai.html https://biospectrumindia.com/news/108/26820/icici-bank-pledges-rs-625-cr-to-set-up-radiation-therapy-facilities-at-tata-memorial-centre-navi-mumbai.html Sun, 19 Oct 2025 00:00:00 +0530 ICICI Bank, along with Tata Memorial Centre (TMC), has announced the commencement of construction of a new cancer care building at TMC’s Advanced Centre for Treatment, Research & Education in Cancer in Navi Mumbai, Maharashtra. Funded through the Bank’s CSR contribution of Rs 625 crore, the facility will be among India’s largest radiation therapy centres, equipped with cutting-edge cancer treatment technologies. This is part of the Bank’s larger commitment of Rs 1,800 crore to TMC for setting up of three state-of-the-art cancer care buildings, one each at Navi Mumbai in Maharashtra, Mullanpur (New Chandigarh) in Punjab and Visakhapatnam in Andhra Pradesh. The 11-storey building with a ground floor and two basements will span across 3.4 lakh square feet. It will house 12 state-of-the-art Linear Accelerators (LINACs), and other advanced cancer care equipment. LINACs deliver precise radiation to cancer cells thereby minimising damage to surrounding healthy tissues. The ‘ICICI Foundation Block for Radiation Oncology’ will serve 7,200 patients with radiation therapies annually, offering over two lakh radiation sessions to these patients. In addition, the block will provide OPD consultations and diagnostics to 25,000 new patients a year. It is expected to be completed by 2027. ICICI Foundation for Inclusive Growth, the CSR arm of ICICI Bank, will oversee its implementation.                                                                                                                       ]]> https://biospectrumindia.com/news/108/26821/biorad-medisys-accelerates-vascular-and-stroke-care-through-new-partnerships-and-technology.html https://biospectrumindia.com/news/108/26821/biorad-medisys-accelerates-vascular-and-stroke-care-through-new-partnerships-and-technology.html Sun, 19 Oct 2025 00:00:00 +0530 Pune-based Biorad Medisys has outlined a series of product development initiatives and investments in the neurovascular and peripheral vascular markets.  Biorad has invested in Frid Mind Technologies (FMT), a Belgium-based company founded by Noureddine Frid. FMT has developed a patented stroke-prevention product using advanced braiding technology. The technology has completed preclinical trials and two first-in-human cases with positive long-term follow-up.  In addition, Biorad has acquired 10 % stake in Motion Informatics (formerly Stroke Rehab), an Israel-based company specialising in stroke rehabilitation solutions. Motion Informatics manufactures and markets the US FDA-approved Stimel-03 device, which integrates NMES, FES, and Biofeedback technologies to support patient rehabilitation. Biorad also holds manufacturing and distribution rights for the device in select geographies, including India and the United States.  Commenting on these initiatives, Mr. J. M. Hegde, Managing Director, Biorad Medisys, said, “Our collaborations with FMT and Motion Informatics, together with our work in advanced braiding technologies, reflect our ongoing efforts in the field of vascular and stroke care.”  ]]> https://biospectrumindia.com/news/108/26805/serum-institute-of-india-and-cepi-supercharge-pandemic-response-preparedness-targeting-h5n1.html https://biospectrumindia.com/news/108/26805/serum-institute-of-india-and-cepi-supercharge-pandemic-response-preparedness-targeting-h5n1.html Tue, 14 Oct 2025 00:00:00 +0530 Norway-based Coalition for Epidemic Preparedness Innovations (CEPI) is collaborating with Pune-based Serum Institute of India (SII), part of Cyrus Poonawalla Group, to boost pandemic response preparedness using a baculovirus vaccine platform to target H5N1 bird flu as a prototype for a potential Disease X—an as-yet-unknown pathogen with pandemic potential.  Supported by CEPI funding of up to $16.4 million, SII will use its validated baculovirus-based platform to produce and compare two H5 antigens for a recombinant protein vaccine: a wild-type and an AI-optimised, broad-spectrum H5 antigen designed by scientists at Houston Methodist Research Institute. The broad-spectrum approach is designed to elicit immune responses across multiple strains of H5 viruses, rather than just one, making it particularly suited for use in unpredictable outbreak situations.  The collaboration will ultimately pressure-test the baculovirus platform's ability to quickly produce new antigens against H5 viruses, simulating a fast response to a future pandemic threat. The work will also serve as proof of concept for using AI to design vaccine antigens capable of inducing broadly protective immunity. Antigens are proteins that trigger an immune response and are a critical part of an effective vaccine.  Adar Poonawalla, CEO, Serum Institute of India, said, “Our validated baculovirus platform gives us the ability to rapidly develop and produce vaccines for emerging threats. This project will test that readiness in real terms, reinforcing our commitment to pandemic preparedness. The learnings will not only support faster response times but also ensure that effective vaccines can reach vulnerable populations without delay.” ]]> https://biospectrumindia.com/news/108/26800/hikal-unveils-state-of-the-art-high-potency-api-lab-at-integrated-innovation-centre-in-pune.html https://biospectrumindia.com/news/108/26800/hikal-unveils-state-of-the-art-high-potency-api-lab-at-integrated-innovation-centre-in-pune.html Mon, 13 Oct 2025 00:00:00 +0530 Hikal, the preferred long-term partner for leading global life sciences companies, has announced the inauguration of its state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) Laboratory at its Integrated Innovation Centre in Pune. This world-class facility marks a significant milestone in Hikal’s innovation journey, further strengthening its end-to-end CDMO capabilities and enhancing its ability to safely develop and test and deliver highly potent compounds for the global pharmaceutical industry. The new cGMP-compliant HPAPI Laboratory is equipped with state-of-the-art isolators designed to meet Occupational Exposure Band 5 (OEB-5) requirements. The lab is purpose-built to support the development of complex oncology and specialty molecules, including components of Antibody Drug Conjugates (ADCs), Peptide Drug Conjugates (PDCs), and Proteolysis Targeting Chimeras (PROTACs). The HPAPI Lab complements Hikal’s existing validation lab, process safety lab, solid state lab, flow chemistry lab, instrumentation and synthesis laboratories, creating a truly integrated innovation ecosystem at the Pune site. This ecosystem supports the seamless transition of projects, from early-phase studies to commercial manufacturing, covering scales from milligrams to >100 Kg batch size in its pilot plant. ]]> https://biospectrumindia.com/news/108/26779/entod-pharma-launches-indias-first-ocular-probiotic-blend-designed-for-healthy-eyes.html https://biospectrumindia.com/news/108/26779/entod-pharma-launches-indias-first-ocular-probiotic-blend-designed-for-healthy-eyes.html Tue, 07 Oct 2025 00:00:00 +0530 Mumbai-based ENTOD Pharmaceuticals, a global leader in eye health innovation, has announced the launch of OCUBIOME™, India’s first ocular probiotic blend designed for healthy eyes. This proprietary formulation has been exclusively developed by the company’s R&D at their Navi Mumbai research centre. With today’s fast-paced, screen-dominated lifestyles and rising corrective eye surgeries, conditions like dry eye syndrome and ocular discomfort are becoming widespread. Millions silently struggle with burning eyes, blurred vision, and post-surgical recovery issues every day. While existing therapies such as lubricants provide only short-lived relief, there remains a need for holistic, long-term solutions. OCUBIOME™ complements the action of lubricants by restoring ocular and gut microbiota balance, thereby adding sustained benefits to immediate relief Delivered in a convenient, mouth-melting, no-added sugar sachets, it offers a simple once-daily routine that helps supports ocular comfort, digital eye strain recovery and promotes long-term eye health. The launch marks a turning point for preventive eye care. As awareness around the gut–eye axis grows, OCUBIOME™ opens a new avenue for proactive management of eye health, offering patients a bold step beyond symptom relief. OCUBIOME™ will be available against the prescription of an eye doctor from November 2025. ]]> https://biospectrumindia.com/news/108/26699/metropolis-healthcare-acquires-kolhapurs-ambika-pathology-laboratory.html https://biospectrumindia.com/news/108/26699/metropolis-healthcare-acquires-kolhapurs-ambika-pathology-laboratory.html Fri, 19 Sep 2025 00:00:00 +0530 Metropolis Healthcare has announced the completion of its fourth acquisition in the last 10 months, with Dr. R.S. Patil’s Ambika Pathology Laboratory in Kolhapur joining the Metropolis network. Founded and operated by Dr Rajendra Sadashiv Patil, the NABL-accredited facility is among the region’s leading diagnostic providers and has been acquired through a Business Transfer Agreement. This marks a key milestone in Metropolis’ “String of Pearls” strategy, which focuses on building strong regional clusters and expanding access to advanced diagnostics across India. Established in 1995, Ambika Pathology Laboratory has built a strong reputation for quality, accuracy, and patient-centric care. The facility operates a central laboratory supported by 12 patient touchpoints and offers a comprehensive portfolio of tests. With nearly 75% of its revenue derived from B2C walk-in patients, Ambika has earned the trust of both patients and clinicians across Kolhapur and neighbouring towns. Its strong local connect makes it a strategic addition to Metropolis’ Western Maharashtra cluster, where the company already operates 19 laboratories across Pune, Kolhapur, Sangli, Satara, Solapur, Nashik, and Ahmednagar, supported by more than 200 patient service centres and a growing franchise network. Commenting on the acquisition, Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited said: “Maharashtra continues to be a key growth market for Metropolis, contributing nearly 40% of our total revenues. The acquisition of Ambika Pathology further strengthens our Western Maharashtra cluster and supports our ambition to make high-quality diagnostics accessible to more communities."   ]]> https://biospectrumindia.com/news/108/26664/peptides-complex-generics-symposium-2025-to-spotlight-indias-leadership-in-advanced-therapeutics-.html https://biospectrumindia.com/news/108/26664/peptides-complex-generics-symposium-2025-to-spotlight-indias-leadership-in-advanced-therapeutics-.html Thu, 11 Sep 2025 00:00:00 +0530 This landmark gathering, set to take place on 25–26 September 2025 at The Lalit, Mumbai, aims to spotlight India’s growing role in shaping the future of advanced therapeutics.  The inaugural edition brings together key stakeholders from industry leaders, academicians, pharmaceutical organizations and regulators, to foster cross-sector dialogue in this rapidly evolving domain  Peptides and complex generics are among the fastest growing and most challenging areas of drug development. With rising global demand, India is uniquely positioned to lead the conversation on innovation, manufacturing excellence, and accessibility in this field. PCG 2025 will serve as a stage to showcase groundbreaking research, foster strategic collaborations, and explore pathways for global impact.  Key Highlights of PCG 2025:  Plenary Panel on the Rapid Rise of GLP1 Drugs - Join us as leaders from Novo Nordisk A/S, Eli Lilly and Company, Dr. Reddy’s Laboratories Ltd., and Biocon Limited take the stage for an engaging discussion on the future and impact of the new ‘miracle’ drug in the Indian market.   Scientific Exchange at Scale – Gain insights from thought leaders, CXOs, and global industry powerhouses such as Danaher Group, Mettler Toledo, Swiss Business Hub, etc. Engage in panel discussions on cutting-edge topics like GLP-1 with experts from academia, pharma, and biotech niche.   Innovation Opportunities – Young researchers and innovators are invited to submit abstracts for a chance to win prestigious awards, travel grants, and international recognition for their work.   Exhibition Highlights – Explore solutions and offerings from leading global and domestic players including Rx Propellant Private Limited, Swiss Business Hub India, CPC Scientific Inc., Agilent Technologies, Inc., Zelle Biotechnology Private Limited, Sartorius AG, and more.    Networking & Partnerships – PCG 2025 will be a unique platform fostering collaboration between academia, industry, and policymakers, driving the future of peptides and complex generics together.  Speaking on the launch, Dr. Ratnesh Jain, Convenor of PCG 2025”, said:  “India’s pharmaceutical landscape has made significant strides in the generics space. With peptides and complex generics emerging as the next frontier, PCG 2025 aims to catalyze collaboration, inspire innovation, and position India at the forefront of global drug development.”  Why Attend?  This highly focused symposium brings together an action-oriented agenda featuring leading experts for vital conversations shaping the future of this domain.  For academia, PCG 2025 provides a chance to engage directly with industry leaders and showcase pioneering research.   For industry professionals, the symposium offers insights into cutting-edge science, regulatory pathways, and emerging opportunities.   For young scientists and entrepreneurs, PCG is a launchpad to gain recognition, mentorship, and potential collaborations.  The symposium will also feature keynote addresses, panel discussions, and interactive sessions that cover critical aspects of peptides and complex generics, from R&D breakthroughs and scalable manufacturing technologies to global regulatory trends and commercialization strategies.  Be a part of the dialogue that matters.  Be a part of #PCG2025.    Register Now: https://www.mumbaibiocluster.org/peptides-complex-generics-symposium   For any queries, reach out to Ms. Simran Siddiqui at marketing.associate@mumbai.biocluster.org     ]]> https://biospectrumindia.com/news/108/26588/brainhap-and-iit-bombay-announce-launch-of-brain-mapping-technology-neurocalm-42.html https://biospectrumindia.com/news/108/26588/brainhap-and-iit-bombay-announce-launch-of-brain-mapping-technology-neurocalm-42.html Mon, 25 Aug 2025 00:00:00 +0530 On 23rd August 2025, the AI–Drone–Robotics Workshop became the stage for a groundbreaking moment in education and technology, as BrainHap in association with the Indian Institute of Technology (IIT) Bombay and Aerobott unveiled NeuroCalm 42. With Atharva University and Rahul Education Trust joining as academic partners, the event blended neuroscience, artificial intelligence, drones, and robotics into a powerful vision for the future of learning. At the heart of the workshop was the unveiling of NeuroCalm 42, BrainHap’s revolutionary brain-mapping technology designed to analyse students’ cognitive skills, focus levels, and emotional balance. Developed in collaboration with IIT Bombay under the leadership of Jyoti Gupta, Founder of BrainHap, the solution is positioned as a timely response to the growing challenges of digital distractions and fragmented attention spans among learners. The event featured an expert session by Azizuddin Khan, Professor at IIT Bombay, whose three decades of research in psychology, neuroscience, and digital behaviuor emphasised the urgent need for cognitive training and digital wellness in today’s fast-evolving world. His insights underscored how brain mapping and emotional balance are essential tools for preparing students for the future. Sharing her vision, Jyoti Gupta said, “NeuroCalm 42 is not just technology, it is a movement to bring focus, calm, and emotional strength back into the lives of students. By merging neuroscience with AI, we are giving schools and parents a way to truly understand the minds of young learners and help them grow into balanced, confident individuals ready for the future.” ]]> https://biospectrumindia.com/news/108/26560/abbott-launches-next-gen-freestyle-libre-2-plus-in-india.html https://biospectrumindia.com/news/108/26560/abbott-launches-next-gen-freestyle-libre-2-plus-in-india.html Thu, 21 Aug 2025 00:00:00 +0530 Abbott, the global healthcare company, has announced the launch of the FreeStyle Libre 2 Plus sensor, Abbott’s latest addition to the FreeStyle Libre sensor portfolio. The launch took place at an event in Mumbai. This innovative device offers automatic glucose readings every minute straight to your phone, empowering people with diabetes to manage their condition with confidence, precision, and ease. People living with diabetes can see their glucose readings, without having to scan, and receive alerts automatically on their compatible smartphone when low glucose levels or high glucose levels happen, letting them make informed decisions. With 101 million people living with diabetes, India is home to the second-largest diabetes population in the world. This staggering number highlights the urgent need for accessible, real-time tools like continuous glucose monitors (CGMs) to help people manage their diabetes confidently and proactively. Glucose monitoring, alongside appropriate therapy, is key to managing the condition and preventing complications. “Abbott’s pioneering FreeStyle Libre technology is transforming the way diabetes is managed for over seven million individuals across the globe. We are thrilled to introduce this life-changing innovation to India, where it holds immense potential to empower people to be able to manage the condition better,” said Dr Kenneth Lee, Regional Medical Affairs Director, Asia Pacific, Diabetes Division, Abbott. “FreeStyle Libre2 Plus performance meets robust accuracy standards to ensure reliable glucose readings for all intended patient populations and glycemic ranges. It gives people the freedom to monitor their glucose levels without routine fingersticks, helping them make more informed decisions.” Studies show that FreeStyle Libre technology can help reduce low blood sugar episodes by up to 43%, a 0.9% to 1.5% drop in HbA1c levels, and even cut hospital visits by 66%. Libre technology has been shown to reduce cardiovascular complication risk by 78% in people with Type 1 diabetes post-severe hypoglycemia, and lower hospitalisation risk for stroke and diabetes-related complications by 44% in insulin-treated Type 2 diabetes. And for caregivers, real-time alerts offer peace of mind and the chance to act before situations get serious. ]]> https://biospectrumindia.com/news/108/26549/himedia-labs-secures-cdsco-manufacturing-licenses-for-advanced-hepatitis-b-c-detection-kits.html https://biospectrumindia.com/news/108/26549/himedia-labs-secures-cdsco-manufacturing-licenses-for-advanced-hepatitis-b-c-detection-kits.html Tue, 19 Aug 2025 00:00:00 +0530 Mumbai-based HiMedia Laboratories, a global leader in diagnostics and life sciences, has received manufacturing licenses from the Central Drugs Standard Control Organization (CDSCO) for two advanced molecular diagnostic kits: Hi-PCR® Hepatitis B Virus (HBV) Detection and Quantitation Probe PCR Kit Hi-PCR® Hepatitis C Virus (HCV) Detection and Quantitation Probe PCR Kit These regulatory approvals empower HiGenoMB - HiMedia to manufacture these highly sensitive and specific diagnostic tools on a large scale, developed indigenously as part of the Make in India initiative to tackle two of the most significant viral infections impacting both the global and Indian populations. This achievement aligns strongly with HiGenoMB's vision to help make India hepatitis free by enabling early, accurate diagnosis and effective management of hepatitis B and C. Hepatitis B and C are leading causes of chronic liver disease, cirrhosis, and liver cancer. Early diagnosis is vital for timely treatment and preventing transmission. Hi-PCR® HBV Kit (MBPCR181) Detects HBV DNA across all genotypes (A–J) with 100% specificity. Analytical Sensitivity ≈15 IU/mL Includes quantitative standards for precise viral load measurement Includes endogenous internal control Compatible with various RT-PCR instruments Based on TaqMan chemistry Quantitative standards calibrated against 5th WHO International Standard (NIBSC Code: 22/120)   Hi-PCR® HCV Kit (MBPCR182) Detects HCV RNA across all genotypes (1–7) with 100% specificity. Analytical Sensitivity ≈43 IU/mL Includes quantitative standards for precise viral load measurement Includes endogenous internal control Compatible with various RT-PCR instruments Based on TaqMan chemistry Quantitative standards calibrated against 6th WHO International Standard (NIBSC Code: 18/184) Both kits are validated for EDTA plasma samples and intended for In vitro diagnostic use by trained clinical laboratory personnel. “This achievement underscores our commitment to delivering world-class affordable diagnostics from India to the world. These kits offer accuracy, speed, and accessibility, helping healthcare providers diagnose and manage hepatitis more effectively, even in resource-limited settings,” said Dr Rajas V. Warke, Director, Molecular Biology & Virology, HiMedia Laboratories. With CDSCO approval, HiMedia will supply these kits to hospitals, diagnostic labs, and public health programs across India, ensuring improved testing availability in both urban and rural regions. ]]> https://biospectrumindia.com/news/108/26529/manipal-health-enterprises-to-set-up-rs-700-cr-hospital-at-nagpur.html https://biospectrumindia.com/news/108/26529/manipal-health-enterprises-to-set-up-rs-700-cr-hospital-at-nagpur.html Wed, 13 Aug 2025 00:00:00 +0530 Manipal Hospitals, one of the leading healthcare providers in India, has signed a Memorandum of Understanding (MoU) with the Government of Maharashtra to build a state-of-the-art 350-bed multi-speciality Hospital at Nagpur. This important partnership being explored reflects the common aim to improve healthcare infrastructure and access in the area. The proposed hospital will entail an investment of nearly Rs 700 crore and is expected to create about 3,000 new jobs. The MoU was signed in Mumbai and the Government of Maharashtra has promised to facilitate all permits, approvals and fiscal incentives necessary to complete this project in a time bound manner. The hospital will start in 2029 making it a significant landmark for healthcare development, providing high-quality medical services to the people of Nagpur and its nearby areas. Commenting on the announcement, Dilip Jose, Managing Director and CEO of Manipal Hospitals, said, “I would like to thank the Government of Maharashtra for their support and for entrusting us with this opportunity to serve the people of the state. This strategic expansion aligns with Manipal Hospitals’ vision to make advanced medical care accessible to all. The new facility in Nagpur will bring high-quality, multidisciplinary healthcare closer to communities that need it most, reinforcing our commitment to equitable and impactful care across Maharashtra.” Additionally, the new hospital in Nagpur will offer an extensive range of specialised departments such as cardiology, neurology, orthopaedics, oncology services etc.   ]]> https://biospectrumindia.com/news/108/26478/robogynindia-2025-in-partnership-with-vattikuti-foundation-showcases-indias-leadership-in-robotic-gynaecologic-surgery.html https://biospectrumindia.com/news/108/26478/robogynindia-2025-in-partnership-with-vattikuti-foundation-showcases-indias-leadership-in-robotic-gynaecologic-surgery.html Mon, 04 Aug 2025 00:00:00 +0530 RoboGynIndia 2025, the flagship annual event of the Association of Gynaecological Robotic Surgeons of India (AGRS) held for the fourth year, concluded with high momentum and meaningful engagement at Mumbai. Held on August 2 & 3, the conference was themed “Robotic Surgery in Gynaecology—Redefining Boundaries” and brought together the country’s most prominent robotic gynaecologic surgeons and global experts for a two-day academic and clinical exchange. The event was held in association with the Vattikuti Foundation, a pioneering force behind the growth of robotic surgery in India. As part of its commitment to nurturing the next generation of robotic surgeons, the Foundation sponsored the  prestigious Vattikuti Scholar awards and honoured five winners for their outstanding surgical video presentations, each recipient earning a grant of $500 and the distinguished title of AGRS Vattikuti Scholar.  Speaking on the occasion, Dr. Mahendra Bhandari, CEO, Vattikuti Foundation, said, “RoboGynIndia 2025 has once again demonstrated the incredible depth of talent and innovation within India’s robotic surgical community. Our association with this platform reflects the Foundation’s commitment to nurturing the ecosystem, beginning with training the early pioneers in robotic gynaecology to now enabling the next generation of surgical leaders. Through initiatives like the AGRS Vattikuti Scholars and Champions Awards, we are proud to recognize emerging talent, foster innovation and drive the future of women’s healthcare.” Dr. Rooma Sinha, Founder & President of AGRS and a Senior Mentor at Vattikuti Foundation, added, “RoboGynIndia is not just a conference; it is a catalyst for change in the way we approach surgical care for women. Over last 3 years since it was registered at Hyderabad, Telangana, the  years, it has grown into a movement that celebrates innovation, fosters academic rigor and inspires a new generation of surgeons to think beyond boundaries. Our partnership with the Vattikuti Foundation has played an important role in this evolution. From mentoring early adopters to now empowering young clinical minds, the Foundation’s vision has always been aligned with advancing excellence and equity in robotic gynaecology. Together, we are shaping a future where precision surgery which has now become the standard, not the exception, in women’s healthcare.” The event concluded with a strong sense of purpose, highlighting India’s increasing leadership in robotic-assisted surgery and the role of global collaboration, technology and academic exchange in redefining the future of women’s health. ]]> https://biospectrumindia.com/news/108/26468/laxmi-dental-to-acquire-majority-stake-in-ai-dent-to-expand-ai-capabilities-in-digital-dentistry.html https://biospectrumindia.com/news/108/26468/laxmi-dental-to-acquire-majority-stake-in-ai-dent-to-expand-ai-capabilities-in-digital-dentistry.html Fri, 01 Aug 2025 00:00:00 +0530 Mumbai-based Laxmi Dental, a dental products company, has announced that its Board of Directors has approved an investment in IDBG AI Dent Global, a Gujarat-based healthcare technology company focused on artificial intelligence applications in dentistry. Upon completion, Laxmi Dental Limited will hold 58% of the capital in AI Dent. The objective of the acquisition is to strengthen the company’s research and development and expand its technology offerings. The move also supports India’s efforts to promote domestic manufacturing and self-reliance under the Make in India and Aatmanirbhar Bharat initiatives. AI is becoming a foundational technology in dentistry across the world. From diagnostics to treatment planning, AI tools are improving decision-making and clinical outcomes. Through this investment, Laxmi Dental aims to build local capability in AI for dental care, enabling dentists to adopt faster, data-driven processes while reducing procedural complexity for patients. The focus is on creating systems that support dentists in delivering consistent care and give patients improved access, accuracy, and clarity in diagnosis and treatment. AI Dent is developing AI-based dental imaging and diagnostic tools, including software for image analysis and X-ray interpretation. ]]> https://biospectrumindia.com/news/108/26413/maharashtra-gets-first-operational-ai-powered-heart-disease-prevention-model.html https://biospectrumindia.com/news/108/26413/maharashtra-gets-first-operational-ai-powered-heart-disease-prevention-model.html Mon, 21 Jul 2025 00:00:00 +0530 Jaslok Hospital & Research Centre has partnered with AnginaX AI, India’s first licensed AI Doctor Assistant in cardiology, to launch Maharashtra’s first operational AI-powered heart disease prevention model. This collaboration places Jaslok at the forefront of India’s shift from late-stage cardiac intervention to early, technology-driven prevention. The advanced AnginaX AI system, now deployed across Jaslok’s outpatient departments, enables doctors to assess cardiovascular risk in just seconds using structured, science-backed reports that identify risk even before symptoms appear and recommend personalised lifestyle and treatment plans. With heart disease affecting millions of Indians and often going undetected until it’s too late, this prevention model brings speed, clarity, and access to the very first point of contact: the OPD. The AnginaX system evaluates more than 20 critical clinical and lifestyle-based indicators, including extended lipid profiles, blood sugar, inflammatory biomarkers, metabolic complexities, family history, and lifestyle patterns. Based on validated Indian data, the system generates a structured clinical summary that includes individualized risk stratification, investigation recommendations specific to each patient, and clear, actionable treatment and follow-up guidance. Recognising that cost and fear are often barriers to early checkups, Jaslok and AnginaX have ensured the programme is fast, accessible and affordable, making prevention routine rather than rare. Jaslok has also launched AI-powered initiative “Dil Fit, Life Hit” under the leadership of Dr Ashwin B. Mehta, bringing structured cardiovascular prevention into everyday clinical care. The programme empowers doctors, transforms OPD practice, and makes prevention accessible to every patient, not just those with symptoms.   ]]> https://biospectrumindia.com/news/108/26347/maharashtra-medical-council-allows-homeopathy-practitioners-to-prescribe-modern-medicines.html https://biospectrumindia.com/news/108/26347/maharashtra-medical-council-allows-homeopathy-practitioners-to-prescribe-modern-medicines.html Tue, 08 Jul 2025 00:00:00 +0530 The Maharashtra Medical Council (MMC) has recently notified to allow practitioners of homeopathy to prescribe modern medicines after a one-year pharmacology course. The government has directed all qualified doctors (after completing Certificate Course in Modern Pharmacology or CCMP) to register under MMC for which MMC is launching a portal on its website for the registration process. However, experts have gathered their concerns regarding the potential implications of this decision. Pavan Choudary, Chairman & Director General, The Medical Technology Association of India (MTaI) said, "While acknowledging the intent to broaden healthcare access, it's crucial to consider the fundamental differences in the core training methodologies and philosophies of homeopathy and allopathy. Homeopathy, with its core principle of 'Similia similibus curentur' (like cures like), operates on a distinctly different philosophical and curricular foundation than allopathy. Allopathic medical professionals, in contrast, undergo extensive education spanning several years, with a deep emphasis on anatomy, physiology, pathology, and evidence-based medicine.” "A one year Certificate Course in Modern Pharmacology (CCMP), while theoretically illuminating, may not adequately bridge this complex, multi-layered educational spectrum," Choudary added. He also said that this could be particularly problematic in rural, Tier 2, and Tier 3 cities, leading to negative public health outcomes. While we do not question the intent, safeguarding public health and maintaining the integrity of modern medical practice should remain the foremost priorities. ]]> https://biospectrumindia.com/news/108/26349/iit-bombay-and-icici-foundation-partner-for-expansion-of-biomedical-innovation-hub.html https://biospectrumindia.com/news/108/26349/iit-bombay-and-icici-foundation-partner-for-expansion-of-biomedical-innovation-hub.html Tue, 08 Jul 2025 00:00:00 +0530 Indian Institute of Technology (IIT) Bombay and ICICI Foundation for Inclusive Growth (ICICI Foundation), the CSR arm of ICICI Bank, have forged a partnership to expand the biomedical innovation hub at the country’s premier technology and engineering institute. Under this partnership, ICICI Foundation has pledged Rs 70 crore to set up additional floors at the Biomedical Engineering and Technology Innovation Centre (BETIC) at IIT Bombay and equip this area with advanced facilities.  The new floors, named ‘IIT-ICICI BETIC Hub’, will significantly expand IIT Bombay’s capabilities in biomedical engineering, increasing its space five-fold to 19,700 sq. ft. The hub will foster collaboration among researchers, clinicians, and industry leaders to develop affordable, cutting-edge medical devices and diagnostic solutions. It will be equipped with state-of-the-art resources for product development, medical grade manufacturing, safety testing, inspection, and packaging. This enhanced ecosystem will support med-tech startups and companies, train professionals in healthcare innovation, and generate high-value jobs, ultimately benefiting millions of patients. Speaking on the collaboration, Prof. Shireesh Kedare, Director, IIT Bombay, said, "This partnership exemplifies how industry-academia alliances can drive innovation towards real-world impact. With ICICI Foundation’s generous support, IIT Bombay is poised to revolutionise biomedical research and technology, addressing critical healthcare gaps in India, fostering home-grown solutions that are accessible, affordable, and scalable.” Commenting on the partnership, Pradeep Kumar Sinha, Chairman, ICICI Bank, said, “The ‘IITB-ICICI BETIC Hub’ will facilitate the development of indigenous medical innovations ensuring affordable healthcare solutions to patients. We are delighted to collaborate with IIT Bombay to drive a meaningful change in the healthcare ecosystem.”    ]]> https://biospectrumindia.com/news/108/26253/serum-institute-of-india-partners-with-dndi-to-advance-development-of-new-dengue-treatment.html https://biospectrumindia.com/news/108/26253/serum-institute-of-india-partners-with-dndi-to-advance-development-of-new-dengue-treatment.html Tue, 17 Jun 2025 00:00:00 +0530 Pune-based Serum Institute of India (SII), part of Cyrus Poonawalla Group, the world’s largest vaccine manufacturer, and the not-for-profit medical research organization Drugs for Neglected Diseases initiative (DNDi) have signed a Memorandum of Understanding (MoU) to accelerate the clinical development of a monoclonal antibody treatment for dengue that will be affordable and accessible in low- and middle-income countries (LMICs). Through this collaboration, both SII and DNDi will develop a work plan to implement R&D, additional Phase III clinical trials, and access activities, along with a joint strategy to raise necessary funds and resources. Additionally, a joint project team will be formed to advance clinical trials, with the goal of registering and deploying the dengue monoclonal antibody in India and other dengue-endemic countries, provided the studies confirm its safety and efficacy. SII has already conducted pre-clinical studies and Phase I and II clinical trials that show the candidate (formerly VIS513) is safe and effective. Currently, SII is leading the pivotal Phase III clinical trial in India for licensure. SII and DNDi will now work together to conduct additional Phase III trials in other dengue-endemic countries, including Brazil. DNDi will act as the lead partner for these Phase III clinical trials, including trial leadership, sponsorship, and implementation in Brazil and potentially other endemic countries in Southeast Asia. DNDi and SII will lead strategic engagement efforts with the Dengue Alliance, relevant industry stakeholders, and policymakers in low- and middle-income countries. For the DNDi-led trial in Brazil and other countries, SII will provide development background and technical support. Furthermore, SII will be responsible for the manufacture, development, and provision of clinical supplies of the monoclonal antibody candidate. The company will define and execute the regulatory strategy in India and will lead the commercialization of the product in the country.   Image caption- (L-R) Dr André Siquiera, Head of Dengue at DNDi and Sunder Lata A Kavitkar, Company Secretary, Serum Institute of India ]]> https://biospectrumindia.com/news/108/26238/sava-healthcare-secures-cdsco-nod-for-nasal-spray-targeting-allergic-rhinitis-with-congestion.html https://biospectrumindia.com/news/108/26238/sava-healthcare-secures-cdsco-nod-for-nasal-spray-targeting-allergic-rhinitis-with-congestion.html Thu, 12 Jun 2025 00:00:00 +0530 SAVA Healthcare Limited, a leading contract development and manufacturing organization (CDMO) in the Indian pharmaceutical sector, has received its first drug approval from the Drug Controller General of India (DCGI) for a combination nasal spray indicated for the treatment of allergic rhinitis with nasal congestion. The approved formulation contains Fluticasone Furoate (27.5 mcg) and Oxymetazoline Hydrochloride (50 mcg) and is designed for targeted relief of allergy-induced nasal symptoms, including inflammation and congestion. The product will be manufactured at SAVA Healthcare’s state-of-the-art facility in Surendranagar, Gujarat, which complies with stringent regulatory requirements and quality standards. Packaged in high-density polyethylene (HDPE) bottles equipped with a metered spray pump, the nasal spray ensures precise dosing and user-friendly administration. This formulation combines the anti-inflammatory properties of fluticasone, a corticosteroid, with the decongestant effect of oxymetazoline, offering comprehensive symptomatic relief for patients suffering from seasonal and perennial allergic rhinitis. All regulatory and technical prerequisites laid out by the Central Drugs Standard Control Organisation (CDSCO) were met during the approval process, highlighting SAVA Healthcare’s growing competency in complex formulations and respiratory drug delivery systems.  With the launch of this formulation, SAVA Healthcare not only enters a new product category under its own license but also sets the stage for future filings and tech transfers in the complex nasal spray segment, both for India and international markets. ]]> https://biospectrumindia.com/news/108/26239/govt-extends-financial-support-to-clearsynth-labs-to-establish-bulk-manufacturing-facility-for-deuterated-reagents-.html https://biospectrumindia.com/news/108/26239/govt-extends-financial-support-to-clearsynth-labs-to-establish-bulk-manufacturing-facility-for-deuterated-reagents-.html Thu, 12 Jun 2025 00:00:00 +0530 In a decisive step towards building India’s capabilities in advanced specialty chemicals, the Technology Development Board (TDB), under the Department of Science and Technology (DST), Government of India, has extended financial support to Mumbai-based Clearsynth Labs for setting up a dedicated manufacturing facility for the commercial-scale production of deuterated reagentsand building blocks. The non-nuclear applications of deuterium are increasingly finding traction across industries. Bulk manufacturing of deuterated reagents and building blocks is becoming increasingly important globally, as other than the use of Deuterium labelled compounds for clinical research applications andpPharma research, it has potential application in medicinal chemistry and non-medicinal industrial sectors of the market. Currently, India imports the majority of deuterated solvents. The initiative comes at a time when deuterated compounds are witnessing increasing global demand across sectors such as pharmaceuticals, OLEDs, semiconductors, and fiber optics. Despite India’s robust pharmaceutical manufacturing base, most Indian manufacturers are geared for standard APIs, not isotope-labelled compounds. The country has remained reliant on imports in this strategically important yet niche segment due to the lack of scalable, high-purity production technologies within the domestic ecosystem.This project is a transformative move to strengthen domestic capabilities in high-value chemicals for pharma, OLED, semiconductors, and fiber optics. The new facility, backed by TDB, will serve high-end global and domestic customers engaged in pharmaceutical research, complex chemical synthesis, and advanced industrial applications.  ]]> https://biospectrumindia.com/news/108/26195/govt-supports-indigenous-manufacturing-of-complex-pharma-excipients-by-nitika-pharmaceutical-specialties.html https://biospectrumindia.com/news/108/26195/govt-supports-indigenous-manufacturing-of-complex-pharma-excipients-by-nitika-pharmaceutical-specialties.html Tue, 03 Jun 2025 00:00:00 +0530 The Technology Development Board (TDB), Department of Science and Technology (DST), Government of India has extended financial support to Nitika Pharmaceutical Specialties Private Limited, Nagpur, for their project titled “Manufacture of Complex Excipients.” Excipients, though pharmacologically inactive, are critical to the functionality, stability, and delivery of medicines. As drug formulations become increasingly sophisticated—with the rise of complex generics, biopharmaceuticals, and novel delivery systems—the demand for high-quality, tailor-made excipients has surged globally. Through this project, Nitika Pharmaceutical Specialties aims to establish a state-of-the-art manufacturing facility for commercial-scale production of 14 complex excipients that cater to advanced pharmaceutical applications. These products will be developed in line with the Quality by Design (QbD) framework, ensuring precision in parameters like surface area, particle size, and stability to meet international standards. Established in 1991 and later incorporated as a Private Limited Company in 2011, Nitika has evolved into a trusted global supplier of fine chemicals and specialty excipients. With a DSIR-recognised in-house R&D facility and a global footprint across 90 countries, the company is well-positioned to translate this project into a significant leap toward self-reliance in pharma auxiliary production. The project is also aligned with the Government of India’s Production Linked Incentive (PLI) scheme for pharmaceuticals, under which Nitika has been selected as a beneficiary under Group C – MSME (Pharmaceuticals). TDB’s support complements the broader national mission of fostering indigenous manufacturing, reducing import dependency, and expanding India’s export potential in high-value pharmaceutical components.   ]]> https://biospectrumindia.com/news/108/26173/sir-h-n-reliance-foundation-hospital-launches-advanced-clinic-to-fight-pulmonary-disorders.html https://biospectrumindia.com/news/108/26173/sir-h-n-reliance-foundation-hospital-launches-advanced-clinic-to-fight-pulmonary-disorders.html Tue, 27 May 2025 00:00:00 +0530 In a significant stride towards elevating pulmonary healthcare in the city, Mumbai-based Sir H. N. Reliance Foundation Hospital has announced the launch of its Advanced Lung Disease Clinic, a dedicated centre of excellence for the diagnosis, treatment, and long-term management of rare and complex lung disorders. This clinic integrates advanced diagnostics, interventional pulmonology, and lung transplant expertise under one roof, offering patients comprehensive and personalised care. According to the Lancet Respiratory Medicine report, India is home to approximately 33 million asthma patients and 55 million individuals with chronic obstructive pulmonary disease (COPD), representing over 10% of the global burden for these respiratory illnesses. The Advanced Lung Disease Clinic aims to bridge this critical healthcare gap by delivering cutting-edge diagnostic and therapeutic interventions, including life-saving lung transplant services. The clinic specialises in managing severe and advanced lung diseases such as: Severe Interstitial Lung Disease (ILD); End-stage COPD and emphysema; Severe, treatment-resistant asthma; Occupational and environmental lung disorders; Progressive lung failure requiring ventilatory or ECMO suppor.t Equipped with state-of-the-art interventional pulmonology technologies-including high-precision bronchoscopy, cryotherapy, endobronchial ultrasound (EBUS)-guided biopsies, and airway stenting-the clinic also offers personalised pulmonary rehabilitation, oxygen therapy, and lifestyle support programs tailored to each patient’s needs. ]]> https://biospectrumindia.com/news/108/26127/lupin-and-honeywell-move-forward-jointly-with-plans-for-hfo-technology-in-inhalers.html https://biospectrumindia.com/news/108/26127/lupin-and-honeywell-move-forward-jointly-with-plans-for-hfo-technology-in-inhalers.html Tue, 20 May 2025 00:00:00 +0530 Mumbai-based pharma major Lupin has announced its plan to use Honeywell’s Solstice® Air (HFO-1234ze(E) cGMP) propellant to transform respiratory care through the development of next-generation inhalers. Designed for patients with asthma and chronic obstructive pulmonary disease (COPD), Honeywell Solstice Air has the potential to prevent the release of high global warming potential (GWP) molecules, marking a major step forward in helping to reduce carbon emissions. Lupin intends to become the first pharmaceutical company in India to use Honeywell’s Solstice Air product at scale as a next-generation propellant in pressurized metered-dose inhalers (pMDIs). Solstice Air offers an alternative to traditional hydrofluorocarbon (HFC)-based propellants, helping to reduce greenhouse gas emissions by up to 99.9% By investigating the use of this innovative, non-flammable propellant in its pMDIs, Lupin is taking a significant step toward minimizing the environmental impact of respiratory solutions while providing effective treatment options for patients with asthma and COPD. “Solstice Air can play a critical role in ensuring that Lupin’s respiratory inhalers provide safe and effective treatment options that also leverage the latest advancements in technology to reduce harmful greenhouse gas emissions,” said Ashish Modi, President, Honeywell India. “By continuing to research and develop advanced technologies for reducing carbon, Honeywell is dedicated to driving innovation that enhances the efficacy of health solutions while pioneering emissions reducing practices that support industry advancements.” ]]> https://biospectrumindia.com/news/108/26130/neuberg-diagnostics-and-star-imaging-announce-strategic-joint-venture-in-maharashtra.html https://biospectrumindia.com/news/108/26130/neuberg-diagnostics-and-star-imaging-announce-strategic-joint-venture-in-maharashtra.html Tue, 20 May 2025 00:00:00 +0530 Neuberg Diagnostics has announced a strategic joint venture with Star Imaging to expand integrated diagnostics centres combining advanced Pathology and advanced Radiology across Maharashtra. For over 13 years, Star Imaging has pioneered the introduction of next-generation radiology technologies in Pune. Under the visionary leadership of Dr Ashish Atre, a globally acclaimed radiologist, alongside a team of highly skilled, organ-specific radiologists has become a trusted name for high-end imaging services. Star Imaging currently operates state-of-the-art, fully integrated diagnostic centres across Deccan, Bund garden road, Wakad and Baner in Pune and in Akluj. Dr GSK Velu, Chairman and Managing Director of Neuberg Diagnostics, said “We see Maharashtra as a key market for growth and innovation, and this collaboration lays a strong foundation for long-term investment, infrastructure expansion, and the democratization of high-quality healthcare diagnostics. As part of the expansion strategy, we plan to launch new integrated diagnostic centres across Pune, Nashik, Nagpur, Aurangabad, and other key cities in Maharashtra over the next two years” In India, the growing burden of chronic diseases, rising demand for preventive healthcare, and the increasing complexity of clinical decision-making have created a strong need for integrated diagnostic services. Traditionally, radiology and pathology have operated in silos, often leading to fragmented information and delayed diagnoses. By bringing multiple diagnostic modalities radiology, pathology, wellness, and genomics under one roof, integrated diagnostics enhances accuracy, speeds up diagnosis, and enables more informed and timely treatment decisions. This model is particularly vital in India’s healthcare landscape, where early intervention can significantly reduce disease burden and improve patient outcomes. The Neuberg Diagnostics and Star Imaging partnership directly addresses this gap by offering a unified, patient-centric approach to diagnostics. ]]> https://biospectrumindia.com/news/108/26117/medvital-raises-rs-8-4-cr-pre-seed-funding-to-accelerate-transformation-in-skin-repair-restoration-and-regeneration.html https://biospectrumindia.com/news/108/26117/medvital-raises-rs-8-4-cr-pre-seed-funding-to-accelerate-transformation-in-skin-repair-restoration-and-regeneration.html Thu, 15 May 2025 00:00:00 +0530 Mumbai-based startup MedVital, a new-age medtech startup focused on making advanced and innovative technologies for hard-to-heal wounds and minimally invasive aesthetics more smart and accessible, has raised Rs 8.4 crore in pre-seed funding. The round was led by Nihar Parikh’s 4point0 Health Ventures, with participation from a marquee group of operator-investors, including founders of Tata 1mg, NephroPlus, SafeExpress, Eye Q Hospital, Hexa Health, and AstroTalk. India’s healthcare system is undergoing a pivotal shift. A growing burden of hard-to-heal wounds driven by ageing, diabetes, obesity, and trauma is intersecting with the rising demand for minimally invasive aesthetic solutions. At the heart of both lies a shared need for advanced, outcome-oriented, evidence-led technologies that can repair, restore, and regenerate skin. Yet access to such solutions remains limited, held back by systemic gaps in reach and scale. MedVital is addressing this gap by building India’s first integrated platform for complex wound care and minimally invasive aesthetics, two underserved domains despite their clinical urgency. Its flagship brand, NoWound, is a state-of-the-art Negative Pressure Wound Therapy (NPWT) device designed to offer precision-controlled healing across hospital, clinic, and home-care settings. Unlike traditional NPWT systems, NoWound is compact, digitally enabled, and made in India, allowing seamless deployment even in resource-constrained environments. This fresh capital injection will be directed towards expanding MedVital’s product portfolio, strengthening its supply chain, and broadening its distribution network to cover tertiary care hospitals, rural clinics, and home-care settings. MedVital will soon launch liquid chitosan-based dressings for hard-to-heal wounds, and expand into dermal and hair regeneration solutions—unlocking new clinical pathways in both therapeutic and aesthetic care. ]]> https://biospectrumindia.com/news/108/26101/cosette-pharmaceuticals-inaugurates-global-business-operations-in-india.html https://biospectrumindia.com/news/108/26101/cosette-pharmaceuticals-inaugurates-global-business-operations-in-india.html Mon, 12 May 2025 00:00:00 +0530 US-based Cosette Pharmaceuticals has officially inaugurated its Global Business Operations centre in Navi Mumbai, the company’s first office outside the United States (US). This strategic expansion aims to leverage India’s deep talent pool and core competencies across the pharmaceutical value chain. The newly established office currently supports key functions such as Regulatory Affairs, SAP, Finance, HR, Data Analytics, Operational excellence, and other enabling services that directly support Cosette’s US operations. Inaugurating the office, Apurva Saraf, CEO of Cosette Pharmaceuticals, said, “This expansion represents a significant milestone in our journey to build a globally integrated organization. The India office will be instrumental in accelerating innovation and operational excellence. We believe in empowering talent and creating value through collaboration, and this centre reflects our vision to build a scalable and agile operating model that supports our long-term growth strategy. It’s more than a location — it’s a hub of ideas, execution, and opportunity.” Richard Casten, CFO, added, “Our Global Business Operations in India will enhance agility, improve cost efficiency, and strengthen our ability to support the business through shared services and strategic initiatives. This move enables us to access world-class capabilities while maintaining financial discipline. It also gives us the flexibility to respond faster to evolving market needs and regulatory demands.” The entire setup was executed under a Build-Operate-Transfer (BOT) model in partnership with Amviak Consulting, experienced in establishing global operations. Amviak led the initiative from the grassroots level — setting up infrastructure, enabling core functions, and ensuring operational readiness. ]]> https://biospectrumindia.com/news/108/26090/government-of-maharashtra-to-revolutionise-emergency-medical-services-in-india.html https://biospectrumindia.com/news/108/26090/government-of-maharashtra-to-revolutionise-emergency-medical-services-in-india.html Wed, 07 May 2025 00:00:00 +0530 Sumeet SSG BVG Maharashtra EMS has signed 10-year concessionaire agreement with Public Health Department, Government of Maharashtra to revolutionise emergency medical services in India. The initiative will begin in Maharashtra with a total investment of nearly Rs 1,600 crore. The project aims to implement the new ‘Maharashtra Emergency Medical Services’ (MEMS) 108 Ambulance Program across the state. Under the agreement, the partners will deploy a fleet of 1756 state-of-the-art ambulances equipped with advanced medical technology to provide critical care during the vital “golden hour” of emergencies. The rollout of the new MEMS 108 Project will take place across Maharashtra in five phases beginning in November 2025. The new fleet of advanced ambulances will be fitted with cutting-edge technologies such as Mobile Data Terminals (MDT), tablet PCs, RFID, GPS, caller location tracking, CCTV, and TRIAGE systems. These vehicles will also integrate inbuilt systems for Customer Relationship Management (CRM), Computer-Aided Dispatch (CAD), Vehicle Tracking and Management (VTMS), and patient arrival notifications. The fleet will include Advanced Life Support (ALS) ambulances, Basic Life Support (BLS) ambulances, neonatal care units, first responder bikes, as well as sea and river boat ambulances. From a long-term perspective, the MEMS 108 program aims to feature medical application drones and helicopter-based emergency medical services. This initiative will set a new benchmark for emergency medical services in India. It will offer cutting-edge technology and enhanced operational efficiency as well as establish a sustainable model for future public-private partnerships in high-quality service delivery. ]]> https://biospectrumindia.com/news/108/26081/celcius-logistics-raises-rs-250-cr-in-series-b-funding-to-expand-cold-chain-network.html https://biospectrumindia.com/news/108/26081/celcius-logistics-raises-rs-250-cr-in-series-b-funding-to-expand-cold-chain-network.html Tue, 06 May 2025 00:00:00 +0530 Mumbai-based startup Celcius Logistics has closed its oversubscribed Series B round, raising a substantial amount of Rs 250 crore through a combination of equity investment, debt financing, and secondary transactions.  Leading equity investors Eurazeo and Omnivore co-led the round, which saw participation from existing investors IvyCap Ventures, along with debt partners including Trifecta Capital, Lighthouse Canton, BlackSoil, UCIC, and GetVantage, among others. Celcius Logistics’ proprietary tech solutions address critical industry needs, such as food safety, temperature control, and end-to-end monitoring of sensitive shipments, all while reducing wastage and maintaining quality. This funding will help the company expand its network to more than 1000 cities in India and enhance its technology platform to meet the growing demand for temperature-sensitive logistics across multiple sectors. Recently, Celcius has made significant inroads into pharmaceutical logistics, ensuring safe and efficient transportation of critical medical supplies nationwide. “The funding comes at a pivotal time as we scale our operations and strengthen our capabilities across all verticals, said Swarup Bose, Founder & CEO of Celcius Logistics. We are focused on expanding our reach, deepening customer partnerships, and delivering seamless, reliable, and efficient temperature-sensitive logistics using our tech-driven cold chain solutions. This support enables us to bridge critical industry gaps and drive meaningful transformation in the ecosystem.” Earlier in May last year, the end-to-end cold chain solutions provider raised Rs 40 crore in a pre-series B round. Till date, the company has raised around Rs 390 crore to expand its cold chain network and capabilities. Established in 2020, the company currently operates in 600+ cities with a network of 4,000+ vehicles and 150+ cold storage and distribution facilities. Celcius has shown consistent top line growth of 2.5x YoY since 2021.    ]]> https://biospectrumindia.com/news/108/26082/tpg-acquires-35-stake-in-schott-poonawalla-from-serum-institute-of-india.html https://biospectrumindia.com/news/108/26082/tpg-acquires-35-stake-in-schott-poonawalla-from-serum-institute-of-india.html Tue, 06 May 2025 00:00:00 +0530 Schott Pharma, a pioneer in drug containment and delivery solutions, has announced that TPG, a leading global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in its joint venture Schott Poonawalla from Serum Institute of India (SII).  Schott Poonawalla is a joint venture of Schott Pharma and SII, part of the Cyrus Poonawalla Group and a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide. TPG Growth, TPG’s middle market and growth equity platform, is funding the investment, along with Novo Holdings as a co-investor. Following the transaction, SII will retain a minority stake in the company. With deep healthcare investing experience and local expertise in India, having TPG join the partnership alongside Schott Pharma and Serum Institute of India represents a significant milestone in Schott Poonawalla’s growth, equipping the company with additional resources and strategic insight to support its long-term global ambitions. Schott Poonawalla designs advanced drug containment and delivery solutions for pharmaceutical and biotechnology customers. The company’s portfolio features a large range of products including cartridges for auto-injector pens, prefillable syringes for a wide variety of biologics, vials, ampoules, as well as regulatory services for biotech and pharmaceutical companies, and Contract Development and Manufacturing Organisations (CDMOs).   The transaction is subject to customary closing conditions and is expected to close within the first half of 2025. ]]> https://biospectrumindia.com/news/108/26069/sunact-opens-its-first-facility-in-mumbai-offering-car-t-cell-therapy-for-solid-state-tumours.html https://biospectrumindia.com/news/108/26069/sunact-opens-its-first-facility-in-mumbai-offering-car-t-cell-therapy-for-solid-state-tumours.html Fri, 02 May 2025 00:00:00 +0530 SunAct - Advanced Cancer Therapies, the oncology startup founded by Dr Vijay Patil and Dr Ashay Karpe, aimed at making the world’s most advanced and innovative cancer care accessible and affordable in the country, has launched its third facility in India and the first in Mumbai city, at the Dr. Gupte Surgical Hospital in Khar (West). The new centre will offer India’s first CAR-T cell therapy for solid-state tumours along with various therapies which will be introduced in India via SunAct. SunAct's Khar centre will not only offer CAR-T for haematological cancers like Lymphoma, Leukemia and Myeloma, but it is also India’s first CAR T-cell therapy for solid tumours, a revolutionary approach previously unavailable in the country. In addition to this milestone, the centre will provide TCR (T-Cell Receptor) Therapies; TIL (Tumor-Infiltrating Lymphocyte) Therapies; Gamma Delta T-Cell Platforms; Gene Therapies; Bone Marrow Transplantation & Clinical Trials. Addressing a question on SunAct’s plans for the future, Kushagra Sharma, CEO, SunAct-Advanced Cancer Therapies said, “We definitely aim to expand all over India including in Maharashtra. The idea is to spread awareness through marketing, through social media and also to spread awareness among more and more doctors that these treatments are now available in India.” ]]> https://biospectrumindia.com/news/108/26065/shashvi-remedies-secures-rs10-lakh-grant-from-maharashtra-state-innovation-society.html https://biospectrumindia.com/news/108/26065/shashvi-remedies-secures-rs10-lakh-grant-from-maharashtra-state-innovation-society.html Thu, 01 May 2025 00:00:00 +0530 Mumbai-based Shashvi Remedies, a pioneer in healthcare innovation, has received a grant of Rs ten lakh for international patents from the Maharashtra State Innovation Society (MSINS) under the Government of Maharashtra's Skill Development and Entrepreneurship Department (SDED). This acknowledgement is the demonstration of Shashvi Remedies’ persistent endeavour to identify pharma solutions for critical cancer disease that contributes to making a difference. With breast cancer affecting over 670,000 women worldwide each year and one woman diagnosed every four minutes in India, the need for breakthrough treatments has never been more urgent. Shashvi Remedies’ patented innovation offers new hope by targeting and eliminating cancerous cells while preserving healthy tissue, representing a major step forward in patient-centered treatment options. As the global pharmaceutical industry braces for the upcoming patent cliff of 2030, which will see the expiration of several major drug patents, Shashvi’s patented innovation is poised to capture attention. Industry analysts predict that pharmaceutical giants will be investing heavily in patented oncology solutions, with over $500 billion in reserves for acquisitions and pipeline growth. Shashvi’s patented breast cancer treatment is a highly valuable asset, with both Indian and global pharmaceutical companies recognizing its potential. A recent example of this trend is the acquisition of a US-based R&D firm by a leading Indian pharmaceutical company, securing a derma-oncology product for approximately $355 million—demonstrating the industry’s keen interest in breakthrough, early-stage oncology solutions.   ]]> https://biospectrumindia.com/news/108/26059/lytus-technologies-expands-healthcare-footprint-with-acquisition-of-blod-in.html https://biospectrumindia.com/news/108/26059/lytus-technologies-expands-healthcare-footprint-with-acquisition-of-blod-in.html Wed, 30 Apr 2025 00:00:00 +0530 Mumbai-based startup Lytus Technologies has announced the completion of its acquisition of Blod.in, India’s first on-demand blood component management and logistics platform (powered by advanced artificial intelligence- AI and machine learning algorithms) - currently operational in Chennai and soon to be available nationally. The acquisition of Blod.in, through Lytus HealthTech, its fully owned HealthTech subsidiary, underscores Lytus’ commitment to working alongside and together with hospitals and blood banks (private and public) in efficiently serving critical healthcare needs, optimising logistics, and ultimately saving lives. This last-mile partnership fosters an extremely gratifying and supportive relationship, ensuring timely access to life-saving blood products and enhancing the overall efficiency of the healthcare ecosystem. Over the last twelve months, Blod.in scaled rapidly, growing from 30 to 140 hospitals with a 20% month-on-month growth trajectory. Now operating in Chennai, it plans to expand to 100 more hospitals and 15+ blood banks, with further growth in Bengaluru, Mumbai, and Hyderabad and other cities in the next phase. Blod.in's AI-driven technology will soon expand to global markets like the US and UAE, optimising inventory, minimising wastage, and ensuring timely blood availability for patients, hospitals, and blood banks. Lytus Technologies has secured and committed Rs 1000 crore as growth capital over the next three years to scale operations both organically and inorganically, expand its digital ecosystem, and advance HealthTech innovations. A significant portion of this investment is dedicated to advancing AI- and ML-powered solutions across Lytus HealthTech, including Blod.in’s AI engine, which optimises blood inventory forecasting, real-time supply-demand mapping, and last-mile routing intelligence for temperature-sensitive deliveries. Following a successful pilot phase, Blod.in is set to officially launch, transforming blood logistics through its flagship platform, Blod+. The pilot proved its ability to cut blood procurement time from hours to just 90-120 minutes, addressing India's 650,000-unit annual blood deficit, which contributes to 12,000 daily deaths. ]]> https://biospectrumindia.com/news/108/26028/researchers-in-nashik-develop-blood-test-to-detect-30-different-types-of-cancer.html https://biospectrumindia.com/news/108/26028/researchers-in-nashik-develop-blood-test-to-detect-30-different-types-of-cancer.html Thu, 24 Apr 2025 00:00:00 +0530 In a landmark advancement for global oncology, a multi-institutional research team led by Prof Dr Raj Nagarkar, Managing Director and Chief of Surgical Oncology & Robotic Services at HCG Manavata Cancer Centre (HCGMCC), Nashik, has developed a revolutionary blood test that can detect 30 different types of cancers including pancreatic, lung, and ovarian cancers across both genders, with an average accuracy of 98.4 per cent. The pioneering study, recently published in Cancer Reports, is the largest clinical trial of its kind in India. It utilised a novel serum metabolome-based diagnostic platform powered by machine learning to identify distinct metabolic signatures associated with cancer. The trial included 6,445 participants, with over 2,800 confirmed, treatment-naïve cancer patients across four stages of the disease. Remarkably, the platform showed consistent high sensitivity even in early-stage (Stage I/II) cancers, a feat rarely achieved by current diagnostic standards. The model’s robustness was validated across multiple age groups, showing detection sensitivity consistently above 96 per cent across all demographics and cancer stages. Unlike other multi-cancer early detection (MCED) tests that rely on detecting tumour DNA or cells that are often limited by low biomarker concentration, this test captures changes in metabolites, providing a more reliable and sensitive readout, especially for early-stage cancers. The serum samples were analysed using high-resolution mass spectrometry and the data was interpreted through a proprietary Cancer Detection Artificial Intelligence (CDAI) algorithm developed in collaboration with PredOmix Technologies. “Currently, plans are underway to initiate larger, multi-centre clinical trials and eventually work toward commercial deployment. There are also on-going efforts to integrate tissue-of-origin prediction capabilities, which would further support physicians in initiating precise follow-up diagnostics and treatment strategies,” said Dr Nagarkar. ]]> https://biospectrumindia.com/news/108/26020/brain-health-startup-ivory-raises-1m-in-fresh-funding.html https://biospectrumindia.com/news/108/26020/brain-health-startup-ivory-raises-1m-in-fresh-funding.html Tue, 22 Apr 2025 00:00:00 +0530 Mumbai-based Ivory, an early-stage brain health startup, has announced the successful close of its latest $1million funding round. The round was co-led by IIM-A Ventures, the entrepreneurship center at IIM Ahmedabad that incubates, accelerates and invests in early-stage technology startups, and Capital-A, a fund known for backing innovative early-stage startups, which had previously backed Ivory in the pre-seed stage.The funding round saw additional backing from 1Crowd, and Stanford Angels, along with eminent angel investors such as Dr. Sanjay Arora, Adarsh Narahari and Juhi Bhatnagar.According to various researches, 90% of cognitive impairment remain underdiagnosed. With no definitive cure for neurodegenerative conditions like dementia, prevention is the only real defense. Ivory is on a mission to shift the focus from late-stage diagnosis to proactive brain health solutions. Through neuroscience-based digital assessments, it enables early detection of cognitive decline—empowering individuals to take action long before symptoms escalate.With this new capital, Ivory plans to strengthen the technology for its clinical grade assessments and scale distribution to reach more individuals across India.Rahul Krishnan, Co-founder and CPO, Ivory said “With this capital, we aim to further invest in our technology—enhancing the accuracy, depth and reach of our cognitive assessments. As conversations around longevity and preventive health gain momentum, Ivory stands at the intersection of technology, healthcare and aging to reshape how we approach long-term brain wellness.”In the past year, apart from being directly available to consumers through its app, Ivory has also built a robust pipeline of clinicians, psychologists, insurance and corporate partners, like Ather Energy, WeWork and PUMA, who are relying on Ivory to power their Cognitive Risk Screenings.The startup recently garnered national attention with the release of India’s first-of-its-kind Brain Health Report, offering valuable insights into the state of cognitive well-being in the country. Ivory also gained national visibility through its appearance on Shark Tank India Season 4.Looking ahead, the team plans to expand its footprint across new geographies, deepen AI capabilities to personalise assessments further, and invest in longitudinal research to build benchmarks for cognitive health specific to Indian populations. ]]> https://biospectrumindia.com/news/108/25913/lubrizol-to-open-state-of-the-art-technology-and-innovation-centre-in-maharashtra.html https://biospectrumindia.com/news/108/25913/lubrizol-to-open-state-of-the-art-technology-and-innovation-centre-in-maharashtra.html Tue, 01 Apr 2025 00:00:00 +0530 To accelerate India-based innovation, US-based company Lubrizol has announced it will open a state-of-the-art Technology and Innovation Centre in Maharashtra. The first of its kind for the company globally, the facility is designed to progress breakthrough innovations, expand collaboration, and enhance speed to market for Lubrizol and the many customers and industries it serves both in the region and globally, including the pharma sector. The centre will empower collaboration across Lubrizol, co-locating lab capabilities and expanding on the success of existing in-region technology Centres of Excellence (COE). The site will also include a Customer Experience Centre, allowing Lubrizol to co-develop solutions with customers and partners. The facility will feature advanced analytical capabilities to support research needs, including automation and digital tools, allowing teams to apply decision science to accelerate next-generation solutions. Lubrizol’s Technology and Innovation Centre announcement follows multiple Lubrizol investment announcements, with more than $350 million commitment into India over the last 18 months. The company also opened a Global Capability Centre in Pune last year, doubled its capacity at its Dahej, Gujarat, manufacturing site and announced several other projects. The new Lubrizol Technology and Innovation Centre will continue to expand Lubrizol’s network in India. ]]> https://biospectrumindia.com/news/108/25917/emcutix-and-wiqo-sign-licensing-partnership-to-revolutionise-derma-cosmetic-treatments-in-india.html https://biospectrumindia.com/news/108/25917/emcutix-and-wiqo-sign-licensing-partnership-to-revolutionise-derma-cosmetic-treatments-in-india.html Tue, 01 Apr 2025 00:00:00 +0530 Emcutix Biopharmaceuticals, a wholly owned subsidiary of Mumbai-based Emcure Pharmaceuticals, has announced an exclusive in-licensing agreement with WiQo, an innovative Italian derma-cosmetic and medical device company specialised in scientifically validated products. The strategic partnership grants Emcutix the rights to import, promote, distribute and sell WiQo's ground- breaking product PRX-PLUS in India. The collaboration is set to redefine the landscape of non-invasive skin treatments in the region. PRX-PLUS has a unique product feature with its deep-impacting formula that instantly tightens the skin, offering a non-invasive, pain-free alternative to traditional aesthetic treatments for those seeking effective results with convenience. Over 40,000 dermatologists and aesthetic doctors worldwide use WiQo’s patented formulas. Since 2011, over 8 million needle-free skin booster professional procedures have been performed globally. PRX-PLUS is an innovative combination. It features a cutting-edge droplet-based skincare solution that promotes immediate skin lifting without the use of injections, recovery time, or discomfort. It is safe for all skin types and phototypes and suitable for use in all seasons.   The dermatology market in India has been seeing consistent and significant growth in the last few years, owing to increasing awareness about skincare fuelled by growing disposable incomes. According to Indian Pharmaceutical Market (IPM) data, the dermatology market size is estimated to be around $1.8 billion, with a potential growth rate of 11-12% in the near future.  ]]> https://biospectrumindia.com/news/108/25920/madhav-netralaya-eye-hospital-research-centre-to-open-in-nagpur.html https://biospectrumindia.com/news/108/25920/madhav-netralaya-eye-hospital-research-centre-to-open-in-nagpur.html Tue, 01 Apr 2025 00:00:00 +0530 The foundation stone for Madhav Netralaya Eye Hospital & Research Centre was laid recently in a distinguished ceremony attended by Prime Minister Narendra Modi. Planned to be a pioneering institution in ophthalmic care, the facility is being designed by HOSMAC, Asia’s leading hospital planning, management, and design consultancy, overseeing the turn-key design consultancy services. Madhav Netralaya’s architectural vision seamlessly integrates functionality with aesthetics, prioritising patient-centric care. Its elliptical eye-shaped architecture is strategically aligned along the east-west axis to maximize natural light towards the north while reducing heat exposure. The building's rooftop solar panels have an installed capacity of 550 kWp, showcasing HOSMAC’s commitment to sustainability and energy efficiency in healthcare architecture. The hospital’s facade is an eyelid which features curved sandstone walls, protecting the interior clinical spaces from noise and dust pollution. The stone is richly coloured, adding visual depth and textures that are contrasted with panoramic windows. Spread across 5.8 acres, this 250-bed super-specialty eye hospital will offer world-class yet affordable eye care services. With a built-up area of approximately 4 lakh sq. ft., the institute will feature 10 specialised OPDs, 2 dedicated OPDs for community services (Samudayik Sewa), 14 cutting-edge modular operation theatres (OTs), including a dedicated Lasik Surgery Unit, an Eye Bank, and a comprehensive Research Centre. The BARN OT features an open-plan surgical area, where multiple patients are treated in dedicated spaces alongside one another, with each station equipped with an ultra-clean air canopy to minimize the risk of infection. To advance ophthalmic research and treatment, the hospital is benchmarked against leading global institutions and will incorporate advanced facilities such as a Gene Therapy Unit, Biorepository, Genetic Lab, Clinical Trials Centre, Outreach Camp Office, Simulation Lab, and Vision Research Centre. The facility will also include a conference hall, learning centre, and an AYUSH department to ensure a holistic approach to eye care.   ]]> https://biospectrumindia.com/news/108/25867/entod-pharma-and-infigo-eyecare-hospitals-join-hands-to-revolutionise-under-eye-aesthetics.html https://biospectrumindia.com/news/108/25867/entod-pharma-and-infigo-eyecare-hospitals-join-hands-to-revolutionise-under-eye-aesthetics.html Fri, 21 Mar 2025 00:00:00 +0530 Entod Pharmaceuticals has announced a strategic collaboration with Infigo Eyecare Hospital, Mumbai, to introduce advanced treatment options for under-eye dark circles and other ocular aesthetic concerns. This partnership aims to address an often-overlooked aspect of dermatological and ophthalmic care, periorbital health, by integrating progressive innovations into clinical practice. The skin around the eyes is thinner, more sensitive, and prone to issues like pigmentation, fine lines, and puffiness, yet conventional skincare solutions often fail to deliver precise and lasting results. Current treatments frequently rely on temporary solutions such as topical creams that offer limited absorption and performance. There is a strong need for breakthroughs in this space to invent specialised, scientifically backed solutions that attend the root causes of periorbital concerns rather than providing superficial improvements. Nanotechnology has transformed dermatology, boosting treatment efficacy for various skin conditions. It enables deeper penetration of active ingredients, augments bioavailability, and provides sustained release mechanisms, making treatments more impactful. Periorbital hyperpigmentation (POH) affects a significant portion of the population, with prevalence rates reaching up to 30% in India, particularly in individuals with darker skin tones. Genetic predisposition, lifestyle habits, and environmental factors contribute to the condition, often causing distress, particularly among women. Infigo Eyecare Hospital, known for its expertise in ophthalmic care, will integrate these developments into its clinical offerings. The collaboration will provide patients access to state-of-the-art treatment protocols designed to mend under-eye pigmentation, reduce puffiness, and promote overall under eye skin health. Beyond Mumbai, Entod and InfigoEyecare Hospital plan to expand these specialised treatment options to other cities, making modern under-eye care accessible to a wider population.    ]]> https://biospectrumindia.com/news/108/25841/akrivia-biosciences-secures-pre-seed-funding-to-advance-precision-cancer-diagnostics.html https://biospectrumindia.com/news/108/25841/akrivia-biosciences-secures-pre-seed-funding-to-advance-precision-cancer-diagnostics.html Mon, 17 Mar 2025 00:00:00 +0530 Akrivia Biosciences, a Mumbai-based deeptech startup in oncology precision diagnostics, has closed its pre-seed funding through Compulsory Convertible Debentures (CCDs) from JITO Incubation and Innovation Foundation (JIIF) and Rebalance Angels. This funding will be utilised for Proof of Concept trials, the formation of an internal R&D team, and scientific publications that support its breakthrough innovations in cancer treatment. Akrivia Biosciences is revolutionising cancer diagnostics with its next-generation molecular subtyping tests. By leveraging a multi-omics approach, Akrivia is transforming cancer treatment by providing oncologists with precise and comprehensive data to guide personalized therapy. This innovation is reducing overtreatment, improving patient outcomes, and marking a paradigm shift in how cancer is diagnosed and treated. “The world is recognising the significance of precision medicine, which aims to provide the right cancer treatment to the right patient at the right time based on their unique molecular makeup. Akrivia Biosciences is bringing a multi-omics-based next-generation precision treatment solution that can transform cancer treatment strategies from a one-size-fits-all approach to precision medicine in its truest sense,” said Sagar Gosalia , COO of JIIF. He further added “Our investment in Akrivia Biosciences aligns with our commitment to backing deeptech ventures that address critical healthcare challenges. Akrivia’s work in oncology precision diagnostics has the potential to redefine cancer treatment by enabling targeted, effective, and personalized therapies,” Akrivia was founded based on a breakthrough discovery made by Dr Amit Gupta while analysing cancer genomic data. His research has led to a deeper understanding of tumour biology and its impact on disease progression and treatment response. This knowledge has been validated through studies involving approximately 8,000 cancer patients over four years. “Our tests are designed to go beyond conventional genetic panels. They provide oncologists with actionable insights, including long-term risk assessment of cancer recurrence and selection of the most effective targeted therapies for individual patients,” said Dr Amit Gupta, Co-founder of Akrivia Biosciences.     ]]> https://biospectrumindia.com/news/108/25836/h-e-l-group-signs-research-agreement-with-the-institute-of-chemical-technology-in-mumbai.html https://biospectrumindia.com/news/108/25836/h-e-l-group-signs-research-agreement-with-the-institute-of-chemical-technology-in-mumbai.html Fri, 14 Mar 2025 00:00:00 +0530 H.E.L Group, a global developer and manufacturer of innovative laboratory tools for process optimisation, safety, and scale-up, has announced a research agreement with the Institute of Chemical Technology (ICT) in Mumbai to advance process safety in the chemical synthesis industry. The three year strategic alliance will focus on H.E.L’s Process Safety Hub combined with ICT Mumbai’s academic leadership and research acumen in the field of chemical sciences, engineering and allied fields. As part of the agreement, H.E.L will provide ICT Mumbai with a Simular Process Development Reaction Calorimeter, designed for applications including adiabatic calorimetry, autocatalysis, and batch and semi-batch reactors. By leveraging the derived thermodynamic and kinetic information of a reaction, the system enables optimization of process conditions, determination of safest conditions, and provides accurate and reliable measurements for precise process control. The Simular Reaction Calorimeter will be installed in ICT Mumbai’s research lab, where it will be integrated into chemical synthesis workflows as part of the Institute’s educational, mentoring and research programs enabling the development of safe processes to address real-world challenges. Professor Virendra Rathod, former Head of Chemical Engineering at Institute of Chemical Technology, Mumbai, said: “Process optimisation is a critical part of developing safe chemical synthesis workflows. H.E.L’s Simular Reaction Calorimeter offers a highly flexible approach to process development, making it applicable across many of our focus areas Integration of the system into our research and academic programmes, combined with access to H.E.L’s wider expertise in process safety, will be invaluable as we look to develop cutting edge solutions now and in the future.” Rajeev Kumria, General Manager, H.E.L India commented, “Through this collaboration, we look forward to driving innovation and education in process safety, enabling development of efficient, safe chemical synthesis protocols, supporting both parties in our mission to increase focus on sustainability in the chemical technology industry." ]]> https://biospectrumindia.com/news/108/25809/mit-world-peace-university-pune-develops-iot-enabled-pill-dispenser.html https://biospectrumindia.com/news/108/25809/mit-world-peace-university-pune-develops-iot-enabled-pill-dispenser.html Tue, 11 Mar 2025 00:00:00 +0530 MIT World Peace University (MIT-WPU), Pune has developed a modular Internet of Things (IoT)-enabled tablet and capsule dispenser, designed for automated and remotely monitored medication management. This innovative device is intended to assist individuals with complex dosing schedules by ensuring precise and timely medication dispensing. Addressing the limitations of traditional medication dispensers, which often require manual intervention and lack remote monitoring capabilities, MIT-WPU’s solution integrates a modular design with advanced IoT connectivity. The device features an equilateral-shaped container, a motor-driven dispensing system, and a controller unit that enables user-defined dispensing schedules and real-time remote monitoring. Dr Amol Tagalpallewar, Professor, School of Pharmacy at MIT-WPU said, “In today's fast-paced world, maintaining consistent medication adherence is a significant challenge, particularly for individuals managing complex medical regimens. This innovative IoT-enabled pill dispenser represents a leap forward in addressing this challenge. By automating the dispensing process and providing remote monitoring capabilities, we are empowering patients and their caregivers with greater control and peace of mind." Dr C. H. Patil, Associate professor, School of Computer Science and Engineering added, “Furthermore, this device represents a significant step towards the future of healthcare delivery, where technology and human-centred design converge to create more accessible, efficient, and effective solutions. We envision a future where technology is not just a tool, but a partner in promoting well-being and enhancing the quality of life for all.” Functionally, the dispenser utilises dispensing units arranged circumferentially and connected with sprockets, powered by a motor. The controller unit sends command signals at user-specified times, automating the dispensing process. IoT integration allows caregivers and healthcare professionals to monitor medication adherence in real time, enhancing patient safety and care. The device is intended to improve medication management in home care, assisted living, and hospital settings.     ]]> https://biospectrumindia.com/news/108/25820/haystackanalytics-secures-patent-for-cutting-edge-secure-genomic-analysis-technology.html https://biospectrumindia.com/news/108/25820/haystackanalytics-secures-patent-for-cutting-edge-secure-genomic-analysis-technology.html Tue, 11 Mar 2025 00:00:00 +0530 In a country like India, with a rapidly advancing healthcare landscape and a growing focus on equitable access to enhance disease diagnosis and personalized treatment, Mumbai-based startup HaystackAnalytics, a pioneer in genomics-based diagnostic solutions, has secured a patent for its groundbreaking invention, “Systems and Methods for Secure Genomic Analysis Using a Specialised Edge Computing Device.”  This patent marks a significant advance, enabling real-time genomic analysis at the point of use, reducing reliance on complex infrastructure and specialized personnel. It empowers laboratories and hospital labs with real time reporting capabilities with accurate, simplified and timely insights for enhanced patient diagnosis and treatment.  HaystackAnalytics holds exclusive rights to this patent for the next 20 years and is committed to integrating it into all its solutions while making it widely accessible. As genomic sequencing becomes more widespread, the lack of standardised analysis tools has been a major bottleneck. This patent allows real-time sequencing data analysis, minimizing dependence on bioinformatics experts and complex infrastructure. With rising concerns over antimicrobial resistance (AMR), tuberculosis (TB), and emerging infectious diseases, India urgently needs scalable genomic tools that can be seamlessly deployed in hospitals and labs without complex setup requirements. This milestone reinforces the company’s commitment to advancing genomic diagnostics, ensuring standardised, cutting-edge analysis is accessible across diverse healthcare settings. By collaborating with its network of 250+diagnostic labs, 100+ hospitals, and potential public and private healthcare partners, the IIT-B-based company aims to establish this technology as a cornerstone of precision medicine on a global scale. ]]> https://biospectrumindia.com/news/108/25804/sun-pharma-to-acquire-checkpoint-therapeutics-for-355-m.html https://biospectrumindia.com/news/108/25804/sun-pharma-to-acquire-checkpoint-therapeutics-for-355-m.html Mon, 10 Mar 2025 00:00:00 +0530 Mumbai-based Sun Pharmaceutical Industries Limited and US-based Checkpoint Therapeutics, Inc. have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company. Checkpoint is a Nasdaq-listed commercial-stage company focused on developing novel treatments for patients with solid tumour cancers. Checkpoint has received approval from the US Food & Drug Administration (FDA) for UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. The transaction is expected to be completed in the second calendar quarter of 2025. The deal involves an upfront cash payment of $4.10 per share of common stock, representing aggregate upfront consideration of up to $355 million. cSCC is the second-most common type of skin cancer in the United States, with an estimated annual incidence of approximately 1.8 million cases according to the Skin Cancer Foundation. Important risk factors for cSCC include chronic ultraviolet exposure and immunosuppressive conditions. While most cases are localized tumors amenable to curative resection, each year approximately 40,000 cases become advanced and an estimated 15,000 people in the United States die from this disease. ]]> https://biospectrumindia.com/news/108/25789/urgent-need-to-integrate-cognitive-health-screening-into-routine-check-ups-report.html https://biospectrumindia.com/news/108/25789/urgent-need-to-integrate-cognitive-health-screening-into-routine-check-ups-report.html Thu, 06 Mar 2025 00:00:00 +0530 Ivory, an early-stage brain health startup based in Mumbai, has released its latest report, Brain Health Primer on India, shedding light on the state of cognitive well-being in the country. By leveraging neuroscience-based assessments, Ivory is pioneering early detection of cognitive decline, empowering individuals to proactively safeguard their brain health and extend their health span. The report is being released ahead of Brain Awareness Week, which is globally observed from 10th to 16th March to increase public awareness of the progress and benefits of brain research. Dr Anoop Amarnath, Geriatrician and Clinical Advisor to Ivory, emphasised the importance of early cognitive assessments, stating, “With India’s ageing population and rising lifestyle-related diseases, early detection of cognitive decline is crucial. Ivory’s Brain Health Primer report highlights the urgent need to integrate cognitive health screening into routine check-ups, enabling timely interventions for better brain health outcomes.” Over six months, Ivory conducted two assessments to evaluate cognitive health, each with varying degrees of sensitivity and specificity. The first is a 7-minute mini-assessment using neuroscience-based games to determine a user’s cognitive age. The second is an FDA-registered health and lifestyle assessment, a 35-40 minute evaluation, featuring 17 interactive games designed to analyze cognitive function across five key domains: Attention, Memory, Reasoning, Coordination, and Perception. According to the report, approximately 1 in 4 participants reported suffering from psychological concerns (anxiety, depression, PTSD and mild cognitive impairment). Data in the report notes that participants scored above average on skills linked to Attention and Memory when compared to skills linked to Coordination and Perception. Further, 71% of participants had at least one pre-existing clinical risk factor for Dementia, with hypertension and diabetes being the most prevalent. “Our findings underscore that even in a young nation like India, a significant at-risk population exists. This is a call to action,” said Issac John, Co-founder & CEO, Ivory. “Prevention remains our strongest ally, and technology today allows for early detection and intervention.” ]]> https://biospectrumindia.com/news/108/25790/eris-lifesciences-appoints-murari-ranganathan-to-spearhead-cardiometabolic-business.html https://biospectrumindia.com/news/108/25790/eris-lifesciences-appoints-murari-ranganathan-to-spearhead-cardiometabolic-business.html Thu, 06 Mar 2025 00:00:00 +0530 Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company has appointed Murari Ranganathan as President, Cardiometabolic Business. He will be based out of the company’s Mumbai office and take charge of the company’s Anti-Diabetes and Cardiology businesses. Prior to joining Eris, Ranganathan was Commercial Director, Women’s Health, Metabolics, and International Business at Abbott India Limited. He joined Abbott in 2010 as Head Sales, Medical Nutrition and played a variety of roles in his 15-year stint with the Company. Prior to Abbott, he has worked with organisations like Baxter, Novo Nordisk, and Torrent Pharma. He has a bachelor’s in physics and mathematics from Bangalore University and has completed his Postgraduate Diploma in Marketing from St. Joseph College of Business Administration, Bengaluru. On his new appointment, Ranganathan, Eris Lifesciences said, “I’m excited to join Eris Lifesciences in its growth journey. Eris is the youngest among the Top-20 companies in the Indian Pharmaceutical Market with a dynamic and entrepreneurial culture. I look forward to working together with the team and set new benchmarks in disease management and patient care.” ]]> https://biospectrumindia.com/views/108/25765/there-is-limited-investment-in-the-area-of-infection-control-in-indian-hospital-settings.html https://biospectrumindia.com/views/108/25765/there-is-limited-investment-in-the-area-of-infection-control-in-indian-hospital-settings.html Sat, 01 Mar 2025 00:00:00 +0530 What are some of the new technologies being introduced by Getinge, to make surgeries smarter and safer for Indian patients? Philippe Rocher: The transformation of Operating Rooms (ORs) has already started to support the development of new surgical techniques such as minimally invasive surgery, guided surgery or robotic surgery that are safer for patients. These techniques require the integration of new equipment inside the OR. We also see an increasing demand for providing the surgical team with comprehensive patient information in a seamless and consolidated manner. Rooms with high technology density must be designed intelligently to respond to these changing trends. Within our portfolio, we offer complete turnkey solutions to our customers using the IN2 Modular System combined with our medical equipment such as anaesthesia machines, operating tables, ceiling pendants and surgical lights. We have recently introduced the Maquet Corin, a next-generation premium operating table with intuitive user controls, patient recognition, and a unique colour-coding system; and the Maquet Ezea surgical light, which offers user-friendly simplicity and robust reliability for a wide range of surgical applications. These products are innovative and comply with the latest and most stringent international quality standards. We have also recently launched Torin, an OR management software that is using artificial intelligence to improve OR scheduling. It helps in better planning surgeries by managing resources, accurately predicting the duration of interventions, and notifying all relevant stakeholders in real-time. This ensures efficient scheduling, minimises wait time, and maximises operating room utilisation; ultimately improving patient care and safety.    How does Getinge plans to further strengthen its presence in the Indian market? Are you looking for partnerships with more hospitals? Aruna Nayak: India is today in the top 12 of our leading markets in terms of net sales. It has been a high-growth market, and we have observed significant advancements in healthcare infrastructure. The government’s focus through initiatives like Ayushman Bharat and its goal of establishing an All India Institute of Medical Sciences (AIIMS) in every state is creating substantial opportunities.  We are very excited about the rapidly growing healthcare infrastructure in India, particularly driven by the government’s efforts. This will help India catch up to global norms on average bed capacity. We have worked with about 10,000 hospitals and clinics in tier I and tier II cities to create world-class infrastructure.  Another major trend is the increasing adoption of digital solutions, essential not only to address cost pressures but also to manage the shortage of trained clinical staff. Our digital health solutions and modular operating room enable hospitals to optimise workflows, including patient management, hospital operations, and central sterile service department (CSSD) workflows. This allows healthcare providers to get more out of their existing infrastructure. Additionally, our Innovation Center in Bengaluru has recently supported the development of software called Twin View. It replicates the interface of our ventilator screen and allows clinicians to monitor parameters remotely, even outside the ICU. This software not only supports better patient monitoring but also acts as a valuable training tool for clinicians to be more efficient. We find clinicians in India are highly supportive and eager to adopt newer technologies. For example, we have introduced advanced technologies like Fluoptics, NAVA, advanced hemodynamic monitoring, which address key challenges in the patient treatments and helps in decision making and improving clinical outcomes.  Right next to our Mumbai Experience Center, we have a dedicated training room where we will conduct sessions for healthcare professionals on cardiovascular and critical care. We also have an Experience Center in Chennai where we organise numerous training sessions. We also offer hands-on training for the technicians and clinicians directly in their hospitals. For government hospitals, we typically conduct on-site training sessions. We have organised programmes at AIIMS, R&R (rest and recuperation) and other prominent government hospitals. In India, we have around 250 employees, a combination of sales and service teams. We have one of the largest service teams based throughout India, with coverage across the country. Our sales team operates nationwide, primarily covering metro cities and tier-1 cities. We work with about 150 distributors who help cover the entire country.    What is the company’s current share within the Indian market? Aruna Nayak: We have a 90 per cent market share for Endoscopic Vessel Harvesting (EVH), 85 per cent for Extra Corporeal Membrane Oxygenation (ECMO), 70 per cent for Intra-aortic Balloon Counterpulsation and 30 per cent for Advanced Ventilation in India. We have a very broad portfolio across Critical Care, Cardiovascular Surgical Workplaces, Infection Control, and Life Sciences. We have a large portfolio, and we face competition from around 5 to 10 major manufacturers, but the competition overlaps in specific areas only. We provide equipment used in the research and production of sterile injectables including biosimilars and vaccines. Specifically, we supply GMP sterilisers, GMP washers, sterile transfer equipment, isolators, and bioreactors. We work with leading sterile manufacturers in India, both in the biologics and small molecules sectors, particularly for injectables.   What are some of the challenges within the healthcare settings that Getinge is addressing through its innovative products? Philippe Rocher: Getinge is a leading player in Infection Control worldwide. In India, however, the focus and the budget allocated to central sterile service departments (CSSD) are currently limited. While we would be happy to equip more hospitals, there has been limited investment in this area so far. That said, we are committed to expanding our presence and have developed more affordable products for the mid-segment to help address this issue. Our offering includes a large range of washers, sterilisers and consumables designed to improve hospital standards and reduce cross-contamination. Our washer and steriliser systems are user-friendly, featuring two doors: one for the loading and one for the unloading. The dirty instruments enter through the loading door and undergo the washing cycle, and the clean instruments exit through the other door, creating a single flow to avoid cross-contamination. After washing, the instruments are moved to the steriliser, where they pass through a similar process. This design ensures that no instrument skips any step in the cycle. We have designed these systems to be foolproof and guarantee the complete cycle of washing and sterilisation is followed. Given that India is such a vast country, another big challenge that we face is geographical coverage. But there is a strong motivation among many clinicians in India to adopt newer technology. This is very encouraging for us. We have a portfolio of innovative products, and our focus is on continuing to provide the necessary training to ensure that they can be used safely and effectively on patients.   Abhitash Singh abhitash.singh@agrospectrumindia.com ]]> https://biospectrumindia.com/news/108/25744/citiustech-introduces-real-world-data-platform-for-life-sciences-organisations.html https://biospectrumindia.com/news/108/25744/citiustech-introduces-real-world-data-platform-for-life-sciences-organisations.html Wed, 26 Feb 2025 00:00:00 +0530 Mumbai-based CitiusTech, a leading provider of healthcare technology, services & solutions, has announced the launch of a highly scalable and integrated Real-World Data (RWD) platform designed for efficient data management and accelerated insights. The platform provides out-of-the-box support in ingesting datasets from industry’s leading real-world data vendors, and offers a flexible, customizable data pipeline to onboard newer datasets. CitiusTech HealthSPARX streamlines real-world-data management and empowers companies with cutting-edge analytics to drive impactful insights across clinical, research, medical, and commercial operations. Built to support transformative analytics, including SaMD development, the platform accelerates data-driven innovation for life sciences and healthcare organisations.  It is offered as a Platform-as-a-Service (PaaS) model, designed for real-world data management and advanced analytics. Its features include seamless data integration, regulatory-grade analytics capabilities, and a dynamic environment for reporting and visualization. With support for personalised healthcare insights and collaborative data sharing, the platform eliminates traditional bottlenecks and ensures smarter, faster decision-making. For small and medium-sized biopharma companies, CitiusTech HealthSPARX provides a cost-effective alternative to building expensive, custom analytics platforms—saving millions of dollars and years of development time. Large pharmaceutical companies benefit from the ability to rapidly ingest and analyse fit-for-purpose data, reducing costs associated with managing distributed data assets. ]]> https://biospectrumindia.com/news/108/25731/merck-opens-formulation-technology-centre-in-navi-mumbai.html https://biospectrumindia.com/news/108/25731/merck-opens-formulation-technology-centre-in-navi-mumbai.html Tue, 25 Feb 2025 00:00:00 +0530 Merck Life Science has unveiled its Formulation & Technology Centre in Turbhe, Navi Mumbai. As a key part of Merck’s global R&D network, this next-generation facility will serve as a hub for industry collaboration, equipping pharmaceutical companies with advanced tools to optimise drug formulation and accelerate time-to-market across India, APAC, Middle East, and Africa. The Formulation & Technology Centre intends to function as a technology storefront, offering advanced formulation and processing solutions to address the growing demand for complex drug formulations. More than being just a lab; it is a space where knowledge meets practice. The facility is designed to bridge the gap between research and commercial production, helping pharmaceutical manufacturers navigate patent challenges and enhance their product pipelines.  Customers will have access to hands-on training, technical consulting, and tailored solutions designed to tackle challenges in formulation development, production scaling, and troubleshooting. Dr Jitendra Kumar Managing Director, Biotechnology Industry Research Assistance Council (BIRAC) and Archana Jatkar, Associate Secretary General, Indian Pharmaceutical Alliance attended the launch event virtually of the Formulation & Technology Centre, while key dignitaries, including Achim Fabig, Consul General, German Consulate Mumbai; Stefan Halusa, Director General, Indo-German Chamber of Commerce; Makarand Avachat, Executive Vice President, Pharma Research, Lupin Ltd. joined Merck’s leadership team. Pratima Reddy, Country Speaker for Merck India & MD, Merck Specialties, Dhananjay Singh, Managing Director - Life Science, Head of Science and Lab Solutions, India at Merck Life Science, Aditya Sharma, Head of Process Solutions, India Region Dr. Alessandra Ambruosi, Director & Head of Solid Formulations & Pharm Materials R&D, Merck Life Science and Dr Hemgir Gosavi, Head of Formulation & Technology Center, R&D- Solid formulation, Merck Life Science represented the India leadership team at Merck to celebrate this occasion.  The Centre reinforces the company’s commitment to industry-academia collaboration, sustainability and customer-centric innovation. By expanding its capabilities, Merck aims to empower scientists, researchers, and pharmaceutical manufacturers with technical consulting, tailored solutions, and expert-led training programs that support advanced drug formulation and development. By supporting our customers and partners in their journey, we are contributing to the global advancement of pharmaceutical sciences. ]]> https://biospectrumindia.com/news/108/25733/motilal-oswal-alternates-invests-rs-460-cr-in-megafine-pharma.html https://biospectrumindia.com/news/108/25733/motilal-oswal-alternates-invests-rs-460-cr-in-megafine-pharma.html Tue, 25 Feb 2025 00:00:00 +0530 Motilal Oswal Alternate Investment Advisors Private Limited (MO Alts) has agreed to invest upto Rs 460 crore for a majority stake in Mega Fine Pharma Private Limited. The Sanghvi Family, one of the founding-promoter groups, has also participated in this transaction, increasing their stake in the company. Megafine is a Mumbai based export focused API company with two USFDA approved manufacturing facilities in Nashik and Vapi. The company specialises in the manufacture and sale of a diverse range of high-value, low-volume niche Active Pharmaceutical Ingredients (APIs) for chronic therapies. Established in 1995, Megafine is backward integrated to manufacture its own intermediates while also offering contract manufacturing services for APIs and Intermediates to third-party customers. The company has long-standing relations with leading global pharmaceutical companies and has achieved global market leadership in some of its key APIs.  Shailesh Sanghvi, Founder, Promoter and now Managing Director of Megafine stated, “Our focus remains on delivering high-quality products as an independent API supplier in specialized and niche segments. With our manufacturing facilities approved by all major global regulatory authorities, we are committed to excellence. We look forward to partnering with the MO Alts’ team as we embark on the next stage of growth." Rohit Mantri, Managing Director and Co-Head of Private Equity at MO Alts commented, “India’s API industry is witnessing a double-digit growth, driven by increased outsourcing, lower costs and de-risking of global supply chains from China. This is our first sole control investment as MO Alts and we would focus on further strengthening R&D and manufacturing capabilities and creating a platform for further inorganic opportunities." Megafine and its shareholders were advised by Deloitte (financial advisor), JSA (legal) & Pioneer (legal) on the Transaction. Quillon Partners (legal), Alvarez and Marshall (financial), PWC (tax) & MP Advisors (commercial) advised MO Alts. ]]> https://biospectrumindia.com/views/108/25728/cotecna-is-actively-seeking-strategic-collaborations-to-drive-innovation-in-india.html https://biospectrumindia.com/views/108/25728/cotecna-is-actively-seeking-strategic-collaborations-to-drive-innovation-in-india.html Mon, 24 Feb 2025 00:00:00 +0530 What motivated Cotecna to establish a new laboratory in India, and how does it fit into your global operations? Cotecna’s decision to establish a new laboratory in India is driven by the country’s growing demand for high-quality TIC (Testing, Inspection, and Certification) services. As India emerges as a global trade hub, industries such as agriculture, food safety, pharmaceuticals, and consumer goods require world-class compliance solutions. From a strategic and operational standpoint, this facility strengthens Cotecna’s presence in South Asia, aligning with our global vision of expanding in high-growth markets. The decision is driven by strong market demand and client proximity, as India’s TIC market experiences rapid growth fueled by increasing investments in manufacturing, automotive, consumer goods, and food safety. Our strategic location enhances service efficiency and accelerates turnaround times. The new laboratory significantly boosts Cotecna’s regional testing capabilities, particularly in the pharmaceutical sector, allowing us to serve a wider range of industries with high-quality testing solutions. Additionally, the facility is expected to contribute substantially to Cotecna’s revenue growth in India, capturing a significant market share in its first year and targeting sustained double-digit annual growth over the next five years. Designed to meet ISO/IEC 17025 standards, the lab ensures compliance with both local and global regulatory frameworks. It incorporates AI-powered testing, advanced instruments, and digital reporting systems to enhance accuracy and reduce reporting times. Operational efficiency is further optimised through Lean Management and Amoeba Management, driving cost efficiencies and measurable savings. By establishing this laboratory, Cotecna reinforces its commitment to global quality standards, innovation, and client-centric solutions, further solidifying our leadership in the TIC industry.   How does this facility align with Cotecna’s long-term vision for growth in India and Asia? Cotecna’s long-term vision in India and Asia is to strengthen our presence, enhance service offerings, and drive innovation in the TIC sector. This new laboratory is a strategic investment that expands our regional footprint and reinforces our commitment to providing world-class solutions tailored to market needs. Strengthening Cotecna’s presence in South Asia, this facility aligns with our global vision of expanding in high-growth markets. The decision is driven by India’s rapidly growing TIC market, fueled by rising investments in manufacturing, automotive, consumer goods, and food safety. Strategically positioned for client proximity, the facility enhances service efficiency and accelerates turnaround times. It also significantly expands Cotecna’s regional testing capabilities, particularly in the pharmaceutical sector, enabling us to serve a broader range of industries with high--quality testing solutions. Designed to meet ISO/IEC 17025 standards, it ensures compliance with both local and global regulatory frameworks. The facility integrates AI-powered testing, advanced instruments, and digital reporting systems to enhance accuracy and efficiency. Furthermore, operational excellence is driven by Lean and Amoeba Management principles, optimising processes and reducing costs. With a strong commitment to sustainability, the facility is designed to be energy-efficient, minimising its carbon footprint compared to traditional laboratories.   What are the key capabilities and technologies featured in the new state-of-the-art lab, and how it aims to revolutionise testing and inspection solutions? The facility is designed as a state-of-the-art analytical and testing centre, equipped with advanced instruments such as chromatography, mass spectrometry, and molecular biology tools. AI-driven testing and automation enhance accuracy while minimising human error, ensuring precise and reliable results. Additionally, real-time digital reporting and cloud-based data management streamline accessibility and significantly reduce reporting times. With a high-throughput testing capacity, the facility boosts efficiency and accelerates sample processing speeds, catering to industries with stringent timelines. Specialising in agriculture, food safety, pharmaceuticals, and consumer goods compliance, the facility offers tailored solutions to meet diverse industry needs. These cutting-edge capabilities revolutionise testing and inspection by improving accuracy, speed, and regulatory compliance. By providing faster, more reliable results, the facility supports industries that depend on advanced analytical solutions for quality assurance and regulatory adherence.   What steps have been taken to ensure the facility meets global quality standards and compliance? Cotecna adheres to strict international quality and regulatory frameworks to ensure the highest standards of testing and inspection. The facility is accredited with ISO/IEC 17025, a globally recognised standard that guarantees compliance with international testing and calibration requirements. Rigorous quality control measures are implemented through continuous process improvements, ensuring that every analysis meets precise accuracy and reliability standards. Regular audits and regulatory inspections further reinforce industry best practices, maintaining transparency and adherence to evolving compliance norms. Additionally, Cotecna actively collaborates with regulatory bodies and industry leaders to stay aligned with the latest advancements and best practices in testing and certification. These comprehensive measures not only uphold global quality benchmarks but also enhance the facility’s credibility, providing clients with trusted, high-precision testing solutions.   How will the new lab contribute to India’s economy through job creation and skill development? This facility catalyses economic growth and workforce development by creating new job opportunities in scientific, technical, and regulatory fields. The expansion of testing and certification services, drives significant employment growth, attracting skilled professionals and fostering career development. To further enhance expertise in the industry, Cotecna implements specialised skill development programs aimed at training laboratory professionals and industry stakeholders, equipping them with advanced knowledge and technical proficiency. Additionally, the facility collaborates with universities and training centres to develop future industry talent, bridging the gap between academic learning and practical application. By supporting local industries, the facility enables businesses to comply with global standards, enhancing product quality and boosting their export potential. Through these initiatives, Cotecna not only strengthens India’s position in the global TIC (Testing, Inspection, and Certification) market but also contributes to sustainable economic growth by fostering a highly skilled workforce and promoting industry excellence.   Are there plans to collaborate with local research institutions, universities, or government bodies? Yes, Cotecna is actively seeking strategic collaborations to drive innovation, enhance regulatory compliance, and strengthen industry standards in India. Partnerships with universities and research institutions play a crucial role in advancing research and development (R&D), fostering innovation in analytical testing, and equipping future professionals with cutting-edge expertise. By working closely with regulatory bodies and government agencies, Cotecna ensures alignment with evolving policies, compliance requirements, and global best practices, contributing to a more robust and transparent regulatory framework. Additionally, collaborations with industry associations help in setting higher industry benchmarks, improving testing methodologies, and enhancing overall compliance standards across various sectors. These partnerships not only facilitate knowledge-sharing and capacity-building but also create a collaborative ecosystem that drives technological advancements, promotes regulatory excellence, and supports the long-term growth of India's testing, inspection, and certification (TIC) industry.   What key trends and challenges do you see in India’s testing, inspection, and certification industry? Trends include increased regulatory scrutiny and demand for higher safety standards; adoption of AI, automation, and digital solutions in compliance testing; growth in sustainability and ESG-driven testing services. While the challenges include keeping up with evolving regulations across multiple industries; bridging the skill gap for specialised testing professionals, and maintaining cost efficiency while delivering high-quality services. Cotecna is addressing these challenges by investing in technology, regulatory expertise, and industry partnerships to stay ahead of evolving market needs.   sanjiv.das@mmactiv.com ]]> https://biospectrumindia.com/news/108/25695/midcs-proposed-pharma-hub-set-to-transform-sindhudurg-into-pharma-powerhouse.html https://biospectrumindia.com/news/108/25695/midcs-proposed-pharma-hub-set-to-transform-sindhudurg-into-pharma-powerhouse.html Tue, 18 Feb 2025 00:00:00 +0530 Sindhudurg, known for its pristine coastline and eco-sensitive zones, is now poised to emerge as Maharashtra’s next big pharmaceutical hub. In a strategic move to strengthen the pharmaceutical sector and drive industrial growth, the Maharashtra Industrial Development Corporation (MIDC) has unveiled plans to establish a dedicated Pharma Hub at the Adali Industrial Area. This ambitious initiative aims to attract investments, generate employment, and bolster the region’s economic landscape. Sindhudurg's geographical advantage makes it an attractive destination for industrial development. The proposed Pharma Hub enjoys excellent connectivity via multiple transport modes via road, rail and air transport access. The National highways provide seamless connectivity to major cities and ports. The Manohar International Airport in Mopa, Goa is merely 14 kilometres away, facilitating quick access for logistics and business operations.  The Sawantwadi railway station, located 21 kilometres from the site, ensures efficient transportation of goods and workforce.  Additionally, the region boasts an uninterrupted power and water supply, ensuring smooth industrial operations without infrastructural bottlenecks. One of the key factors driving this initiative is the availability of skilled manpower. Sindhudurg is home to numerous educational institutions, including engineering colleges and Industrial Training Institutes (ITIs), producing a steady stream of qualified professionals. Currently, many local graduates migrate to Goa in search of employment due to limited industrial opportunities in Sindhudurg. The Pharma Hub is expected to reverse this trend by creating ample job openings in pharmaceutical and allied industries. MIDC has already completed substantial infrastructure developments at the Adali Industrial Area, including internal road networks for seamless mobility within the industrial estate, adequate power supply to support energy-intensive pharmaceutical operations, and reliable water facilities to meet the stringent requirements of the pharma industry. Furthermore, MIDC has committed to establishing a Central Effluent Treatment Plant (ETP) if many pharmaceutical companies set up operations, ensuring adherence to environmental norms and sustainable industrial practices. Given Sindhudurg's designation as an eco-sensitive zone, only non-polluting industries will be allowed to operate in the Pharma Hub. The permitted industries include pharmaceutical formulation units, pharmaceutical machinery manufacturing, printing and packaging solutions for the pharma sector, HDPE bottle and allied component manufacturing As the Adali Industrial Area falls under the Zone D Category of MIDC, the government offers substantial incentives to attract investments. These incentives include financial assistance, tax benefits, and relaxed regulatory norms to ensure ease of doing business for pharmaceutical firms. The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has taken a keen interest in the initiative. Speaking on the project, Raja Bhanu K, Director General of Pharmexcil, highlighted the immense potential of the Pharma Hub, stating, “The proposed Pharma Hub at Adali Industrial Area presents a tremendous opportunity for the pharmaceutical industry. With a strong infrastructure, a skilled workforce, and attractive incentives, this initiative will drive industrial growth and employment in Sindhudurg. We encourage stakeholders to engage actively and capitalise on this strategic expansion.” The establishment of the Pharma Hub in Sindhudurg signals a paradigm shift in the region’s economic trajectory. By fostering industrial growth while maintaining environmental sustainability, the initiative is set to transform Sindhudurg into a thriving pharmaceutical and allied manufacturing hub, reinforcing Maharashtra’s position as a leader in the pharma sector.   Bhagwati Prasad ]]> https://biospectrumindia.com/news/108/25687/iscrs-18th-annual-conference-highlights-innovation-technology-and-patient-centricity.html https://biospectrumindia.com/news/108/25687/iscrs-18th-annual-conference-highlights-innovation-technology-and-patient-centricity.html Mon, 17 Feb 2025 00:00:00 +0530 Indian Society for Clinical Research (ISCR), an association of clinical research professionals, hosted its 18th Annual Conference at CIDCO Exhibition & Convention Centre, Vashi, Navi Mumbai on January 31 and February 1, 2025. Marking two decades of advancing clinical research in India, ISCR also celebrated its 20-year journey at the event. The conference welcomed participation from over 2100 delegates and featured 300 eminent speakers. It brought together a diverse group of experts to discuss key themes, including advancements in patient-centric approaches in clinical trials, ethics, artificial intelligence, innovations in data management, statistical reporting, medical writing, programming, and increased academic participation in research. All discussions revolved around the central theme: "Enhancing India’s Success in Clinical Research: Unifying Innovation, Technology, and Patient Centricity." A key highlight of the conference was the launch of ISCR’s Artificial Intelligence (AI) and Machine Learning (ML) paper during the inaugural session, highlighting the growing impact of AI and ML in clinical research. Dr Santosh Kadam, President of IMA Maharashtra, emphasised the importance of innovation and addressing unmet medical needs during his inaugural address. He highlighted how clinical research plays a pivotal role in ensuring that new medicines, vaccines, diagnostics, and devices are thoroughly tested for safety and efficacy. Prominent industry thought leaders and experts like Dr. Arijit Nag (Tata Memorial Center), Dr Rahul Purwar (IIT Mumbai), Dr Ganesh Dakhle (AIIMS, Nagpur), Dr Kshitij Jadhav (IIT Mumbai), Dr Anant Patil (DY Patil Medical College, Nerul) etc. were part of sessions which discussed the evolving role of clinical research in healthcare. Other speakers at the event included representatives from leading R&D organisations such as Sun Pharma, Dr Reddy’s,  Biocon Ltd. as well as other multinational R&D organisations. They enriched the dialogue with valuable insights on cutting-edge technologies, innovative methodologies, and patient-centric approaches shaping the future of the sector. The conference also emphasised the importance of collaboration and innovation in enhancing clinical trial methodologies. Interactive sessions like “Revolutionising Dose Decision Making” and “Harnessing the Power of Statistics in Cancer Care” provided attendees with practical strategies for improving trial outcomes and patient-centric solutions. The event concluded with engaging panel discussions on preparing effective regulatory submissions and bridging data gaps using advanced statistical tools. Highlighting importance of clinical research in India, Dr Sanish Davis, President of ISCR, said, “The 18th Annual Conference exemplifies our commitment to advancing the discipline of clinical research in India by fostering collaboration and innovation. As methodologies like artificial intelligence, machine learning, decentralized trials, adaptive designs, and patient-centric approaches rapidly evolve, this platform enables meaningful discussions on integrating these advancements into the Indian clinical research ecosystem. Together with academia, regulators, innovation driven R&D organizations and patients, ISCR aims to push  the vision of Viksit Bharat to bring forth impactful healthcare solutions, prioritising both quality and accessibility." In its journey to becoming a global leader in clinical research, India’s evolving policy landscape continues to play a pivotal role in shaping the research ecosystem. With ongoing regulatory advancements, the country is well-positioned to foster innovation, enhance patient outcomes, and establish itself as a hub for cutting-edge discoveries, innovations and clinical trials. Beyond the conference, ISCR actively builds public awareness about clinical research. In 2024, ISCR's Run4Research engaged the public in discussions on its healthcare impact, reinforcing ISCR’s commitment to bridging knowledge gaps and fostering trust in clinical research. ]]> https://biospectrumindia.com/news/108/25679/maxivision-group-of-eye-hospitals-joins-hands-with-ojas-group-of-eye-hospitals.html https://biospectrumindia.com/news/108/25679/maxivision-group-of-eye-hospitals-joins-hands-with-ojas-group-of-eye-hospitals.html Sat, 15 Feb 2025 00:00:00 +0530 Maxivision Group of Eye Hospitals has announced its entry into Maharashtra through a strategic partnership with Ojas Group of Eye Hospitals, a world renowned and reputed eye care provider in Mumbai. Together, the newly formed Joint Venture – Ojas Maxivision Eye Hospitals aims to invest Rs 500 crore to expand operations across Maharashtra. Under the visionary leadership of Dr Niteen Dedhia, Ojas Group of Eye Hospitals currently operates three premier centers in Mumbai—Bandra (W) and Kandivali (E)—providing exceptional eye care with international standards to patients through a team of expert Eye Surgeons and Faculty staff. Ojas is the first eye hospital in Western India to introduce advanced eye treatments such as the flapless ELITA SILK procedure for vision correction, 3D imaging and robotic cataract procedures, phakic lens treatment for correction of very high eye powers and advance dry eyes treatment. The hospital remains dedicated to utilizing state-of-the-art technology to deliver the best visual outcomes to the patients. Maxivision Super Specialty Eye Hospitals is one of the leading eye care facilities in India today.  Presently, the network has expanded to include over 50+ centers, with continued growth, covering six states in South and West India. Maxivision has its network of hospitals in Telangana, Andhra Pradesh, Tamilnadu, Kerala, Gujarat and now entering Maharashtra and Madhya Pradesh. The company has also raised Rs 1300 crore from Quadria Capital last year to drive organic expansion and inorganic growth and cement its position as one of India’s leading eye care platforms. By merging Ojas Eye Hospitals expertise in state-of-the-art surgical interventions and patient-focused care with Maxivision’s extensive network and commitment to innovation, the collaboration aims to revolutionise eye care standards in Maharashtra and reach out to the people in the interiors of the State.   ]]> https://biospectrumindia.com/news/108/25655/uk-gives-nod-to-glenmark-pharmas-winlevi-for-treatment-of-acne.html https://biospectrumindia.com/news/108/25655/uk-gives-nod-to-glenmark-pharmas-winlevi-for-treatment-of-acne.html Mon, 10 Feb 2025 00:00:00 +0530 Mumbai-based Glenmark Pharmaceuticals has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi in the United Kingdom. Winlevi is a topical treatment for acne vulgaris in patients aged 12 years and older, marking a significant milestone in the commitment of both companies to providing innovative, patient-focused dermatology solutions. Winlevi is the first topical acne treatment in nearly 40 years with a first-in-class mechanism of action. Its active ingredient, clascoterone, is the first commercially available topical androgen receptor inhibitor, targeting androgen receptors in sebaceous glands with no systemic anti-androgen effects, and as such it can be used safely in both males and females. This approach is believed to help reduce sebum production and intervene early in acne pathogenesis. Two identical phase 3 studies demonstrated that clascoterone cream,1%, applied topically twice daily for 12 weeks, was more effective than the application of vehicle cream in achieving the Investigator’s Global Assessment (IGA) of success, reducing non-inflammatory lesion count (NILC) and inflammatory lesion count (ILC) in patients with facial acne vulgaris. clascoterone cream, 1%, was generally well tolerated. As part of the agreement signed in September 2023, Glenmark has in-licensed the product from Ireland-based Cosmo Pharmaceuticals for distribution in Europe and South Africa.  According to Christoph Stoller, President & Business Head - Europe and Emerging Markets, Glenmark Pharmaceuticals, "This approval by the MHRA represents a significant step forward in our mission to enhance dermatology care. Our partnership with Cosmo Pharmaceuticals plays an important role in enabling us to expand our dermatology portfolio."     ]]> https://biospectrumindia.com/news/108/25647/tata-chemicals-signs-mou-with-bsdts-integrated-cancer-treatment-and-research-centre-in-pune.html https://biospectrumindia.com/news/108/25647/tata-chemicals-signs-mou-with-bsdts-integrated-cancer-treatment-and-research-centre-in-pune.html Fri, 07 Feb 2025 00:00:00 +0530 Tata Chemicals Limited (TCL) a leading sustainable and science-led chemistry solutions company has signed a Memorandum of Understanding (MoU) with Bharatiya Sanskriti Darshan Trust (BSDT)’s Integrated Cancer Treatment and Research Centre (ICTRC) in Pune. This collaboration aims to explore the beneficial effects of TCL's prebiotic, soluble dietary fibers, and their derivatives on gut health and overall wellness. This initiative underscores Tata Chemicals' and BSDT's shared commitment to delivering science-backed nutrition solutions that enhance quality of life. The MoU was signed in the presence of Tata Chemicals' R&D team, led by Dr Richard Lobo, and the BSDT team, led by Dr Sushrut S. Sardeshmukh, Trustee, BSDT, and Dr Vineeta V. Deshmukh, Deputy Director, ICTRC. This partnership will focus on integrating scientific research with Ayurvedic principles to develop advanced solutions for health and wellness. Speaking on the occasion of signing the MoU, Dr Richard Lobo – Head - Innovation, R&D, Business Excellence and Chief Ethics Counsellor at Tata Chemicals said "This is a momentous occasion for us as BSDT’s Integrated Cancer Treatment and Research centre's mission and its values are closely aligned with that of Tata Chemicals. We are committed to working together in understanding and improving the functionality of our science-differentiated products in Ayurvedic formulations, for improving the quality of life & alleviating pain through Ayurvedic disciplines.” Dr Sushrut S. Sardeshmukh , Trustee at Bharatiya Sanskriti Darshan Trust added “We are very pleased to be working closely with Tata Chemicals. At BSDT, our mission has always been to integrate Ayurveda with modern science to enhance patient care and improve quality of life. This collaboration is a significant step towards advancing research in Ayurveda integrated in wellness products with science-backed innovations. By combining our expertise in holistic healing with Tata Chemicals’ commitment to Innovative products, we aim to further explore solutions that support holistic well-being.”   ]]> https://biospectrumindia.com/views/108/25635/pioneering-sustainable-innovation-dr-nagaraj-rao-on-rrr-labs-journey-and-future-vision.html https://biospectrumindia.com/views/108/25635/pioneering-sustainable-innovation-dr-nagaraj-rao-on-rrr-labs-journey-and-future-vision.html Wed, 05 Feb 2025 00:00:00 +0530   In an interview with BioSpectrum India, Dr. rer. nat. Nagaraj Rao, Director of RANE RAO RESHAMIA LABORATORIES PVT LTD (RRR Labs), delves into the company’s inspiring journey—from its origins as a venture by three first-generation entrepreneurs to becoming a niche innovator in sustainability-driven biotech and industrial solutions. Dr. Rao discusses the company's groundbreaking work in platinum recovery, nanosilver applications, and industry collaborations, as well as the strategic vision for 2025, including the launch of a new facility in Navi Mumbai. He also reflects on the challenges of scaling a deep-tech enterprise and how Indo-German partnerships can bolster India’s biotech ecosystem. Can you share the story behind the founding of RRR Labs?  RRR Labs was founded by three first generation entrepreneurs, as our name suggests, who had studied together in Mumbai. Success in group activities such as inter-collegiate science exhibitions and rural camps inspired us to venture into industry. What inspired you to venture into research and innovation? I think there were several reasons. With backgrounds in chemistry and pharmaceutical and fine chemical technology, I got an opportunity to develop a stable, all-purpose skin cream in my very first job with a global FMCG company in Mumbai, which became a best-seller. During my years of study and research in Germany, I was keenly interested in various subjects including biochemical engineering and organic/medicinal chemistry. The large network of former students in the German University where I taught as well as friends and colleagues from my doctoral and post-doc Research Institute and in industry gave a sense of motivation assurance to venture into doing something different in India. RRR Labs is known for its focus on sustainability and cutting-edge technologies. Could you elaborate on the unique solutions your company offers and how they stand out in the industry? Circular economy is in fashion only now, although it is absolutely necessary in every industry. In the field of Surface Coating Technologies, we developed equipment and processes for recovering precious metals for reuse, with quick returns on investment. Platinum remains a critical raw material for certain anti-cancer drugs, apart from various other industrial applications. Our recently developed eco-friendly, non-hazardous process for onsite cleaning and recovery of platinum metals from caprolactam and nitric acid plants, which is awaiting patent approval, eliminates the use of mineral acids and is poised become a global game changer in the industry. In the field of Life Sciences, we have recently filed a patent application for medical use of nanosilver incorporated in natural textiles. What challenges did you face in establishing and scaling RRR Labs? The beginnings in the early 1990’s after a long stay in Germany were quiet challenging, especially because while we had local experience in the service industry, we were new into the manufacturing business. Capital was scarce and we ploughed back all profits for the growth of business for several years. We used to manufacture a bulk drug for some years but had to give it up due to cheap imports from China. This made us realise that in certain fields of business, large capital investments and large-scale production are very critical. We had to choose between expanding our production capacities with large borrowings and  remaining small and focussed. We consciously chose to focus on niche products and niche markets.  What helped you to overcome these challenges? Doing business with customers in Europe in general was easier compared to doing business with local customers, though things have improved here since recent times. Since we are active in different areas of industry, ranging from Life Sciences to Defence Hardware and Surface Coating Technologies, technical employees have to be trained considerably and for a long time, before they can start thinking holistically. Consistent support and encouragement from the family helped in overcoming many of the challenges we faced over the years. Collaboration is key in the biotech and healthcare industries. Can you discuss any notable partnerships or collaborations that have significantly impacted your company’s growth? Biotech and Healthcare being capital intensive industries and our focus being on niche products and niche markets, our collaborations are slightly different in nature. We have as yet not ventured into manufacturing. Working with small and mid-size European biosciences companies and research institutes has been mutually beneficial. Personal contacts and long-standing relationships have helped us to forge partnership with reputed, innovative companies. I had the privilege of being a visiting faculty for bioprocess technology for the first Masters course, started in 1993 at the Institute of Chemical Technology, Mumbai (formerly UDCT), for fifteen years and many of those students occupy leading positions in industry today. Although all fields of technology have always excited me, I have been focussing more on biotechnology since some years and the response of the Indian industry has been very positive, particularly from companies which manufacture Biosimilars and Vaccines in India. It is heartening to note here that we are getting encouraging signs from Indian research institutes and universities, at a time when the biotech industry’s sentiments are a bit different than during the COVID-19 pandemic. You seem to value your relationships in Germany a lot? How could it help the Indian biotech industry?   There are several innovative biotech companies and research institutes in Germany, whose offerings could be of great relevance to Indian companies. Although such companies meet potential partners from India, particularly at conferences and exhibitions, our field requires more than just sales and marketing inputs. Although English is becoming the language of communication, there are several cultural and communication gaps, which can lead to failures or delays, and which require to be addressed quickly and professionally. As we look ahead to 2025, what are RRR Labs' strategic goals and priorities, and how do you plan to drive innovation and sustainability in the coming year? We shall soon be inaugurating a 10,000 Sq ft facility in Navi Mumbai with continued emphasis on new product development. We shall also be strengthening our cold storage capacities to meet local requirements. Simultaneously, we are working on increasing our intellectual property bank with new patent applications.   (ankit.kankar@mmactiv.com ) ]]> https://biospectrumindia.com/news/108/25638/goqii-and-acrannolife-genomics-launch-ai-driven-initiative-for-post-transplant-care.html https://biospectrumindia.com/news/108/25638/goqii-and-acrannolife-genomics-launch-ai-driven-initiative-for-post-transplant-care.html Wed, 05 Feb 2025 00:00:00 +0530 Mumbai-based GOQii, a leading smart preventive healthcare company, has joined forces with Acrannolife Genomics, a pioneer in precision diagnostics in Chennai, to launch the GrafCare Programme. This ground breaking initiative leverages advanced genomic diagnostics, artificial intelligence (AI), and personalised health monitoring to redefine post-transplant care for organ recipients in India. To address the unique challenges faced by transplant recipients, the GrafCare Programme combines Acrannolife’s patented Trunome test with GOQii’s smart health ecosystem. This powerful integration offers early detection, real-time health monitoring, and tailored support to enhance patient outcomes and quality of life. Acrannolife’s US-patented Trunome test is a non invasive blood test that identifies early signs of organ rejection or infection. Powered by advanced genomic research and AI, the test provides clinicians with precise, actionable insights to intervene before complications escalate. Patients receive a GOQii Smart Vital Device, which tracks vital parameters such as heart rate, blood pressure, and oxygen levels in real time. AI-driven predictive analytics assess patient data to generate early alerts and personalised recommendations, enabling proactive care. With over 20,000 transplants performed annually in India and a growing global demand for post-transplant solutions, the GrafCare Program is poised to redefine healthcare delivery. ]]> https://biospectrumindia.com/news/108/25630/alkem-launches-kojiglo-serum-in-india-to-manage-facial-hyperpigmentation.html https://biospectrumindia.com/news/108/25630/alkem-launches-kojiglo-serum-in-india-to-manage-facial-hyperpigmentation.html Tue, 04 Feb 2025 00:00:00 +0530 Mumbai-based Alkem Laboratories has announced the launch of Kojiglo serum in India for managing facial hyperpigmentation. Alkem is the first Indian company to introduce a liposomal serum with Duo-Lipo technology. The serum is suitable for all skin types. This innovative formulation combines cutting-edge ingredients such as liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide, making it a first of its kind in India to have a Duo-Lipo technology. This advanced serum encapsulates the active ingredients in a liposomal form to enhance penetration in the skin and deliver targeted action. This formulation ensures effective results while reducing the risk of skin sensitivity and irritation. The active pharmaceutical ingredients are carefully sourced to meet global quality standards, offering a high-quality, reliable solution for facial hyperpigmentation. With the introduction of Kojiglo serum, Alkem aims to broaden its portfolio and increase its market share in the skincare segment. Dr Vikas Gupta, Chief Executive Officer, Alkem, said, “The prevalence of skin hyperpigmentation among Indian population is quite high and awareness about managing this condition is gradually increasing. We are pleased to introduce an advanced serum designed to effectively address hyperpigmentation concerns." ]]> https://biospectrumindia.com/views/108/25634/integration-of-cutting-edge-technologies-and-personalised-treatment-approaches-is-revolutionising-the-field-of-radiation-oncology.html https://biospectrumindia.com/views/108/25634/integration-of-cutting-edge-technologies-and-personalised-treatment-approaches-is-revolutionising-the-field-of-radiation-oncology.html Tue, 04 Feb 2025 00:00:00 +0530 You being the first to implement advanced precision radiation therapy for Deep Inspiration Breath Hold (DIBH), how does this technology work and what does it makes superior to conventional treatments? Yes, indeed it is a proud moment for our expert team at Sahyadri Hospital to achieve the milestone of becoming the first Cancer care institutions in the world to implement advanced precision radiation therapy for Deep Inspiration Breath Hold (DIBH). This innovative technology is designed to enhance patient care by minimizing radiation exposure to critical organs, such as the heart, during treatment. Before initiating the first treatment, the hospital conducted rigorous quality assurance checks and validation tests to ensure the reliability and accuracy of the technology. The first patient to benefit from this advancement was a 45-year-old woman with early-stage left-sided breast cancer who had previously undergone surgery and chemotherapy. To reduce radiation exposure to her heart, DIBH with Surface Guided Radiation Therapy (SGRT) was employed using the VitalHold feature on the Radixact System. Over her 15-day therapy, the patient adapted effortlessly to the process, finding the system intuitive and comfortable. She particularly valued the non-invasive nature of the setup, which eliminated the need for tattooing. Her feedback underscored the user-friendly design and the simplicity of following breath-hold instructions, making her experience overwhelmingly positive.   With the National Cancer Registry Programme reporting rising cancer cases in India, how do you see this emerging technology addressing the growing demand for advanced diagnostic and treatment solutions? According to recent estimates, India records approximately 1.35 million new cancer cases annually. With only around 900 radiotherapy installations currently available, the country faces a significant shortfall, requiring an additional 850 to 900 installations to adequately meet population coverage needs. This demand is projected to rise as cancer cases continue to increase over the next decade. Utilizing empty cobalt bunkers presents an opportunity to enhance efficiency and improve patient access to radiotherapy technology. The field of radiation oncology is undergoing a transformative shift, driven by the integration of advanced technologies and personalised treatment approaches. These innovations are delivering better treatment outcomes and elevating the overall patient care experience. Radiation therapy remains a cornerstone in the treatment of various cancers, and emerging advancements such as Artificial Intelligence (AI) and Machine Learning (ML) are paving the way for a new era in cancer care. Techniques like Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), and Stereotactic Body Radiation Therapy (SBRT) allow oncologists to target tumours with remarkable precision, minimizing damage to healthy tissues. This precision not only improves the effectiveness of treatments but also reduces side effects, significantly enhancing patients' quality of life during and after therapy.   What advantages do you see in precision radiation therapy's ability to target tumours more accurately while minimising damage to healthy tissues? What advancements in this field do you believe will shape the future of oncology? The advancements in precision radiation therapy are poised to significantly shape the future of oncology by enhancing treatment efficacy while minimizing collateral damage to healthy tissues. Technologies such as Intensity-Modulated Radiation Therapy (IMRT) and Stereotactic Body Radiation Therapy (SBRT) allow for highly targeted radiation delivery, which is crucial for tumours that may be located near critical organs. These methods enable oncologists to adapt treatment plans in real-time based on imaging data, ensuring that radiation is accurately directed at moving or changing tumors. Moreover, the integration of artificial intelligence and machine learning into treatment planning is revolutionizing how we approach individualised care. By analysing vast amounts of patient data, these technologies can help predict treatment responses and optimise dosages tailored to each patient's unique tumour biology. The incorporation of genomic profiling further personalizes treatment strategies, allowing us to identify specific molecular targets and adjust radiation plans accordingly. As we continue to refine these techniques, we anticipate a future where precision radiation therapy not only improves survival rates but also enhances the quality of life for patients through reduced side effects and shorter recovery times. The ongoing research and development in this field signal a transformative shift in cancer care, making it more effective and patient-centred than ever before.   What are the challenges in scaling such advanced technology across other hospitals in India? How can these barriers be addressed to make cutting-edge cancer care more accessible nationwide? The integration of cutting-edge technologies and personalised treatment approaches is revolutionising the field of radiation oncology, leading to improved treatment outcomes and an enhanced patient care experience. Technology advances such as the introduction of image-guided radiotherapy (IGRT) have enabled smaller treatment volumes, shorter treatment fractionation schedules, improved outcomes, and minimised toxicity. Emerging technologies like Artificial Intelligence (AI) and Machine Learning (ML) can pave a way for new era in cancer treatment. With cutting-edge technologies like Intensity-Modulated Radiation Therapy (IMRT), Image-Guided Radiation Therapy (IGRT), and Stereotactic Body Radiation Therapy (SBRT), oncologists can precisely target tumours with minimal damage to healthy tissue. This precision not only enhances treatment efficacy but also reduces side effects, improving patients' quality of life during and after therapy. outcomes, and minimised toxicity. The use of hypofractionation, which uses fewer fractions of radiotherapy with a higher dose per fraction compared to conventional fractionated regimens has grown more common as delivery techniques have become more accurate, helping to boost efficiency. The most common examples are stereotactic body radiotherapy (SBRT) and stereotactic radiosurgery (SRS), delivering full treatment over 1-5 sessions. Although these technological advances in planning and treatment delivery have helped to drive new practices in radiotherapy, the need for precise image guidance, patient immobilisation, and motion management may contribute to the perception of complex workflows that can be resource-intensive and prohibitive.   Amguth Raju ]]> https://biospectrumindia.com/news/108/25609/zydus-takeda-to-expand-product-portfolio-with-new-apis-and-ksms.html https://biospectrumindia.com/news/108/25609/zydus-takeda-to-expand-product-portfolio-with-new-apis-and-ksms.html Fri, 31 Jan 2025 00:00:00 +0530 Zydus Takeda Healthcare Private Limited, a joint venture company set up by Zydus Lifesciences Limited and Takeda Pharmaceutical Company Limited, recently celebrated the 25th anniversary of the Vashi manufacturing plant in India. Looking to the future, Zydus Takeda aims to elevate the site’s role within Takeda's strategic network. Key initiatives include expanding the product portfolio with new active pharmaceutical ingredients (APIs) and key starting materials (KSMs), enhancing kilo lab facilities, transitioning to renewable energy to support Takeda’s net-zero emissions goal, investing in digital automation technologies to improve efficiency and reducing waste. Additionally, the focus is on developing new supply chain strategies, strengthening global collaboration, driving employee engagement through continuous learning, and advancing initiatives focused on health and environmental sustainability. Over the past 25 years, the manufacturing site at Vashi has emerged as a supplier of APIs and intermediates for Takeda’s markets in Europe, Japan, Brazil, and Korea. As a 100% export-oriented unit, it has consistently put safety and quality first. Reflecting on its journey, the site successfully executed capacity enhancements and multiple tech transfers for key Takeda small molecule products, and maintained competitiveness, making it an important manufacturing site within Takeda’s network. ]]> https://biospectrumindia.com/news/108/25610/cotecna-life-sciences-india-inaugurates-new-laboratory-in-mumbai.html https://biospectrumindia.com/news/108/25610/cotecna-life-sciences-india-inaugurates-new-laboratory-in-mumbai.html Fri, 31 Jan 2025 00:00:00 +0530 Cotecna Life Sciences India Private Limited, formerly Geo-Chem Pharma, has announced the inauguration of its new, state-of-the-art laboratory in Mumbai. This development represents a significant step in supporting the rapid growth of India’s pharmaceutical industry and demonstrates Cotecna’s dedication to fostering innovation, quality, and customer success. The new facility, FDA-approved and NABL-accredited, is designed to meet the most stringent global standards for pharmaceutical testing and inspection. Equipped with cutting-edge technology, it offers tailored solutions to accelerate drug development, ensure compliance, and uphold the highest levels of quality control—key factors in helping pharmaceutical companies thrive in an increasingly competitive and regulated market. Speaking on the occasion, Sebastien Dannaud, CEO at Cotecna Inspection, said, “This new laboratory marks a significant milestone in our mission to support India’s pharmaceutical sector. It highlights our commitment to driving quality, innovation, and efficiency in drug development. By combining advanced technology with the expertise of our global network—including SHIVA Labs in India and Neotron Pharma in Europe—we are dedicated to delivering safe and effective solutions to global markets.” Leveraging its global network, Cotecna Life Sciences combines the expertise of Neotron Pharma, a premier European GMP analytical laboratory specialising in chemical and physical testing of APIs, drugs, and packaging, with SHIVA Labs in Bengaluru, known for its cGMP-compliant and USFDA-approved analytical services. Together, they provide comprehensive solutions such as impurity analysis, stability studies, and pharmacopeial testing, meeting the highest international standards.     Image caption- Sebastien Dannaud, CEO of Cotecna Inspection (right) and Amit Chopra CEO - South Asia Middle East, Cotecna (centre)inaugurat state-of-the-art laboratory in Mumbai ]]> https://biospectrumindia.com/news/108/25602/lupin-and-avas-launch-namuscla-in-italy.html https://biospectrumindia.com/news/108/25602/lupin-and-avas-launch-namuscla-in-italy.html Tue, 28 Jan 2025 00:00:00 +0530 Global pharma major Lupin, based in Mumbai, and Avas Pharmaceuticals SRL have announced the launch of Lupin’s orphan drug NaMuscla (mexiletine) in Italy. Avas will commercialise NaMuscla for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. NaMuscla is the first and only licensed product for this indication. NDM disorders are a group of rare, inherited neuromuscular disorders which is characterised by the inability to relax muscles following voluntary contraction. NaMuscla reduces myotonia symptoms in people with NDM, resulting in a significant improvement in quality of life and other functional and clinical outcomes for patients. NaMuscla, which has been designated orphan drug status, received EU marketing authorisation in December 2018. Under the terms of the agreement, Avas will initially commercialise NaMuscla as a Class C (Tier 2), while Lupin negotiates with AIFA (Agenzia Italiana del Farmaco) for the reimbursement of the product in Italy. This will ensure consistent access to NaMuscla for patients in Italy, leveraging the established supply network that already serves patients across Germany, France, Spain, Austria, Norway, Sweden, and the UK.   ]]> https://biospectrumindia.com/news/108/25576/lilavati-hospital-announces-new-state-of-the-art-cancer-care-institute-in-mumbai.html https://biospectrumindia.com/news/108/25576/lilavati-hospital-announces-new-state-of-the-art-cancer-care-institute-in-mumbai.html Thu, 23 Jan 2025 00:00:00 +0530 Lilavati Hospital has announced the establishment of a new Cancer Care Institute, featuring a 300-bed hospital in Mumbai. This cutting-edge facility is set to revolutionise cancer treatment in India by providing access to the latest technology, advanced treatments, and global best practices in oncology. The new Cancer Care Institute will offer tailored treatments based on patient-specific factors, ensuring that each patient receives personalised and effective care. The high-quality care provided locally will eliminate the need for patients to travel abroad for treatment, saving both time and costs. In addition to providing exceptional patient care, the facility will create numerous job opportunities for healthcare professionals, researchers, and support staff. This significant investment in the community will boost the local economy and contribute to the overall development of the healthcare sector in Mumbai. The Cancer Care Institute will introduce AI-driven diagnostic tools for early and accurate cancer detection, improving patient outcomes and survival rates. Furthermore, Lilavati Hospital will launch awareness campaigns to educate communities about cancer risks, symptoms, and preventive measures, fostering a culture of health and wellness. Lilavati Hospital has also announced the collaboration with the Mayo Clinic to commence the Nursing Excellence Programme. This Memorandum of Understanding (MoU) aims to enhance the skills and knowledge of the nursing staff through specialised training and development. The partnership covers various areas, including Nursing Excellence education, Nursing Quality and Patient Experience, Patient and Staff Safety, Nursing Governance and Leadership Development, Onboarding, Orientation, and Staff Development & Nurse Competency. Through this partnership, Lilavati Hospital will deliver training through observation, real-time best practice considerations, and structured sessions. Upon completion of the programme, nurses will receive a certificate of completion from the Mayo Clinic.     ]]> https://biospectrumindia.com/news/108/25553/erlysign-raises-rs-16-cr-in-pre-series-a-funding-round-to-launch-oral-cancer-detection-kit.html https://biospectrumindia.com/news/108/25553/erlysign-raises-rs-16-cr-in-pre-series-a-funding-round-to-launch-oral-cancer-detection-kit.html Fri, 17 Jan 2025 00:00:00 +0530 Mumbai-based startup CURO Biosciences Private Limited, also known as ErlySign, has secured Rs 16 crore in pre-Series A funding from renowned investor Ashish Kacholia. This significant funding milestone is a testament to the company’s revolutionary approach to early cancer detection.   The investment, advised by DerivativeSaint, a boutique private equity and venture capital advisory firm, marks a pivotal moment for CURO Biosciences. The company is poised to disrupt the global diagnostics market, which is projected to reach $250 billion by 2030.   At the core of ErlySign’s innovation is a biomarker-based test kit capable of detecting oral precancerous conditions within just 15 minutes using a simple, non-invasive saliva sample. This groundbreaking solution addresses the limitations of current diagnostic methods, which are often painful, time-consuming, and expensive. ErlySign's test kit promises a painless, affordable, and immediate alternative for early cancer detection, offering hope for timely intervention and improved survival rates.   The company’s technology has achieved key milestones, including securing an Indian patent in 2022 and a US patent in 2023, underscoring its pioneering role in cancer diagnostics.   Speaking about the progress, Shubhendra Singh Thakur, CEO and Founder of ErlySign, said, “Our initial studies revealed exceptional results, achieving 100% specificity and 98.04% sensitivity. The product, now in the final stages of clinical trials across multiple HCG sites, promises to be a game-changer. Beyond early detection, it will serve as a critical screening tool to eliminate unnecessary biopsies and invasive procedures.”   The funding will be instrumental in finalising clinical trials, securing CDSCO approvals, and bringing ErlySign’s oral cancer detection kit to market. Additionally, it will support research and development, team expansion, and further patent filings.   Looking ahead, ErlySign has ambitious plans to leverage CRISPR miRNA-based testing technology to detect multiple types of cancer using the same saliva sample within 15–20 minutes. ]]> https://biospectrumindia.com/news/108/25504/lupin-acquires-huminsulin-from-lilly-to-enhance-diabetes-portfolio.html https://biospectrumindia.com/news/108/25504/lupin-acquires-huminsulin-from-lilly-to-enhance-diabetes-portfolio.html Fri, 03 Jan 2025 00:00:00 +0530 Mumbai-based global pharma major Lupin Limited has announced the acquisition of Huminsulin in India from Eli Lilly and Company, in the US, to further enhance its diabetes portfolio. Lupin has been marketing the Huminsulin range of products comprising of Insulin Human, including Huminsulin R, Huminsulin NPH, Huminsulin 50/50, and Huminsulin 30/70, through existing Distribution and Promotion Agreements with Lilly, India. The Huminsulin range of products is indicated for the treatment of type 1 and type 2 diabetes mellitus to improve blood sugar control in both adults and children. Insulin treatment is the cornerstone of type 1 diabetes management and often becomes necessary over time in type 2 diabetes as the disease progresses. There is a significant Indian population affected with diabetes for both Type 1 and Type 2 Diabetes Mellitus, where Insulin Human is prescribed for management along with other concomitant therapies. “This acquisition is strategic to our ongoing efforts to expand our diabetes portfolio and provide high-quality, affordable health care to our patients. It reinforces our unwavering commitment to combating diabetes and providing comprehensive care,” said Nilesh Gupta, Managing Director, Lupin.   ]]> https://biospectrumindia.com/news/108/25500/alkem-labs-launches-digital-knowledge-sharing-platform-for-healthcare-professionals.html https://biospectrumindia.com/news/108/25500/alkem-labs-launches-digital-knowledge-sharing-platform-for-healthcare-professionals.html Thu, 26 Dec 2024 00:00:00 +0530 Mumbai-based Alkem Laboratories has launched MediSamvad, an innovative digital platform designed to empower healthcare professionals (HCPs) with the latest global updates from the field of medical science. MediSamvad aims to provide relevant therapeutic updates and cutting-edge medical content to healthcare professionals. The platform also includes a web portal for hosting webinars, offering a convenient space for continuous medical education and knowledge sharing. MediSamvad offers healthcare professionals a seamless and accessible way to stay informed with practice-oriented content, including research articles, case studies, clinical guidelines and medical advancements from across the globe. Dr Vikas Gupta, Chief Executive Officer, Alkem, commented, “MediSamvad is a testament of our commitment to empower healthcare professionals with the latest scientific knowledge and resources. By leveraging digital platforms, we aim to improve access to medical education and foster stronger connections with healthcare professionals, ultimately improving patient care.”   ]]> https://biospectrumindia.com/news/108/25483/iit-b-joins-hands-with-tohoku-university-to-offer-mtech-and-phd-dual-degree-programmes.html https://biospectrumindia.com/news/108/25483/iit-b-joins-hands-with-tohoku-university-to-offer-mtech-and-phd-dual-degree-programmes.html Mon, 23 Dec 2024 00:00:00 +0530 The Indian Institute of Technology, Bombay (IIT-B) has entered into a Memorandum of Understanding (MoU) with Japan's Tohoku University to launch the IIT Bombay-Tohoku University Joint Academic & Research Programme. The initiative will feature collaborative Master’s and PhD programmes, providing participants with the unique opportunity to receive dual mentorship from experts at both IIT Bombay and Tohoku University. In addition, students will gain access to world-class research facilities, cutting-edge resources, and the opportunity to immerse themselves in the academic environments of two prestigious universities. This partnership is designed to foster cross-border academic collaboration, enriching the learning journey and advancing research in various fields of study. The programme will initially focus on a dual degree initiative for research purposes, with the potential to evolve into a Joint Institute over time, pending necessary approvals from both the senate and government. Both IIT Bombay and Tohoku University are eager to launch this collaboration at the earliest, driven by a shared vision to implement cutting-edge academic and research programmes that address global challenges.  ]]> https://biospectrumindia.com/news/108/25476/valneva-expands-access-for-its-chikungunya-vaccine-with-serum-institute-of-india.html https://biospectrumindia.com/news/108/25476/valneva-expands-access-for-its-chikungunya-vaccine-with-serum-institute-of-india.html Fri, 20 Dec 2024 00:00:00 +0530 France-based Valneva SE, a specialty vaccine company, and Pune-based Serum Institute of India (SII), the world’s largest manufacturer of vaccines by number of doses, have announced an exclusive license agreement for Valneva’s single-shot chikungunya vaccine that enables supply of the vaccine in Asia. The collaboration to support broader access to the vaccine in low-and-middle-income countries (LMICs) in the region falls within the framework of the $41.3 million funding agreement Valneva signed with the Coalition for Epidemic Preparedness Innovations (CEPI) in July 2024 with co-funding from the European Union.  The companies will work urgently to bring the vaccine to the Indian market, and certain other Asian countries, subject to local regulatory approvals, as India is currently enduring one of its worst chikungunya outbreaks. Nearly 370,000 cases were confirmed in India between January 2019 and July 2024, a number rapidly increasing due to the current outbreak. Under the agreement, the companies will conduct a technology transfer of the current drug product manufacturing process. Valneva will supply its chikungunya vaccine drug substance to SII, which will complete manufacturing and be responsible for seeking and maintaining regulatory approval of the vaccine in India and other countries in Asia. Future commercialisation will be based on a profit-sharing model along with single-digit million milestone payments towards technology transfer and regulatory approvals to Valneva. SII will also make available a stockpile of 100,000 doses of the drug product to CEPI as an ‘investigational ready reserve’ that could be used in clinical trials in the region. Such research could provide additional data on the performance of the vaccine among local populations.  ]]> https://biospectrumindia.com/news/108/25467/lupin-buys-3-trademarks-from-boehringer-ingelheim-to-strengthen-diabetes-portfolio.html https://biospectrumindia.com/news/108/25467/lupin-buys-3-trademarks-from-boehringer-ingelheim-to-strengthen-diabetes-portfolio.html Tue, 17 Dec 2024 00:00:00 +0530 Global pharma major Lupin has announced the acquisition of anti-diabetes trademarks GIBTULIO®, GIBTULIO MET® and AJADUO® from Boehringer Ingelheim International GmbH (Boehringer Ingelheim), to strengthen its diabetes portfolio in the country. As per the terms of the agreement, the trademark rights for these brands will be transferred to Lupin by March next year. Lupin has been marketing GIBTULIO® and GIBTULIO MET® since 2016, and AJADUO® since 2018 in the Indian market through existing co-marketing agreements with Boehringer Ingelheim India. GIBTULIO® (empagliflozin), GIBTULIO MET® (empagliflozin + metformin) and AJADUO® (empagliflozin + linagliptin) belong to a novel class of oral anti-diabetic drug, sodium glucose co-transporter-2 (SGLT-2) inhibitor (and combinations). These are indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. Empagliflozin is also indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes, and the risk of cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease. An estimated 80 million people above the age of 18 years have diabetes in India, in addition to 25 million that are pre-diabetic. Awareness of diabetes is low with more than 50% of people unaware of their diabetic status, leading to multiple health complications, if not detected and treated early. Adults with diabetes have an increased risk of heart attack and stroke.   ]]> https://biospectrumindia.com/news/108/25469/supriya-lifescience-invests-rs-120-cr-in-new-api-production-block.html https://biospectrumindia.com/news/108/25469/supriya-lifescience-invests-rs-120-cr-in-new-api-production-block.html Tue, 17 Dec 2024 00:00:00 +0530 Supriya Lifescience Liimited (SLL), a leader in the pharmaceutical industry, has taken another significant step on its ambitious growth trajectory with the inauguration of its new multipurpose Active Pharmaceutical Ingredients (APIs) production block, Module E, at the Lote Parshuram site, in Maharashtra. The facility, developed with an investment of approximately Rs 120 crore, adds a substantial capacity of 335 kiloliters to the company’s operations. This expansion boosts the Lote Parshuram capacity by over 55%, increasing it from 597 KLPD kilo liters per day) to 932 KLPD. The new production block is designed to support SLL’s strategic focus on expanding its R&D capabilities and scaling up its pipeline of innovative products. Several new products in niche therapeutic areas are nearing the commercialisation stage, reinforcing SLL’s commitment to achieving a leadership position in these markets through efficient processes and backward integration. The facility is tailored to support the company’s backward integration model, ensuring economies of scale and a competitive edge. It is spread across 5,000 square meters and structured over four levels, the facility enables efficient operations and safe workflows. The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL. The design leverages gravity-based process flows to enhance safety, maintain product integrity, and optimize efficiency. Incorporating closed-system handling at critical stages, the facility is equipped with process control automation systems and material handling systems to ensure compliance with the latest quality standards. The facility is equipped to handle a variety of unit processes and operations, making it adaptable to future needs. ]]> https://biospectrumindia.com/news/108/25449/medtech-firm-getinge-opens-new-experience-centre-in-mumbai.html https://biospectrumindia.com/news/108/25449/medtech-firm-getinge-opens-new-experience-centre-in-mumbai.html Wed, 11 Dec 2024 00:00:00 +0530 Getinge, a global medtech company, has announced the opening of its new Experience Centre in Mumbai. Executives from Getinge with leaders from healthcare and government unveiled the Experience Centre, designed to recreate hospital and other healthcare settings including operating rooms and intensive care units.  The launch event was attended by Sven Östberg, the Consul General of Sweden in Mumbai, who highlighted the significance of this milestone in Getinge's commitment to the Indian healthcare market. The Experience Centre showcases Getinge's innovative solutions, including the Getinge IN2 OR Modular Room System, designed to meet the evolving needs of modern surgery. The system is engineered to offer flexibility, efficiency, and highly customisable options, addressing the key challenges faced by traditional operating theaters. "This centre will offer healthcare professionals an interactive, hands-on experience with our solutions, demonstrating how they can improve efficiency and elevate the patient experience," says Philippe Rocher, President South Asia Pacific. Aruna Nayak, Managing Director, India, adds "The opening of our Experience Center in Mumbai is a significant step in our mission to bring world-class healthcare solutions closer to India’s growing medical needs. With our modular OR system and other advanced technologies, we are confident that healthcare facilities across the country will be able to achieve greater efficiency, sustainability, and quality of patient care. We are excited to support the healthcare sector as it adapts to the needs of modern surgery and rapidly evolving technology." The centre will play a crucial role in helping hospitals and healthcare providers adopt advanced solutions that enhance patient care, improve operational efficiency, and promote sustainability.     ]]> https://biospectrumindia.com/news/108/25450/cipla-brings-revolutionary-diabetes-management-solution-to-india.html https://biospectrumindia.com/news/108/25450/cipla-brings-revolutionary-diabetes-management-solution-to-india.html Wed, 11 Dec 2024 00:00:00 +0530 Mumbai-based pharma firm Cipla has announced regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) for the exclusive distribution and marketing of Afrezza (insulin human) Inhalation Powder in India. Developed and manufactured by MannKind Corporation (USA), Afrezza offers a groundbreaking treatment designed to improve glycemic control in adults with diabetes mellitus. This partnership is set to transform diabetes care in India by introducing a patient-centric solution that is both innovative and convenient, empowering millions to manage their health with greater ease. Afrezza is the first and only rapid-acting insulin that can be inhaled, providing a non-injectable alternative for individuals with both type 1 and type 2 diabetes. Administered through an inhaler at the beginning of a meal, it quickly dissolves upon inhalation into the lungs, delivering insulin to the bloodstream. This process enables it to start working in as little as 12 minutes, closely mimicking the body’s natural insulin response. Its effects last for 2-3 hours, making it particularly effective in reducing the rapid blood sugar spikes associated with meals while eliminating the need for multiple daily insulin injections. Afrezza has been extensively evaluated in over 70 clinical studies involving more than 3,000 patients globally. With over a decade of approval in the United States, it has been prescribed to tens of thousands of patients. Under the partnership agreement, MannKind will supply Afrezza to Cipla, which will handle the drug’s sales and marketing activities in India.   ]]> https://biospectrumindia.com/news/108/25411/venture-center-wins-gold-at-inaugural-cii-amtz-medtech-quality-champion-awards-2024.html https://biospectrumindia.com/news/108/25411/venture-center-wins-gold-at-inaugural-cii-amtz-medtech-quality-champion-awards-2024.html Fri, 29 Nov 2024 00:00:00 +0530 Pune-based Venture Center, India’s leading technology business incubator focused on science and technology startups, has been awarded the Gold Award in the Service Enterprise category at the inaugural CII-AMTZ MedTech Quality Champion Awards 2024. The award was presented at the 32nd CII Excellence Summit held in Bengaluru on November 27, 2024, where Chetna Dharmavat Dabi, Associate Manager – Regulatory Services, received the award on behalf of Venture Center from Dr Jitendra Sharma is the Managing Director and Founder CEO of Andhra Pradesh MedTech Zone (AMTZ). The CII-AMTZ MedTech Quality Champion Awards aim to foster a culture of excellence in the medtech industry by encouraging organizations to set higher standards in quality and innovation. This prestigious recognition highlights Venture Center’s exceptional services that empower medtech startups to innovate and succeed in the competitive healthcare sector. Key to this achievement are Venture Center's ISO-certified MedTech Cleanroom, regulatory support for Indian, European, and US markets, and personalised mentoring for medtech startups. Additionally, the center has built a comprehensive database and library of regulatory information, offering startups valuable access to resources and service providers for standard tests and documentation. Venture Center’s ISO-certified MedTech Cleanroom Facility, which was recently recertified for ISO 13485:2016, is designed to support bio-entrepreneurs, startups and larger enterprises, and enables the manufacturing and packaging of medical devices. ]]> https://biospectrumindia.com/news/108/25394/aster-dm-healthcare-enters-into-agreement-to-acquire-balance-stake-in-aster-aadhar-hospital-kolhapur.html https://biospectrumindia.com/news/108/25394/aster-dm-healthcare-enters-into-agreement-to-acquire-balance-stake-in-aster-aadhar-hospital-kolhapur.html Wed, 27 Nov 2024 00:00:00 +0530 Aster DM Healthcare, one of the largest integrated healthcare providers in India, has entered into an agreement to acquire the balance stake in Aster Adhaar Hospital (Prerana Hospital Limited) in Kolhapur, Maharashtra. With this acquisition, Aster DM Healthcare will own 100% of the target company, from the 87% stake it previously held. The transaction will be completed in two tranches and the indicative time period for completion of the acquisition is December 31, 2025. The complete acquisition of Prerana Hospital Limited marks a significant milestone for Aster DM Healthcare in its continued growth and diversification strategy. The 254-bedded Aster Aadhar Hospital, Kolhapur is the city’s most comprehensive multi-speciality hospital. It is the first hospital in the region to acquire the prestigious NABH Accreditation, the gold standard for quality healthcare. With 25+ specialties offered along with a panel of leading doctors and dedicated support staff, the hospital puts compassionate, quality care at the forefront. Aster DM Healthcare is well-positioned to meet the increasing demand for advanced healthcare in India. Over the next 5 years i.e. FY25-FY29, the India business is set to achieve CAGR ~18% - 20% YoY growth driven by an increased occupancy and addition of capacity. The Operating EBITDA margin is expected to reach a level of ~23%-25% over the next 4-5 years. The subsidiary will operate and leverage the parent company's strengths, including its established market presence and financial stability, to consolidate growth and capture new opportunities. ]]> https://biospectrumindia.com/news/108/25376/samsung-rd-institute-noida-and-iit-bombay-sign-mou-to-pioneer-research-in-digital-health-ai.html https://biospectrumindia.com/news/108/25376/samsung-rd-institute-noida-and-iit-bombay-sign-mou-to-pioneer-research-in-digital-health-ai.html Thu, 21 Nov 2024 00:00:00 +0530 Samsung R&D Institute, Noida (SRI-Noida), has strengthened its commitment to industry-academia collaboration by signing a Memorandum of Understanding (MoU) with the Indian Institute of Technology Bombay (IIT Bombay). Under this MoU, SRI-Noida and IIT Bombay will explore breakthroughs in artificial intelligence (AI), digital health, and other critical areas. The five-year partnership will facilitate joint research projects, providing IIT Bombay students and faculty an opportunity to collaborate with Samsung engineers. This approach will not only open newer avenues for the students, but will enhance their industry readiness. In addition, it will equip Samsung engineers with specialized training and certification programmes from IIT Bombay in emerging technologies such as digital health and AI. The MoU was formally signed by Kyungyun Roo, Managing Director of SRI-Noida, and Prof. Upendra V. Bhandarkar, Associate Dean of Research and Development at IIT Bombay. The event, which took place at IIT Bombay, was attended by faculty members from the Koita Centre for Digital Health (KCDH), including Prof. Ranjith Padinhateeri, Head of KCDH, Prof. Nirmal Punjabi and Dr Raghavendran Lakshminarayanan.  The MoU encourages the publication of joint research papers, promoting knowledge sharing that will drive technological progress and industry-aligned innovation. Through this partnership, Samsung and IIT Bombay are setting the foundation for a sustained exchange of expertise that will push the boundaries of next-generation technologies and inspire future breakthroughs. ]]>